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ABSTRACT
CHARACTERIZATION OF FUNDAMENTAL PARAMETERS THAT MODULATE
ACOUSTOFLUIDIC-MEDIATED MOLECULAR DELIVERY TO CELLS
Connor S. Centner
February 18th, 2022
Cell-based therapies represent the latest biotechnological revolution in
medicine, but significant limitations exist in non-viral intracellular delivery
techniques during manufacturing of cell therapies. To address these limitations, a
novel acoustofluidic device was developed to deliver ultrasound waves into a flow
chamber for rapid molecular delivery to human cells. Our acoustofluidic device
delivers biomolecules by inducing expansion and collapse of exogenous gas-filled
microbubbles (“cavitation”), which enhances molecular delivery to nearby cells.
Experimental studies were conducted to characterize key parameters that
influence acoustofluidic-mediated molecular delivery to human cells. A clinical
ultrasound transducer was generally utilized with varying cationic microbubble
concentrations. Intracellular delivery of a fluorescent dye was assessed using flow
cytometry. Preliminary studies with erythrocytes and primary T cells used a
polydimethylsiloxane-based acoustofluidic device, while subsequent studies with
Jurkat T cells used a 3D-printed acoustofluidic device to increase compatibility for
cell manufacturing applications.
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For erythrocytes, ultrasound pressure and microbubble concentration were
important parameters that influenced fluorescein delivery. Initial Jurkat T cell
studies indicated that microbubble concentration, surface charge, and ultrasound
pressure influenced molecular delivery. Subsequent experiments directly
compared refined parameters of the acoustofluidic device and a static ultrasound
configuration. The acoustofluidic device and the static ultrasound configuration
had similar levels of intracellular delivery with small (calcein) and large (150 kDaFITC Dextran) molecules, although less ultrasound exposure and lower
microbubble concentrations were required in the acoustofluidic device.
Bioeffects from acoustofluidic treatment were assessed in subsequent
experiments. Cell plating density and media formulation influenced acoustofluidicmediated molecular delivery. Confocal microscopy indicated that actin patches
form in response to acoustofluidic treatment and plug perforations in the plasma
membrane. In addition, disruption of organelle structures, such as the nucleus,
were observed after acoustofluidic treatment. Cell cycle phases also influenced
molecular delivery, and cell proliferation was briefly reduced after acoustofluidic
treatment.
The results of this dissertation indicate that acoustofluidic parameters and
biological characteristics have important effects on molecular delivery to human
cells. Our acoustofluidic device achieved similar molecular delivery levels to Jurkat
T cells as a static ultrasound configuration, which indicate that acoustofluidic
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devices offer potential advantages for cell processing applications and may
improve manufacturing of cell therapies.
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CHAPTER I – INTRODUCTION
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I.1. Background and Significance
Cell-based therapies represent the latest biotechnological revolution in
medicine. Potential therapeutic applications include treating cancers, treating
autoimmune disease, treating infectious diseases, and repairing damaged tissue
(Buzhor et al., 2014). Most cell-based therapies are currently undergoing
preliminary evaluation in a laboratory and/or clinical setting, but some cell-based
therapies have reached FDA-approval, such as modified Cytotoxic T Lymphocytes
(CTLs) for treatment of blood related disorders. Recent results in modified immune
cells for cancer applications, specifically CTLs, enhance cytotoxic activity while
reducing off-target effects and has distinct advantages over traditional treatment
regimens (e.g., chemotherapy). Although cell-based therapies have a diverse
range of applications and cell material, there are common translational challenges
that need to be addressed to bring these therapies to the clinical market.
Cell-based therapies may be classified by therapeutic application, donor
source, and/or cell type (Mount et al., 2015). A broad spectrum of cell classes may
be used in a clinical setting depending on the application required. Rather than
assessing the field on cell classes and therapeutic application alone, it may be
beneficial to assess cell-based therapies from a technological perspective, which
has important implications on development of new cell therapies and
manufacturing processes. Cell manufacturing processes comprise numerous
steps, which typically follow a similar process regardless of cell type or application
(Fig. 1). This review focuses on molecular delivery of biomolecules to immune
cells. From a technological perspective of delivering biomolecules, delivery
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vehicles for cell-based therapies will be broadly classified as viral and non-viral
delivery methods.

Figure 1: Flow scheme representing a typical cell manufacturing process for T cell
therapies.
This
process
is
critically
dependent
on
effective
transfection/transduction efficiency to generate the therapeutic product. The total
manufacturing time is typically ~3 weeks, but some products may take longer than
6 weeks to generate (Vormittag et al., 2018).
Currently viral vector technology is being utilized for ex vivo modification of
CTLs (Zhang et al., 2017a). Viral vectors are infectious entities that are adapted to
deliver nucleic acid to the cytoplasm or nucleus (Nayerossadat et al., 2012b).
Transduction for T cell therapies is a common modality for gene delivery, but has
limitations that include low/inconsistent transduction efficiency, potential
insertional mutagenesis, limited transgenic capacity, and limited non-nucleic acid
delivery (Hacein-Bey-Abina et al., 2010; Brentjens et al., 2011; Dai et al., 2015;
Porter et al., 2015). Low/inconsistent transduction efficiency provides a critical
issue as some groups have reported efficiencies between 4-70% in their respective
studies (Brentjens et al., 2011; Dai et al., 2015; Porter et al., 2015). Additionally,
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low/inconsistent transduction efficiency has been observed with other immune
cells, such as dendritic cells (Rossi et al., 2019). These factors may limit novel cellbased therapies from reaching the market, which can impact patient outcomes.
For example, tisagenlecleucel (chimeric antigen receptor (CAR)-T therapy) may
require up to 109 cells/kg bodyweight for the therapeutic applications (Awasthi et
al., 2020). Thus, alternative molecular delivery approaches should be considered
to increase molecular delivery levels along with consistency to expedite the cell
manufacturing process.
Non-viral molecular delivery techniques are in development and are
commercially available for a broad range of biomedical and research applications.
To enhance molecular delivery of biomolecules to cells, common techniques may
include mechanical, electrical, hydrodynamic, or use of laser-based energy
(Nayerossadat et al., 2012b). These techniques commonly focus on modifying the
permeability of the plasma membrane to enhance intracellular molecular delivery
via mechanisms such as transient perforation (Sugar and Neumann, 1984a; Gehl,
2003b; Chen et al., 2006a; Nayerossadat et al., 2012b; Hashimoto and Takemoto,
2015a).
A commercially available technique that is frequently utilized is
electroporation. Large biotechnology companies, such as ThermoFisher, generally
have their own commercially available electroporation devices. Electroporation
induces transient perforation of the plasma membrane, but this involves a
stochastic process and electroporation-mediated molecular delivery to cells is
generally dependent on passive diffusion through transient pores (Sugar and
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Neumann, 1984a). Coupling of electroporation and microfluidic devices have been
demonstrated to address scalability issues (Wang and Lu, 2006; Geng and Lu,
2013). This technology is currently being brought to market by companies such as
Kytopen. Although this technology is being brought to market, limitations such as
passive diffusion have not been fully addressed.
Another non-viral process that has been explored involves microfluidic
squeezing where the distance between capillary walls is smaller than the diameter
of cells. The microfluidic channel constricts cells and transiently increased
permeability of the plasma membrane, enabling uptake of molecular compounds
in the media via diffusion (Sharei et al., 2013). To overcome processing limitations,
microfluidic squeezing devices utilize channel parallelization to increase
throughput rate up to approximately 106 cells/sec (Sharei et al., 2015; Szeto et al.,
2015). However, channel blockage and limited loading efficiency may inhibit
successful translation for many immune cell manufacturing applications (Dressaire
and Sauret, 2016). This technology was brought to market by SQZBiotech and is
under preclinical and clinical evaluation using erythrocytes and professional
antigen presenting cells to treat a variety of diseases by carrying antigens of
interest to spleen or lymph nodes to prime the immune system. This approach can
enable treatment to occur within a week of blood collection since lower amounts
of antigen carrying cells are required than typical cell manufacturing applications.
However, it still requires priming of the adaptive immune system, which can take
multiple weeks to reach significant levels for primary exposure to an antigen. In
fact, high transfection efficiency is not required to generate a cytotoxic T cell
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response. An antigen-specific response can be generated with <1% transfection
efficiency (Grunebach et al., 2003). Thus, successful translational of antigen
presenting cells may not necessarily translate into successful ex vivo modification
of non-antigen presenting cells, such as natural killer (NK) cells or T cells.
Furthermore, microfluidic squeezing intends to deliver cargo into the cytosol and
may be ineffective at nuclear delivery.
Viral and non-viral delivery technologies have key limitations that have
important implications on the potential success of cell-based therapies. Thus, other
technologies should be considered that may have the capacity to induce rapid,
consistent molecular delivery not only to the cytosol but potentially to the nucleus.
Ultrasound-induced molecular delivery may be a viable option to address these
challenges, but further exploration is required.
I.2. Background in Ultrasound-induced Molecular Delivery
B-mode ultrasonography is a common modality that uses ultrasound
echoes originally generated by the ultrasound transducer in the form of pulsed
ultrasound pressure waves, which reflect back to the transducer based on the
material properties such as differences in speed of sound and material density.
Common applications include neonatal imaging and cardiac imaging. Ultrasound
contrast agents (UCAs) are currently utilized to enhance echogenicity of blood and
delineate surrounding structures (Cosgrove, 2006). UCAs are FDA approved for
echocardiograms and generally consist of a perfluorocarbon core and a surfactant,
such as lipid or protein, to stabilize the microbubble for persistence in the
circulatory system.
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For ultrasound-based molecular delivery techniques, mechanical bioeffects
are desired in order to enhance molecular delivery to cells (Izadifar et al., 2017).
To reduce the ultrasound pressure required for generating mechanical bioeffects,
exogenous microbubbles are added to the buffer which enhance molecular
delivery when located near cell membranes. Microbubble cavitation involves rapid
expansion and contraction of microbubbles in response to ultrasound waves. This
process triggers reversible plasma membrane perforation when microbubbles are
near cells, a phenomenon known as “sonoporation”. Additionally, biological effects
induced by cavitation, such as enhanced endocytosis, have been observed
(Hauser et al., 2009).
With advancements of gene and molecular engineering, more scientists
have been exploring ex vivo modifications to cells (Brentjens et al., 2007;
Barrangou and Doudna, 2016; Annesley et al., 2018a). Many studies have utilized
static ultrasound treatment for enhanced delivery of biomolecules to cells, by
utilizing a static solution that contains cells and exogenous microbubbles in a
sample chamber placed in the ultrasound focus. In fact, numerous studies utilizing
immune cells have investigated ultrasound-induced molecular delivery in static
ultrasound configurations, but these studies have mainly utilized dendritic cells
(Deng et al., 2010; De Temmerman et al., 2011). A critical factor for ultrasoundinduced transfection was found to be related to cavitation dynamics, with inertial
cavitation identified as having increased plasma membrane disruption and
molecular delivery compared to stable cavitation activity (Fan et al., 2013).
However, static ultrasound configurations currently have some major limitations
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such as its lack of a standardized process, a more heterogenous solution resulting
in inconsistent ultrasound pressures, and low throughput/slow processing times.
These limitations pose a major hurdle for translation of ultrasound-based
technology into cell manufacturing applications. Thus, utilizing an ultrasoundbased flow chamber is necessary to overcome these limitations. Acoustofluidic
devices in development may address these challenges by combining ultrasound
waves in fluidic channels containing cells and microbubbles.
I.3. Acoustofluidics review
Acoustofluidics technologies have increasingly been utilized to address
challenges in manufacturing and clinical applications, especially in diagnostics and
therapeutics (Li et al., 2015; Chen et al., 2016; Wu et al., 2017). Furthermore,
acoustofluidic-based devices have the potential to enable point-of-care (POC) for
patient bedside and outpatient applications due to their operator simplicity and
rapid processing capabilities. In fact, acoustofluidic-based devices have been
developed for a variety of applications including acoustophoresis (Petersson et al.,
2007; Lenshof et al., 2012), fluid mixing (Shilton et al., 2008; Friend and Yeo, 2011;
Yeo et al., 2011), and biomarker analysis (Wang et al., 2020; Zhou et al., 2021).
One of the first acoustofluidic products to reach the market was the Ekko Acoustic
Cell Processing System by FloDesign Sonics for cell concentration, media
exchange, and cell expansion or differentiation applications to address limitations
in other aspects of the cell manufacturing process. However, few research studies
have been conducted investigating acoustofluidics for molecular delivery
applications to immune cells, which is the focus of this dissertation.
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I.3.1. Acoustofluidic-induced Molecular Delivery Applications
Recent advancements in genome editing have led to significant research
involving ex vivo cell manipulation for therapeutic applications such as treatment
of cancer and HIV (Deeks et al., 2002; Brentjens et al., 2007; Kochenderfer et al.,
2010; Jinek et al., 2012; Mali et al., 2013; Barrangou and Doudna, 2016; Ying et
al., 2019). Recently, acoustofluidic-induced molecular delivery platforms have
been assessed to overcome limitations of viral transduction and other non-viral
delivery methods (Belling et al., 2020a; Centner et al., 2020; Centner et al., 2021b).
Acoustofluidics for molecular delivery applications is a platform technology that
can

allow

delivery

of

a

vast

array

of

biomolecules.

Multiple

parameters/mechanisms can play a fundamental role in enhancing molecular
delivery to cells.
Prior research studies have investigated acoustofluidics for molecular
delivery without exogenous microbubbles. Some acoustofluidic platforms induced
molecular delivery without microbubbles by taking advantage of Gor’kov potential
where acoustic pressure is lowest at the capillary wall opposite of the transducer
(Guo et al., 2016; Belling et al., 2020a). This ultimately induces an acoustic
radiation force on the cell and moves the cell to the capillary wall opposite of the
transducer. Research groups have tethered molecular compounds to the capillary
wall opposite of the transducer to improve molecular delivery to cells as acoustic
radiation force and shear stress are likely involved in increasing permeabilization
of the plasma membrane (Belling et al., 2020a).
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Acoustofluidic-induced molecular delivery with exogenous microbubbles is
a novel concept and requires more research to understand its effects on cells. A
variety of physical parameters may affect biomolecular delivery, such as
ultrasound pressure, ultrasound frequency, exposure time, pulse duration,
acoustofluidic channel dimensions, and microbubble size and composition (Forbes
et al., 2011; Helfield et al., 2016c; Centner et al., 2020). Biological effects may also
affect biomolecular delivery to cells in a static ultrasound configuration or
acoustofluidic device (De Cock et al., 2015). Physical and biological parameters,
however, have only been thoroughly investigated in static ultrasound
configurations. Thus, characterization of physical and biological parameters that
influence molecular delivery in an acoustofluidic device represents a significant
gap in knowledge. Molecular delivery to lymphocytes, specifically T lymphocytes,
and erythrocytes will be the focus, but acoustofluidic systems are platform
technologies that can be used for other cell lines.

I.4. Research Hypotheses and Specific Aims
The motivation of this dissertation is the need for rapid, sequential molecular
delivery to cells for a variety of applications. The overall objective of this
dissertation is to elucidate the role of acoustofluidic parameters and mechanisms
in molecular delivery for modification of cells. The central hypothesis is that an
acoustofluidic platform with exogenous microbubbles in solution enhances
molecular delivery efficiency to human cells. Key parameters in the
acoustofluidic platform with microbubble-enhanced delivery have not been
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assessed in previous acoustofluidic studies. The experiments described in this
dissertation were designed to test the central hypothesis and answer underlying
research questions:
1. What are fundamental parameters that modulate molecular delivery
efficiency?
2. Does microbubble destruction in acoustofluidic channels correlate with
molecular delivery to cells?
3. Does acoustofluidic treatment achieve similar levels of molecular delivery
compared to a static ultrasound system?
4. What bioeffects do acoustofluidic treatment and cell culture media
formulations induce on molecular delivery and cell dynamics?
The underlying research questions in conjugation with the central
hypothesis were used to guide the specific aims:
Specific Aim 1 (Chapter 3): Assess key parameter effects on molecular delivery
efficiency
Specific Aim 2 (Chapter 4): Assess effects of ultrasound and microbubbles in
acoustofluidic system on molecular delivery to human T cells
Specific Aim 3 (Chapter 5): Assess levels of molecular delivery to human T cells
with acoustofluidic treatment compared to treatment with a static ultrasound
chamber
Specific Aim 4 (Chapter 6): Assess key biological and cell culture media factors
on molecular delivery and characterize the effect of acoustofluidic treatment on
subcellular organelle structures
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CHAPTER II – ASSEMBLY AND OPERATION
OF AN ACOSUTOFLUIDIC DEVICE FOR
ENHANCED DELIVERY OF MOELCULAR
COMPOUNDS TO CELLS

1

1

Sections of text and figures in this chapter are reproduced from the following
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JoVE, 167 (2021). Reprinted with permission of JoVE.
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II.1. Introduction
Viral and non-viral platforms have been utilized to enhance molecular
delivery to cells. Viral delivery (transduction) is a common technique utilized in cellbased therapies requiring genomic modification. Limitations with viral delivery
include potential insertional mutagenesis, limited transgenic capacity, and
undesired multiplicity of infection (Wahlers et al., 2001b; Gardlik et al., 2005).
Therefore, non-viral molecular delivery techniques are in development for a broad
range of biomedical and research applications. Common techniques include
mechanical, electrical, hydrodynamic, or the use of laser-based energy to enhance
uptake of biomolecules into cells (Nayerossadat et al., 2012a). Electroporation is
a commonly used non-viral molecular delivery platform which has the ability to
induce transient perforation in the plasma membrane for intracellular delivery of
molecular compounds (Sugar and Neumann, 1984b; Weaver, 1993; Gehl, 2003a;
Lin et al., 2004; Chen et al., 2006b; Hashimoto and Takemoto, 2015b). However,
the transient perforation of the plasma membrane is a stochastic process and
molecular uptake via electroporation is generally dependent on passive diffusion
across the transient membrane pores (Sugar and Neumann, 1984b; Weaver,
1993; Chen et al., 2006b).
An alternative method is the utilization of ultrasound for enhanced
intracellular molecular delivery via cavitation of ultrasound contrast agents (i.e.,
gas-filled microbubbles). Microbubble cavitation induces microstreaming effects in
the surrounding media which can cause transient perforation of nearby plasma
membranes (“sonoporation”) allowing rapid intracellular uptake of biomolecules via
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passive or active transport mechanisms (Klibanov, 2006; Klibanov et al., 2010; Fan
et al., 2014a). Sonoporation is an effective technique for rapid molecular delivery
to cells, but this approach often requires expensive equipment and static
ultrasound treatment methods which are limited by lower throughput and higher
variability in ultrasound exposure conditions (Secomski et al., 2017). To address
these limitations, acoustofluidic devices are currently in development which enable
consistent sonoporation of cells in suspension.
Acoustofluidics is an expanding field that integrates ultrasound and
microfluidic technologies for a wide variety of applications. This approach has
previously been used for particle separation by applying continuous ultrasound
energy to induce standing acoustic waves within the fluidic channels (Shi et al.,
2009a; Shi et al., 2009b; Gedge and Hill, 2012a; Shields et al., 2016). Particles are
sorted toward different parts of the device based on a variety of properties such as
particle size, density, and compressibility relative to the medium (Shi et al., 2009b).
Acoustofluidic technologies are also in development to enable rapid molecular
delivery to a variety of cell types for research applications and manufacturing of
cell therapies (Belling et al., 2020b). Recently, we demonstrated enhanced
molecular delivery to erythrocytes using a PDMS-based acoustofluidic device
(Centner et al., 2020). In the acoustofluidic platform, cell and microbubble
dynamics can be manipulated to induce physical interactions that enable
enhanced delivery of biomolecules. The efficiency and consistency of intracellular
molecular delivery can potentially be increased by optimizing the distance between
cells and microbubbles.
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One important application for acoustofluidic-mediated sonoporation
involves transport of biomolecules into primary human T cells. Immunotherapies
based on adoptive T cell transfer, such as Chimeric Antigen Receptor T cell (CAR
T) therapy, are rapidly emerging for treatment of various diseases, including
cancer and viruses such as HIV (Qi et al., 2020). CAR T therapy has been
particularly effective in pediatric acute lymphoblastic leukemia (ALL) patients, with
complete remission rates of 70-90% (Annesley et al., 2018b). However, T cell
manufacturing for these therapies generally depends on viral transduction which
is limited by potential insertional mutagenesis, long processing times, and
challenges of delivering non-genetic biomolecules such as proteins or small
molecules (Gardlik et al., 2005). Acoustofluidic-mediated molecular delivery
methods can potentially overcome these limitations and improve manufacturing of
T cell therapies.
Another important application for acoustofluidic-mediated sonoporation
involves intracellular delivery of preservative compounds, such as trehalose, which
protect cells during freezing and desiccation. Trehalose is produced by some
organisms in nature and helps them tolerate freezing and desiccation by protecting
their cellular membranes (Hand and Menze, 2015; Zhang et al., 2017b). However,
trehalose is not produced by mammalian cells and is impermeable to mammalian
cell membranes. Therefore, effective molecular delivery techniques, such as
sonoporation, are necessary in order to achieve sufficient intracellular trehalose
levels required to protect internal cellular membranes. This approach is currently
in development for dry preservation of various cell types.
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This protocol provides a detailed description of the assembly and operation
of a relatively low-cost acoustofluidic system driven by a microcontroller.
Ultrasound contrast agents are utilized to induce sonoporation within the fluidic
channels and enable rapid molecular delivery to various cell types, including T cells
and cancer cells. This acoustofluidic system can be used for a variety of research
applications and may also be useful as a prototype system to evaluate
sonoporation methods for improved cell therapy manufacturing processes.

II.2. Protocol
Ethics Statement: Whole blood donations were collected from healthy donors
following protocols approved by the institutional review board at the University of
Louisville.

1. Fabrication of Acoustofluidic Device
1.1

Obtain a photomask with a concentric spiral design containing channels

with a diameter of 500 µm. A CAD file is provided in the supplemental files as an
example. A custom photomask can be ordered from a commercial vendor or
patterned using a mask writer.
1.2

Prepare a mold of the concentric spiral design on a photoresist-coated

silicon wafer using standard photolithography techniques:
1.2.1. Add approximately 2 Tbsp (~30 mL) of SU-8 2100 to a 100 mm silicon
wafer.
1.2.2. Spin-coat the wafer on a spinner at a speed of 150 rpm for 30 s to spread
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out the photoresist, then increase speed to 1200 rpm for 60 s to yield a thickness
of 200 µm.
1.2.3. Cure the photoresist-coated wafer in a polyimide vacuum oven with a 30
min ramp up and 30 min dwell at 115 °C, then ramp down for 30 min.
1.2.4. Expose the photoresist-coated wafer for 130 s using a mask aligner with the
photomask from step #1.
1.2.5. Bake the wafer after exposure following the same process described in step
1.2.3.
1.2.6. Develop the photoresist in SU-8 developer solution for approximately 8 min
CAUTION: only use developer solution in a well-ventilated chemical fume hood.
1.3

Silanize the mold to make the surface more hydrophobic. Place the

photoresist-coated wafer into a desiccator and add a 20 µL drop of trichlorosilane
(C8H4Cl3F13Si, Gelest, Morrisville, PA, USA). Apply vacuum to the chamber for 30
s, then seal the chamber and leave overnight.
CAUTION: Trichlorosilane is very hazardous and flammable. Exposure causes
severe burns and eye damage.
1.4

Combine 54 g of polydimethsiloxane (PDMS) base and 6 g of curing agent

in a cup and mix vigorously and thoroughly with a spatula for at least 1 min.
1.5

Place the cup containing the PDMS solution into a desiccator for

approximately 30 minutes or until remnant air bubbles are removed from the
solution.
1.6

Place photoresist-coated wafer with the patterns facing upward in a 150-

mm petri dish.
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1.7

Pour the PDMS solution over the mold inside the 150-mm petri dish.

1.8

If needed, place the 150-mm petri dish inside a desiccator and apply

vacuum until remnant air bubbles disappear.
1.9

Transfer the 150-mm petri dish into a lab oven and bake for 2 hr at 60 °C to

cure the PDMS.
1.10

After curing, carefully remove the PDMS from the petri dish by cutting

around the edges of the wafer using a razor blade.
1.11

Cut out each individual device using a knife or razor blade.

1.12

Punch holes through the inlet and outlet ports of each device using a 2.5-

mm biopsy punch (Harris Uni-Core, Electron Microscopy Sciences, Hatfield, PA,
USA).
1.13

Place each PDMS device in a plasma asher with channels exposed (facing

upward). Apply oxygen plasma treatment (100 W for 45 s, 500 mbar O2) then
immediately place each PDMS device onto a clean soda lime glass microscope
slide (75 mm x 25 mm x 1 mm) with channels facing the glass surface.
1.14

Let devices bond overnight at room temperature.

1.15

Gently apply silicone to the surface of the 1-cm diameter piezo transducer

at a thickness of ~1-2mm, then carefully align the transducer with the concentric
spiral and gently press it onto the bottom of the glass microscope slide (opposite
side from the PDMS device).

2. Assembly and Operation of Acoustofluidic System
2.1

Connect a microcontroller to a computer using a USB A to B cable. A green
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power LED indicator (labelled PWR) should illuminate.
2.2

Use the associated program on the computer to upload a program which

generates an 8 MHz signal. An example program is provided in the Supplemental
files. After uploading the program, it will be stored into microprocessor memory
and will not need to be uploaded again.
2.3

Solder a 1” 22G wire to the end of each wire on the PZT transducer.

2.4

Connect the negative (black) terminal wire of PZT transducer to a GND pin

via the soldered wire.
2.5

Connect the positive (red) terminal wire of PZT transducer to the output pin

(#9 in the provided example program) via the soldered wire.
2.6

Optionally, mount the acoustofluidic device and the microcontroller in a 3D-

printed case. CAD files are provided in the Supplemental files as examples.
Additional wires can be connected to other microcontroller pins to control an
external LED indicator and on/off push button if desired.
2.7

Cut 3-6” sections of tygon PVC soft plastic tubing (1/16” ID, 1/8” OD) and

push the tubing into the inlet and outlet ports. It may be necessary to rotate the
tubing while applying pressure until it fits in the opening. Optionally, after inserting
the tubing into each port, glue can be applied at the junction to bond the PDMS
and tubing together.
2.8

Assemble microfluidic reservoir according to manufacturer’s instructions.

2.9

Cut a 3-6” section of tygon PVC soft plastic tubing (1/16” ID, 1/8” OD) and

push the tubing over the 1/32” ID tubing from the microfluidic reservoir output
tubing. Optionally, wrap the junction with parafilm to prevent leakage.
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2.10

Fill a 60-mL syringe with ambient air (optionally, filter the air with a 0.2-µm

filter and connect it to tygon PVC tubing (1/16” ID, 1/8” OD) on the side of the
microfluidic reservoir.
2.11

Set the syringe pump to a rate of 200 mL/hr to push the cell/ultrasound

contrast agent solutions through the acoustofluidic device at a volumetric flow rate
of 50 mL/hr and collect the samples from the output of the acoustofluidic device
into a 50-mL centrifuge tube. Optionally, rinse channel prior to acoustofluidic
treatment with 15 mL of 70% ethanol solution to increase sterility of fluidic
channels. Additionally, channels can be rinsed with 15 mL of deionized water to
remove residual ethanol in the device prior to pumping cells through the system.

3. Preparation of ultrasound contrast agents
NOTE: Ultrasound contrast agents significantly enhance acoustofluidic delivery of
molecular compounds by transiently increasing permeabilization of nearby cellular
membranes (Centner et al., 2020). Molecular delivery is very limited without
ultrasound contrast agents in this system.
3.1.

Prepare a phospholipid solution in a 20-mL scintillation vial containing the

following mixture:
3.1.1. Add 25 mg of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
3.1.2. Add 11.6 mg of 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC).
3.1.3. Add 0.26 mg of 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG).
3.1.4. Add 0.88 mg of polyoxyethylene 40 stearate.
3.2.

Add chloroform until all phospholipids are dissolved (e.g., 3 mL of
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chloroform).
3.3.

Evaporate chloroform in a desiccator for 48 hr to form a dry lipid film

(evaporation under argon or with a rotary evaporator can be used to accelerate the
drying process).
3.4.

Rehydrate the lipid film with 10 mL of sterile phosphate-buffered saline

(PBS).
3.5.

Sonicate the lipid solution for 3 min at 40% amplitude to form a cationic

micellar solution.
3.6.

After sonication store the phospholipid solution at 2-6 °C for up to 1 month.

3.7.

To prepare ultrasound contrast agents, add 200 µL of cationic micellar

solution and 600 µL of sterile PBS to a 2 mL glass septum vial.
3.8.

Seal the vial by crimping the cap.

3.9.

Use a 1.5” 20G needle to fill the vial head space with decafluorobutane gas

for 30 s.
3.10. Amalgamate the vial for 45 s at 4350 cpm to form perfluorobutane gas-filled
ultrasound contrast agents.
3.11. Add 25 µL of ultrasound contrast agent solution per 1 mL of cell solution
immediately before pumping the combined contrast agent/cell mixture through the
acoustofluidic device. The cell solution can be modified as desired by the user, but
in our studies the cell solution consisted of primary T cells in step 4.21, and A549
lung cancer cells in step 5.7, respectively.
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4. Preparation of primary T cells
4.1

Isolate peripheral blood mononuclear cells (PBMCs) from whole blood

solutions and store at -150 °C. Density gradient separation containing a substrate
is commonly utilized to separate PBMCs from whole blood.(Ulmer et al., 1984;
Jaatinen and Laine, 2007; Grievink et al., 2016)
4.2

Thaw frozen vial in 37 °C water bath.

4.3

Dilute thawed PBMCs 1:10 with PBS in a 15-mL centrifuge tube. Each 1-

mL vial contains approximately 10 million PMBCs.
4.4

Centrifuge diluted PMBCs at 580g for 11 min at 4 °C.

4.5

Aspirate supernatant and add 13 mL of MACs running buffer then

resuspend the cells.
4.6

Count the PMBCs with an automated cell counter or hemocytometer.

4.7

Centrifuge the PMBCs again at 580g for 11 min at 4 °C and aspirate the

supernatant.
4.8

Add 40 µL of chilled running buffer per 10 million PMBCs.

4.9

To isolate T cells, add 10 µL of Pan T-Cell Biotin Antibody Cocktail per 10

million PMBCs.
4.10

Gently agitate the PMBCs and store the solution at 4 °C for 5 min per 10

million cells.
4.11

Add 30 µL of running buffer and 20 µL of Pan T-Cell MicroBead Cocktail

per 10 million PMBCs.
4.12

Mix the PMBCs and beads thoroughly and incubate for an additional 15 min

at 4 °C.
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4.13

Add running buffer to reach a total volume of 500 µL.

4.14

Separate primary T cells with a commercially available benchtop magnetic

sorting instrument using the “depletes separation” setting following manufacturer’s
protocol. This step should yield between 5-10 million T cells after cell sorting.
4.15

Count T cells using an automated cell counter or hemocytometer.

4.16

Dilute T cells in 10 mL of sterile PBS and centrifuge at 580 x g for 10 min at

4 °C to pellet the cells.
4.17

Aspirate the supernatant and resuspend T cells in 1 mL of PBS.

4.18

Count T cells using an automated cell counter or hemocytometer and

aliquot 1 million/mL for experiments.
4.19

Prepare a 1 mg/mL fluorescein solution in PBS.

4.20

Add 100 µL of 1 mg/mL fluorescein solution per 1 mL of T cell solution (final

fluorescein concentration = 100 µg/mL) immediately prior to processing.
4.21

Add 25 µL of ultrasound contrast agent solution as previously described in

step 3.11.
4.22

Process 1-mL aliquots of cells using the acoustofluidic system (see steps

2.10-2.11). This step enhances delivery of fluorescein into primary T cells.
4.23

Immediately after treatment, wash cells three times via centrifugation at 580

x g for 10 min with 500 µL of PBS to remove extracellular fluorescein. Cells should
be washed within 10 min after adding fluorescein solution.
4.24

After final washing step, resuspend cells in 250 µL of PBS and measure

fluorescence on flow cytometer.
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5. Preparation of A549 lung cancer cells
5.1

Culture A549 (adenocarcinomic human alveolar basal epithelial) cells in

complete DMEM media (10% fetal bovine serum, 1% penicillin/streptomycin) at 37
°C and 5% CO2 in a flat-bottom tissue culture flask.
5.2

Harvest A549 cells when they reach 70-90% confluency. Aspirate media

from the flask and wash the cells once with PBS to remove serum proteins.
5.3

Add trypsin (0.25%) EDTA to the flask and incubate for 5 min at 37 °C.

Trypsin is a digestive enzyme which causes the cells to detach from the bottom
surface of the tissue culture flask.
5.4

Transfer trypsin solution to a 15-mL centrifuge tube and neutralize it by

adding complete DMEM media at a 1:3 ratio.
5.5

Pellet the cells via centrifugation at 1500 x g for 5 min at 4 °C.

5.6

Aspirate the supernatant and resuspend the pellet at a concentration of

100,000/mL in PBS solution containing 200 mM trehalose in 15-mL conical vial.
5.7

Add 25 µL of ultrasound contrast agent solution as previously described in

step 3.11.
5.8

Process 1-mL aliquots of cells using the acoustofluidic system (see steps

2.10-2.11). This step enhances delivery of trehalose into A549 lung cancer cells.
5.9

Immediately after treatment, wash cells three times via centrifugation with

500 µL of PBS to remove extracellular trehalose. Cells should be washed within
10 min after adding trehalose solution.
5.10

After final washing step, resuspend cells in 100 µL of PBS.

5.11

Add 11 µL of 1% Triton X-100 solution to lyse cells and release intracellular
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trehalose.
5.12

Vortex for 15 s, then incubate for 30 min at room temperature.

5.13

Vortex again for 15 s, then measure trehalose concentration using

commercially available trehalose assay following manufacturer’s recommendation.

II.3. Representative Results
An image of the acoustofluidic system assembled inside a 3D-printed case
is shown in Figure 2. This protocol produces an acoustofluidic system that can be
used to enhance intracellular molecular delivery in multiple cell lines using
ultrasound contrast agents.
Figure 3 demonstrates enhanced intracellular delivery of a fluorescent
compound, fluorescein, to primary human T cells with acoustofluidic treatment
compared to an untreated control group (p<0.05, n=3/group). T cells were
suspended at a concentration of 1 million/mL in PBS with 100 µg/mL fluorescein
solution and 25 µL/mL ultrasound contrast agent solution, and the mixture was
passed through the acoustofluidic device for ultrasound treatment. Intracellular
fluorescein delivery and cell viability were measured with flow cytometry after
washing cells via centrifugation to remove extracellular fluorescein. T cells in the
untreated control group were also suspended at 1 million/mL in PBS with 100
µg/mL fluorescein solution, but ultrasound contrast agent solution was not added,
and cells were not passed through the acoustofluidic device. The fluorescence
intensity of T cells increased by 5-fold after acoustofluidic treatment relative to the
fluorescence intensity of T cells in the untreated control group, indicating enhanced
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delivery of fluorescein. Cell viability decreased slightly after acoustofluidic
treatment but remained above 80% (p<0.05, n=3/group).
Figure 4 demonstrates enhanced intracellular delivery of a preservative
compound, trehalose, to human A549 lung carcinoma cells with acoustofluidic
treatment compared to flow alone (no ultrasound contrast agents or ultrasound
exposure) and compared to cells in the untreated control group (ANOVA p<0.05,
n=3/group). A549 cells were suspended at a concentration of 100,000/mL in PBS
with 200 mM trehalose solution and 25 µL/mL ultrasound contrast agent solution,
and the mixture was passed through the acoustofluidic device for ultrasound
treatment. A549 cells in the control groups (“Flow Only” and “No Treatment”) were
also suspended at 100,000/mL in PBS with 200 mM trehalose, but ultrasound
contrast agent solution was not added, and cells were not exposed to ultrasound
treatment. Intracellular trehalose was quantified using a trehalose assay kit and
normalized to the untreated control group. Cell viability was measured with trypan
blue assay. There was no statistical difference in cell viability between groups
(n=3-7/group).
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Figures and Table Legend

Figure 2: Photo of acoustofluidic system. The acoustofluidic flow system
contains a PDMS-based flow chamber with an integrated PZT transducer driven
by a microcontroller. A 3D-printed case with an LED indicator and on/off push
button are optional additional features.

Figure 3: Acoustofluidic treatment enhances fluorescein delivery to human
T cells. (A) Fluorescence intensity in primary T cells increased after acoustofluidic
treatment with fluorescein compared to the untreated control group (no
acoustofluidics and no and no microbubbles) (p<0.05, n=3/group). (B) Cell viability
decreased slightly after acoustofluidic treatment but remained above 80% as
measured by flow cytometry (p<0.05, n=3/group). (C) Representative flow
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cytometry histogram indicating higher fluorescence in the acoustofluidic treatment
group.

Figure 4: Acoustofluidic treatment enhances trehalose delivery to human
lung cancer cells. Trehalose uptake increased in A549 lung carcinoma cells
compared to flow only (no ultrasound and no microbubbles) and the untreated
control group (ANOVA p<0.05, n=3/group). (B) Cell viability remained above 90%
after acoustofluidic treatment as measured by trypan blue assay (n=3-7/group).

II.4. Discussion
This protocol describes the assembly and operation of a low-cost
acoustofluidic system which enhances intracellular delivery of biomolecules for
research applications. There are several important factors to consider when
assembling and operating this system. The acoustofluidic device is fabricated in
PDMS, which is a biocompatible material that can easily be molded with consistent
channel dimensions (Halldorsson et al., 2015). The device channels can be rinsed
with 15 mL of 70% ethanol solution prior to acoustofluidic processing in order to
increase sterility when working with cultured cells. Following ethanol cleaning, 15
mL of deionized water can be used to rinse the device to remove residual ethanol
from the channels prior to adding cell solutions. A limitation of this system is that
the small acoustofluidic channels can easily become blocked by debris or cell
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aggregates. Thoroughly rinsing channels between samples will help prevent
problems with channel blockage. In addition, PDMS devices can be fabricated in
batches and quickly replaced if needed. For ultrasound-based applications, it is
important to produce PDMS devices with a consistent thickness, as differences in
PDMS thickness can affect the ultrasound pressures within the fluidic channels.
Ultrasound waves propagate continuously through the device and transmitted
waves interact with reflected waves to form standing acoustic wave patterns that
are very sensitive to differences in PDMS thickness.(Shields et al., 2016) The
PDMS thickness is primarily determined by the amount of PDMS added to the mold
(step 1.7) and this protocol yields a PDMS thickness of 3.5 mm.
The maximum output frequency of the microcontroller (8 MHz) was selected
to produce the smallest acoustic wavelength within the fluidic channel. The
microcontroller output is typically a square wave, but oscilloscope measurements
revealed that the output at 8 MHz becomes more similar to a sinusoid waveform
due to slew rate limitations. A limitation of this system is that the maximum voltage
output of the microcontroller is 5V and an external RF amplifier is required if higher
voltage outputs are desired. The free-field pressure output of the transducer in this
system was 18 kPa at 1 cm as measured with a needle hydrophone (Precision
Acoustics, Dorchester, United Kingdom). Although this pressure is relatively low,
standing waves within the channels can increase the acoustic pressures which
samples are exposed to as they pass through the ultrasound beam. Operating
outside of resonance frequency (Versluis et al., 2020) and having a low ultrasound
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pressure output, an ultrasound contrast agent is ultimately required for molecular
delivery.
Ultrasound contrast agents are used to nucleate acoustic cavitation within
the acoustofluidic channels which enhances delivery of biomolecules across cell
membranes (Hu et al., 2013a; Helfield et al., 2016b). This protocol describes
synthesis of perfluorocarbon gas-filled microbubbles encapsulated by a cationic
phospholipid membrane. As previously described, this formulation consists of
microbubbles primarily between 1-3 µm in diameter (Kopechek et al., 2015). The
positively charged surface of the microbubbles attracts them toward negativelycharged cell membranes, which increases sonoporation-mediated molecular
delivery when the microbubbles and cells are in close proximity. The concentration
of microbubbles in the cell solution is a critical factor that can influence the
efficiency of molecular delivery and cell viability after acoustofluidic treatment, and
the optimal microbubble concentration may be specific to each cell type (Centner
et al., 2020). The concentration of gas-filled microbubbles with a lipid shell can
decrease over time after synthesis so ultrasound contrast agents should be used
within a few hours after synthesis.
We demonstrated delivery of a fluorescent compound (fluorescein) to
primary non-activated human T cells using the acoustofluidic system in this
protocol. It is important to note that the activation status of primary human T cells
may affect the efficiency of intracellular molecular delivery. The fluorescence
properties of fluorescein enable sensitive intracellular detection with flow
cytometry, but other soluble compounds can also be delivered into cells using this
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acoustofluidic system. For example, we demonstrated acoustofluidic delivery of
trehalose into human lung cancer cells. Acoustofluidic delivery of trehalose into
cells may enable increased recovery after frozen and dry storage, which could
have significant impacts on a range of biomedical and research applications
(Centner et al., 2020).
Acoustofluidic delivery of other biomolecules, such as proteins or DNA
plasmids, is also possible, although a limitation of this system is that the efficiency
of molecular delivery may be lower for larger compounds (Bhutto et al., 2018;
Belling et al., 2020b). Furthermore, a change in ultrasound frequency should be
considered to match the resonance frequency of microbubbles as this may also
influence molecular delivery efficiency. Optimization of ultrasound pressure,
acoustofluidic flow rate, concentrations of ultrasound contrast agents, cell
concentrations, and media may be needed for delivery of other biomolecules. In
addition, optimal parameters may vary between different cell types due to factors
such as cell diameter, morphology, membrane properties, and other phenotypic
properties.
The acoustofluidic system described in this protocol can be easily
assembled and operated at relatively low cost. Additionally, this system can be
customized for other applications by connecting other signal sources or ultrasound
transducers to generate specific output pressures and frequencies (Miller et al.,
1999; Forbes et al., 2011; Helfield et al., 2016c). In addition, the syringe pump
system described in this protocol can be replaced with peristaltic pumps if desired.
At a flow rate of 50 mL/hr the residence time for cells within the ultrasound beam
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as they pass through the acoustofluidic channel is approximately 1 s, but this
residence time can be modified as needed for specific applications by adjusting
the fluid flow rate.
Unlike other common transfection techniques, biomolecules can be
delivered into cells within minutes instead of hours and this system does not
require specialized and expensive equipment. In addition, this system is
compatible with a wide range of commonly used cell culture media or other buffers.
In summary, this acoustofluidic system enables rapid delivery of biomolecules to
cells, which may be useful for a wide range of research applications.
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CHAPTER III – ULTRASOUND-INDUCED
MOLECULAR DELIVERY TO
ERYTHROCYTES USING A MICROFLUIDIC
SYSTEM

2

2

Sections of text and figures in this chapter are reproduced from the following
reference:
Connor S. Centner*, Emily M. Murphy*, Mariah C. Priddy, John T. Moore, Brett R.
Janis, Michael A. Menze, Andrew P. DeFilippis, Jonathan A. Kopechek,
“Ultrasound-induced molecular delivery to erythrocytes using a microfluidic
system,” Biomicrofluidics 14(2):024114 (2020). Reprinted with permission of
American Institute of Physics.
* indicates co-1st author
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III.1. Introduction
Blood transfusions are one of the most common medical procedures
performed in U.S. hospitals (Pfuntner et al., 2006). Current FDA-approved storage
methods for erythrocytes require refrigeration at 1-6 °C for up to 42 days before
blood units expire due to detrimental storage effects on morphological and
biochemical properties (“storage lesions”) (Bunn et al., 1969; Haradin et al., 1969;
Greenwalt et al., 1990; Izzo et al., 1999). The limited shelf-life of refrigerated
erythrocytes can lead to shortages in supply (Nightingale et al., 2003; Shi et al.,
2014), especially when donations decrease due to natural disasters or other
factors. Less common techniques for long-term storage include freezing at -80 °C,
allowing erythrocytes to be stored for up to 10 years. However, freezing
erythrocytes requires a complex and sensitive glycerol-loading process that is
time-consuming and poses challenges in cases where blood transfusions are
required quickly. Significant research efforts have attempted to develop artificial
blood substitutes but these products have failed clinical trials (Chen et al., 2009)
and no artificial blood substitutes are currently approved for routine clinical use
(Silverman and Weiskopf, 2009). As an alternative approach to hemoglobin-based
artificial blood substitutes, recent efforts have focused on generating stem cellderived erythrocytes (Shah et al., 2014). These products are entering clinical trials
and potentially offer a new source of erythrocytes for clinical application. However,
stem cell-derived erythrocytes face similar challenges as described above —
limited shelf-life and thermal stability. Alternatively, an approach to store
erythrocytes in a dried state at ambient temperatures would reduce cell membrane
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oxidation and storage lesion, thereby increasing the shelf-life. In addition, dry
preservation of erythrocytes would enable blood transfusions in locations where it
is not currently feasible or extremely challenging, including remote medical
centers, far forward military operations, and long-duration space missions.
Therefore, there is a significant need for an effective and inexpensive method to
store erythrocytes at ambient temperatures for extended periods of time without
refrigeration or freezing.
A wide variety of organisms in
nature, including tardigrades (“water
bears”)

and

monkeys”),
(“cryobiosis”)

brine
can

shrimp

survive
and

(“sea

MB
Rupture

freezing
desiccation

(“anhydrobiosis”) for decades or longer
before returning to normal physiological
function after thawing or rehydration
(Hengherr et al., 2009; Crowe et al., Figure 5: Illustration of ultrasoundinduced microbubble (MB) rupture
2011; Tsujimoto et al., 2016). Given that leading to transient perforation of cell
membranes — enabling enhanced
entire
organisms
can
survive intracellular delivery of soluble
compounds such as trehalose (not to
desiccation, it seems plausible that scale).
erythrocytes could also be preserved in
this manner. The fact that erythrocytes lack nuclei and other organelles, such as
mitochondria, would suggest that dry-preservation may be even more feasible than
for more complex nucleated cells. Organisms that have developed the ability to
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survive desiccation generally produce various protective compounds, such as late
embryogenesis abundant proteins and the non-reducing sugar trehalose, to
stabilize cellular structures during the freezing and drying process. Trehalose is
biocompatible and already used in vaccines and food products (Patist and Zoerb,
2005). However, high levels of trehalose (~100 mM) are required intracellularly
and mammalian cells lack transporters for this sugar. Therefore, an effective
method is required to load mammalian cells with preservative compounds for
desiccation (Crowe et al., 2005). Prior approaches have focused on passive
loading of erythrocytes, platelets, or other mammalian cells via endocytosis,
genetically engineered pores, or electroporation (Eroglu et al., 2000; Shirakashi et
al., 2002; Satpathy et al., 2004; Zhou et al., 2010; Arav and Natan, 2012;
Fitzpatrick et al., 2013). These studies demonstrated that intracellular trehalose
could protect some mammalian cells during drying and rehydration, but
intracellular loading either required a long process (7+ hours) at 37 °C which
increases susceptibility to oxidative damage and reduces cell viability (Kanias and
Acker, 2009), or the throughput was low and inefficient. An alternative loading
approach by ectopically expressing trehalose transporters in mammalian cells to
facilitate uptake showed promise but scale-up of this approach to large numbers
of cells is very challenging (Kikawada et al., 2007; Chakraborty et al., 2012; Uchida
et al., 2017).
To address these limitations, our group is developing a novel approach to
preserve erythrocytes with protective compounds, such as trehalose, by utilizing
ultrasound and microbubbles to induce transient pore formation in cellular

36

membranes, or “sonoporation” (Figure 5). Sonoporation can occur due to inertial
cavitation when ultrasound waves at sufficient pressure amplitudes induce rapid
collapse of microbubbles proximal to the cell membranes and transiently perforate
the cell membrane enabling rapid uptake of molecular compounds (Fan et al.,
2014b). The pores in the cell membrane typically seal quickly in an active repair
process influenced by factors such as pore size and Ca2+ concentration (Feril et
al., 2006; Kudo et al., 2009; Kumon et al., 2009; Hassan et al., 2010; Crowe et al.,
2011). Thus, this approach can potentially enable rapid loading of compounds into
cells with higher efficiency and viability compared to other methods that are solely
dependent on endocytosis and/or passive diffusion (Feril et al., 2006).
Furthermore, microbubbles are approved for clinical use as intravenous ultrasound
contrast agents to image cardiac blood flow (Villanueva, 2010). Ultrasound and
microbubbles are also in development for targeted gene and drug delivery
applications, including delivery of trehalose into platelets (Hernot and Klibanov,
2008; Zhang et al., 2009; Kopechek et al., 2015; Kopechek et al., 2019).
Consistent intracellular delivery of trehalose is fundamental to preservation
of cells in a desiccated state and variability in trehalose delivery may cause
reduced recovery of viable erythrocytes after drying and rehydration. To address
this need for homogeneous compound delivery we have developed a microfluidic
system for cell processing and molecular loading which utilizes submillimeter
channels that enable consistent flow with a homogeneous mixture of erythrocytes,
molecular compounds dispersed in solution, and microbubbles during ultrasound
exposure. The utilization of biomicrofluidics technologies for cell processing and
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analysis is rapidly expanding due to the microscale manipulation capabilities. It is
being studied extensively for its applications towards single-cell analysis and
measurement, microscale biophysics and biochemistry manipulation, and tissue
engineering. Previous studies have explored molecular delivery to cells through
small microfluidic channels without ultrasound treatment (Wang et al., 2008). The
use of ultrasound-integrated biomicrofluidics (“acoustofluidics”) for intracellular
molecular delivery is a rapidly growing topic of interest to address current
challenges in cell transfection efficiency (Carugo et al., 2011; Bose et al., 2015).
In this study we have characterized an acoustofluidic system designed to enable
more consistent ultrasound and microbubble exposure of each erythrocyte
compared to bulk treatment approaches, thereby leading to increased consistency
of ultrasound-mediated molecular delivery.
The objective of this study was to assess the role of various ultrasound and
flow parameters on the efficiency of molecular delivery into erythrocytes using an
ultrasound-integrated polydimethylsiloxane (PDMS)-based microfluidic device.
Although sonoporation and ultrasound-mediated molecular delivery to cells is a
well-established phenomenon, this study utilizes a novel acoustofluidic setup to
demonstrate the efficacy of loading erythrocytes with molecular compounds via
sonoporation for dry preservation. In addition, this study yields new insights into
the effects of various parameters on the efficiency of intracellular loading in an
acoustofluidic system. We assessed the delivery efficiency of a fluorescent
compound (fluorescein), which can be readily detected intracellularly with flow
cytometry. Various ultrasound pressures, ultrasound pulse intervals, microbubbles

38

doses, and microfluidic flow rates were tested in order to determine the effect of
each parameter. In addition, we also assessed the recovery of erythrocytes after
freeze-drying and rehydration following trehalose loading with the ultrasoundintegrated microfluidic system. These results aim to provide new knowledge
toward optimization of ultrasound-mediated molecular delivery to cells in a
microfluidic system for preservation of erythrocytes or other applications.

III.2. Methods
III.2.1. Acoustofluidic device design and fabrication
Acoustofluidic devices were designed using a concentric spiral in order to
maximize the time that erythrocytes were exposed to ultrasound pulses. A channel
width of 200 μm and height of 180 μm were designed to reduce shear stress on
erythrocytes while increasing time spent within the ultrasound beam. Microfluidic
devices were fabricated using standard photolithography techniques at the
University of Louisville Micro/Nano Technology Center. A photomask was printed
with a UV laser patterning system (DWL 66FS, Heidelberg Instruments,
Heidelberg, Germany). SU-8 photoresist (MicroChem, Westborough, MA, USA)
was spin-coated at a thickness of 200 μm on a 4” silicon wafer and cross-linked
using a mask aligner (MA6/BA6, Suss, Garching, Germany) to form the master,
followed by silane treatment. PDMS was obtained from Ellsworth Adhesives
(Sylgard 184 Silicone Elastomer Kit, Germantown, WI, USA). A 10:1 mixture of
base to curing agent was combined until a net weight of 66 grams was reached.
Air bubbles were removed by vacuum for 30 min and the PDMS was pored over
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the SU-8 master in a 150 mm petri dish. The PDMS was cured for 2 h at 60 °C.
Input and output ports were cut in the PDMS using a 2.5 mm biopsy puncher
(Harris Uni-Core) and the PDMS devices were immediately bonded onto glass
microscope slides after oxygen plasma treatment (100V for 60s, 500 mbar O2, Axic
HF-8 plasma asher, Gardnerville, NV, USA). To set up the microfluidic device for
experiments, the device was held with clamps and ring stands at the surface of a
water-filled 20-gallon aquarium tank. A segment of Tygon PVC clear tubing (1/16”
ID, 1/8” OD, McMaster-Carr, Aurora, OH, USA) was inserted into the inlet and
outlet ports of the device. The inlet tubing was connected to a 3-way valve. One
valve was connected to a syringe filled with the erythrocyte solution on a syringe
pump (NE-300, Farmingdale, NY, USA). The other valve was connected to a
phosphate buffered saline (PBS) solution on a separate syringe pump to push any
remaining erythrocyte sample through the tubing. The outlet tubing was connected
to another 3-way valve to allow sample collection and waste collection into 15-mL
centrifuge tubes (Figure 6).
A

B

C

200 µm

10 mm

Peak Negative Pressure (kPa)

1000
900
800
700
600
500
400
300

200
100
0
-4

-3

-2

-1

0

1

2

3

4

Transverse Distance (mm)

Figure 6: (A) Top: Microfluidic device design with 200 μm channel width. Bottom:
a photo of one of the microfluidic devices. (B) Schematic of experimental setup
(Not to scale). (C) Top: Ultrasound waveform transmitted by the ultrasound probe
(ATL P4-1). Bottom: Transverse profile of the ultrasound beam (-3 dB beamwidth
= ~5 mm).
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III.2.2. Microbubble synthesis
Ultrasound-responsive gas-filled microbubbles were synthesized to
enhance intracellular delivery of molecular compounds to erythrocytes.
Microbubbles were composed of a perfluorocarbon gas core encapsulated by a
phospholipid shell as previously described (Bhutto et al., 2018). Chloroform
solutions of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti Lipids,
Alabaster, AL, USA); 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC,
Avanti Lipids); 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG, Avanti Lipids);
and polyethylene glycol-40 stearate (Sigma-Aldrich, St. Louis, MO, USA) at the
molar ratio of 100:43:1:4.5 were dried with argon gas. An aqueous micellar lipid
solution was prepared by adding PBS and sonicating (Qsonica, Newtown, CT,
USA) to disperse the lipids. The resulting 10 mg/mL lipid solution was diluted 1:4
in PBS and sealed in a glass vial. The vial head space was filled with
decafluorobutane gas (FlouroMed, Round Rock, TX, USA), followed by
amalgamation for 30 s at 4350 cpm (DB-338, COXO, Foshan City, China) to form
perfluorobutane gas-filled microbubbles (MBs). This process yields microbubbles
with a mean diameter of 2 ± 1 µm as previously described (Kopechek et al., 2015;
Kopechek et al., 2016).

III.2.3. Fluorescein delivery to erythrocytes
Human erythrocytes were obtained from de-identified clinical blood samples
following protocols approved by the Institutional Review Board and stored in
citrate-phosphate-dextrose (CPD) solution with additive solution 1 (AS-1) at 4 °C
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for up to 35 days after collection (Simon et al., 2016). A P4-1 ultrasound transducer
with 96 elements (ATL, Bothell, WA, USA) on an ultrasound imaging system
(Vantage 64LE, Verasonics, Kirkland, WA, USA) was placed inside the water tank
below the microfluidic device and the ultrasound focus was aligned to the center
of the microfluidic device at a distance of 40 mm. Ultrasound pulses were
transmitted in flash mode by triggering all 96 elements of the ultrasound transducer
array at the same time.
The stock erythrocyte solution was diluted with PBS to 5 million cells/mL in
presence of 100 µg/mL fluorescein. Microbubbles were added shortly before
running each sample through the acoustofluidic device. After treatment, each
sample was washed 3X via centrifugation with 1 mL of PBS to remove extracellular
fluorescein prior to flow cytometry. Samples were stored on ice prior to analysis.
Flow cytometry was performed using a MACSQuant Analyzer 10 (Miltenyi
Biotec, Auburn, CA, USA) with 10,000 events recorded per sample. Data were
analyzed using FlowJo (Ashland, OR, USA). The mean fluorescence in the FITC
channel was calculated after gating the populations on forward and side scatter
plots. In addition, fluorescence microscopy images of erythrocytes were acquired
with a 40X objective on an EVOS cell imaging system (American Microscopy
Group, Mill Creek, Washington, USA).

III.2.4. Ultrasound image analysis of microbubble destruction
Ultrasound imaging was used to assess the rate of microbubble destruction
at different ultrasound pressures. Microbubbles were imaged using B-mode
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ultrasound with a Verasonics Vantage system (ATL P4-1 probe, 2.5 MHz center
frequency). A region of interest (ROI) was selected and the mean grayscale
intensity was computed using MATLAB to determine the change in contrast over
time due to loss of echogenicity/microbubble destruction at different ultrasound
pressures (0.5 – 1.3 MPa).

III.2.5. Recovery and viability of erythrocytes after freeze-drying and rehydration
The stock cell solution was diluted 40X in PBS with trehalose dissolved at
a concentration of 200 mM. Microbubbles (2 %v/v) were added shortly before
running the sample through the microfluidic device. After trehalose loading in the
device, the samples were transferred to cryovials and frozen to -80 °C at a rate of
-1 °C/min using a CoolCell container (Biocision, San Rafael, CA, USA). After
storage for a minimum of 24 h at -80 °C, samples were quickly transferred to a
lyophilizer (BenchTop 4K, VirTis, Los Angeles, CA, USA) and placed under
vacuum below 300 mTorr for at least 48 h. After freeze-drying, samples were
stored at room temperature for 24 h and rehydrated with 0.5 mL of deionized water.
Recovery of erythrocytes after rehydration was determined by counting cells on a
hemocytometer. Esterase activity was used as a proximate for erythrocyte viability
and determined via flow cytometry using a calcein-AM (Sigma-Aldrich) viability
assay.
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III.2.6. Statistical analysis
Statistical analysis was conducted using Minitab 19 (State College, PA,
USA). Statistical comparisons between groups were determined using ANOVA
with statistical significance defined as p<0.05 (two-tailed). Post-hoc analysis was
performed using Tukey’s test for one-way ANOVA. Bars represent mean ±
standard deviations.

III.3. Results
III.3.1. Effect of ultrasound and flow parameters on erythrocyte viability
Viability of erythrocytes was assessed using flow cytometry after treatment
with various ultrasound and flow parameters (Figure 7). A representative flow
cytometry scatter plot is shown in Figure 7A indicating the gating used to determine
erythrocyte viability. There was high viability in all groups (>80%) with no
statistically significant differences between different ultrasound pressures or
different pulse intervals. A statistically significant decrease in viability was
observed at the highest microbubble dose tested (9% v/v, ANOVA p < 0.05) and
also at a microfluidic flow rate of 20 mL/h (p < 0.05), but viability remained above
80% in those groups.
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Figure 7: (A) Representative flow cytometry scatter plot with the gate used to
detect viable erythrocytes based on forward and side scatter profiles. High
viability of erythrocytes was observed at (B) different microbubble
concentrations, (C) different acoustic pressures, (D) different pulse intervals, and
(E) different microfluidic flow rates. Statistically significant decreases in viability
were detected at a microbubble dose of 9% (ANOVA p < 0.05) and with
ultrasound treatment at a microfluidic flow rate of 20 mL/h (p < 0.05) compared
to the no ultrasound control groups.

III.3.2. Effect of ultrasound and flow parameters on fluorescein delivery into
erythrocytes
Ultrasound-mediated intracellular delivery of fluorescein to erythrocytes
was evaluated at various microbubble concentrations in PBS (%v/v) as measured
by flow cytometry post-treatment. There was a trend toward a statistically
significant difference in fluorescein uptake at a microbubble dose of 2% compared
to the control group which passed through the microfluidic device without
ultrasound or microbubbles (Figure 8A, n=4, ANOVA p=0.12).
Intracellular delivery of fluorescein to erythrocytes at varying ultrasound
pressures was assessed by flow cytometry. Since a microbubble dose of 2 %v/v
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yielded the highest amount of fluorescein delivery as shown in Figure 8, the effect
of peak negative pressure on loading efficiency was examined at this
concentration. Ultrasound treatment enhanced intracellular delivery by up to 73 ±
37% compared to no ultrasound (ANOVA p<0.05). Tukey’s test indicated
statistically significant differences in intracellular delivery between the control
group (0 MPa) and ultrasound pressures of 0.5 MPa or 0.9 MPa (Figure 8B).
The impact of pulse intervals on compound delivery was investigated and
ultrasound-mediated intracellular delivery of fluorescein was assessed at pulse
intervals ranging from 0.1-10 ms. No statistical differences in fluorescein delivery,
as measured by flow cytometry, were detected between different pulse intervals
(Figure 8C, p>0.05, n=3-4/group).
Another factor that can impact the efficiency of ultrasound-mediated
molecular delivery is the time that cells are exposed to ultrasound waves, which
directly correlates with the flow rate through the microfluidic device. Therefore,
ultrasound-mediated intracellular delivery of fluorescein was examined at varying
mean flow rates with or without ultrasound treatment. No statistically significant
differences in fluorescein delivery were observed at different flow rates without
ultrasound. On the other hand, ultrasound treatment enhanced intracellular
delivery of fluorescein by up to 44 ± 33% to erythrocytes at mean flow rates of 20
mL/hr and 30 mL/hr compared to no ultrasound groups, but not at a higher mean
flow rate of 40 mL/hr (Figure 8D, p< 0.05, n=5/group). In addition, ultrasound
treatment at a microfluidic flow rate of 20 mL/hr enhanced fluorescein delivery by
40 ± 32% compared to ultrasound treatment at a flow rate of 30 mL/hr.
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Representative flow cytometry histograms are shown in Figure 9A which
demonstrate the increase in fluorescence intensity of erythrocytes after fluorescein
delivery at ultrasound pressures up to 0.9 MPa. In addition, a representative
fluorescence microscopy image demonstrates enhanced fluorescence of the
erythrocyte after ultrasound-mediated loading with fluorescein (Figure 9B). The
fluorescence intensity of erythrocytes increased slightly 30 minutes and remained
relatively constant up to 60 minutes after treatment, suggesting that leakage was
minimal in that time frame (Figure 9C).
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Figure 8: (A) Effect of microbubble concentrations on ultrasound-mediated
fluorescein uptake. There was a trend toward statistical significance (ANOVA p=0.12,
n=4/group). (B) Effect of peak negative acoustic pressure on ultrasound-mediated
fluorescein uptake. There were statistically significant differences with ultrasound
pressures at 0.5 and 0.9 MPa compared to the 0 MPa (no ultrasound) control group
(ANOVA p = 0.01, n=4-7/group). (C) Effect of pulse interval on ultrasound-mediated
fluorescein uptake. There were no statistically significant differences between the
different pulse intervals (n=4-5/group). (D) Effect of microfluidic flow rate on
ultrasound-mediated fluorescein uptake. Ultrasound treatment and flow rate effect
fluorescein uptake, respectively (p < 0.05, n=5/group).
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Figure 9: (A) Representative fluorescence intensity histograms after ultrasound
treatment at peak negative pressures of 0.25 MPa, 0.5 MPa, 0.9 MPa, or no
ultrasound (negative control). Fluorescence intensity increased up to peak
negative acoustic pressures of 0.9 MPa indicating enhance molecular delivery
to erythrocytes. (B) Representative fluorescence microscopy image of an
erythrocyte after ultrasound treatment at a peak negative acoustic pressure of
0.9 MPa demonstrating fluorescein delivery (scale bar = 5 µm). (C) Fluorescence
intensity of erythrocytes over time after fluorescein treatment as measured by
flow cytometry, indicating no significant difference over time (n=3/group).
III.3.3. Ultrasound Image Analysis of Microbubble Destruction
Ultrasound contrast images were acquired and analyzed to assess the
effect of ultrasound pressure on microbubble destruction (Figure 10). At lower
acoustic pressures (0.5 MPa and 0.9 MPa) there was only a small decrease in
contrast (less than 10%) after 30 seconds of ultrasound exposure, indicating
minimal microbubble destruction. However, at a higher ultrasound pressure (1.3
MPa) ultrasound image contrast decreased rapidly by over 25% within 30 seconds
of ultrasound exposure, indicating a higher rate of microbubble destruction. These
results suggest that there is a pressure threshold between 0.9 MPa and 1.3 MPa
at which there is a notable increase in the rate of microbubble destruction and this
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could potentially have effects on the efficiency of molecular delivery at different
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Figure 10: Ultrasound image mean grayscale intensity as a function of time at peak
negative acoustic pressures of 0.5 MPa, 0.9 MPa, and 1.3 MPa. At higher pressures
(1.3 MPa), the mean grayscale value decreases more rapidly indicating higher rates of
microbubble destruction compared to lower pressures (0.5 MPa and 0.9 MPa).
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III.3.4. Recovery and viability of erythrocytes after freeze-drying and rehydration
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Figure 11: Number of intact viable erythrocytes
freeze-drying
and
rehydration.
microbubbles were loaded in following
Microfluidic ultrasound treatment with trehalose
PBS solution and ultrasound caused a statistically significant increase in recovery
of intact viable cells compared to the control groups
was applied to induce (p<0.05, n=4-8/group).
sonoporation prior to freeze-drying and rehydration, compared samples with no
trehalose and/or no ultrasound treatment (Figure 11, p<0.05, n=4-8/group).

III.4. Discussion
The development of acoustofluidics technologies is rapidly growing for a
wide variety of applications (Antfolk et al., 2015; Bose et al., 2015; Lajoinie et al.,
2016; Pereno et al., 2018; Li and Huang, 2019). In this study, acoustofluidic
devices were designed to enhance ultrasound-mediated molecular delivery to
human erythrocytes. An ultrasound transducer array was used with the PDMSbased microfluidic device placed at the focal distance in order to expose cells to a
relatively uniform ultrasound beam and induce transient sonoporation for rapid
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molecular delivery. In addition, a concentric spiral design was used for the
microfluidic channels in order to maximize the time that erythrocytes were exposed
to ultrasound waves as the cells passed through the channels. Using this
acoustofluidic system, ultrasound-mediated intracellular delivery can be achieved
in small samples within minutes. Larger volumes can also be processed rapidly by
parallelizing the acoustofluidic systems.
The results of this study demonstrate for the first time that ultrasound and
microbubbles enhance molecular delivery to erythrocytes in a microfluidic device
when the ultrasound pressure and microfluidic flow rate are optimized. These
findings represent an early step toward development of optimized methods to
produce dried blood for long-term storage at ambient temperatures. The
experimental findings in this study demonstrate that several key parameters in the
ultrasonic flow system have significant effects on the efficiency of intracellular
molecular delivery using an acoustofluidic approach, including acoustic pressure
and microfluidic flow rate. At the same time, viability remained high (>80%) for all
parameters tested in this study. We conducted initial studies with fluorescein,
which has a similar molecular weight as trehalose (332 Da for fluorescein and 342
Da for trehalose). Fluorescein was tested due to its fluorescent properties that
enable precise intracellular detection via flow cytometry.
In this study, there was a trend toward a statistically significant difference
between microbubble doses (Figure 8A), with the highest fluorescein uptake
detected at a microbubble dose of 2% v/v. Lower microbubbles doses will cause
lower levels of sonoporation resulting in reduced intracellular delivery, while higher
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microbubble doses can cause “shadowing” effects due to scattering and
attenuation of ultrasound waves, resulting in reduced ultrasound pressures within
part of the sample which also limits intracellular delivery. Thus, there is an optimal
“therapeutic window” for the range of microbubble doses which enhance
intracellular molecular delivery to cells.
The effects of ultrasound pressure and pulse interval on intracellular
delivery of molecular compounds have been described in previous studies using a
bulk treatment approach, but acoustofluidic-mediated molecular delivery to
erythrocytes has not been previously investigated (Sennoga et al., 2017; Bhutto et
al., 2018). In this study, a statistically significant increase in fluorescence was
observed at peak negative pressures of 0.5 MPa and 0.9 MPa compared to the no
ultrasound control group (Figure 8B and Figure 9). These results indicate that 0.5
MPa and 0.9 MPa induced significant sonoporation and enhanced intracellular
delivery of fluorescein as erythrocytes passed through the acoustofluidic channels.
Interestingly, higher acoustic pressures (1.3 MPa and 1.8 MPa) were less effective
at enhancing molecular delivery. Although this result was not initially expected, it
is consistent with other previous studies which found that sustained microbubble
cavitation was more effective at inducing therapeutic effects compared to rapid
microbubble destruction caused by inertial cavitation (Datta et al., 2006; Gourevich
et al., 2015; Sun et al., 2017a). It’s important to consider that biological properties
may have important implications on molecular delivery. Thus, these results may
not directly translate to nucleated cells, such as T cells. Furthermore, analysis of
ultrasound image contrast from microbubbles exposed to different ultrasound
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pressures suggests a possible inverse correlation between the rate of microbubble
destruction and fluorescein delivery, where decreased rates of microbubble
destruction at lower acoustic pressures (0.5 MPa and 0.9 MPa) were associated
with higher levels of fluorescein delivery compared to higher acoustic pressures.
Additionally, the effect of ultrasound pulse interval was investigated but no
statistically significant difference in fluorescence was observed between each
pulse interval that was tested (Figure 8C). This suggests that differences in
ultrasound pulse intervals in the range of 0.1 – 10 ms are not a significant factor in
molecular delivery. However, very short pulse intervals or higher duty cycles were
not tested in this study and may have a more significant impact on molecular
delivery. Other studies which used a static bulk treatment approach have reported
that ultrasound duty cycle can influence the efficiency of molecular delivery to
cultured cells, and it is likely that a wider range of pulse intervals and duty cycles
in acoustofluidic devices would cause differences in intracellular delivery as well
(Marin et al., 2001; Rahim et al., 2006).
The results of this study also indicate that the microfluidic flow rate is an
important parameter that affects the efficiency of ultrasound-mediated molecular
delivery to erythrocytes. Interestingly, the fluorescence intensity at 40 mL/hr was
actually higher without ultrasound compared to the ultrasound treated group (p <
0.05). This finding was unexpected and the mechanism is not fully understood,
although it is likely due to a combination of multiple separate factors. Shear forces
on the cells are higher at increased flow rates, so as the flow rate increases and
shear forces become more significant the permeability of the cells increases and
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passive fluorescein uptake is greater, even without ultrasound. When ultrasound
is present the microbubbles surround the cell membrane and may potentially have
a shielding effect on shear forces in the surrounding fluid. On the other hand, the
high flow rates reduce the amount of time that erythrocyte are exposed to
ultrasound as they flow through the channels, which also limits fluorescein uptake.
Cell-microbubble interaction likely requires further investigation to understand the
effect that microbubble surface charge has on molecular delivery. Residence time
in the acoustofluidic device is likely a fundamental parameter, especially with
pulsed ultrasound. These effects could potentially explain the results observed at
a higher flow rate of 40 mL/hr. Relatively low flow rates were used in the concentric
spiral acoustofluidic system for two reasons: (1) to increase the number of
ultrasound pulses that each cell experiences as it passes through the microfluidic
channels, and (2) to reduce shear stress on cells in the microfluidic channels. If
the flow rate is too high some cells could pass through the entire microfluidic
chamber between each ultrasound pulse. Additionally, high flow rates can increase
fluid pressures within the channels and cause failure of the PDMS-bonded devices.
Freeze-drying is a low temperature dehydration process that involves the
removal of ice through sublimation to allow product storage in a desiccated state.
Intracellular delivery of trehalose is critical for cell preservation in a desiccated
state and freeze-drying erythrocytes without trehalose or with only extracellular
trehalose

(without

ultrasound-induced

sonoporation

to

load

trehalose

intracellularly) yielded low recovery of intact, viable erythrocytes compared to
acoustofluidic treatment (Figure 11). This indicates that flowing erythrocytes
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through the microfluidic channels alone without ultrasound exposure does not
induce sufficient uptake of trehalose to confer protection during freeze-drying.
However, ultrasound exposure of erythrocytes with trehalose in the microfluidic
system significantly increased recovery of intact and viable erythrocytes after
freeze-drying and rehydration (Figure 11). This finding suggests that optimized
acoustofluidic parameters can enhance intracellular trehalose delivery which is
required for successful recovery of viable erythrocytes after freeze-drying.
This study explored ultrasound-enhanced delivery of small molecules (i.e.,
fluorescein and trehalose). Larger molecules can also be delivered intracellularly
using sonoporation but the uptake efficiency is decreased as we have previously
described (Bhutto et al., 2018). There are two important limitations to results of this
study. The recovery of erythrocytes after freeze-drying and rehydration was less
than 5% even after acoustofluidic-mediated trehalose loading. Further optimization
of the freezing and drying process is needed and additional improvements in
acoustofluidic techniques are also possible. In addition, other trehalose
concentrations can be tested to determine if a higher trehalose concentration
would increase trehalose delivery and erythrocyte recovery after freeze-drying and
rehydration. The optimal trehalose concentration will be within a specific
“therapeutic window.” If the extracellular trehalose concentration is too low the
amount of delivery will not be sufficient to protect cells during drying and
rehydration, but if the extracellular trehalose concentration is too high there would
be significant osmotic stress and damage to the cells. Our study used a trehalose
concentration of 200 mM based on previous studies in brine shrimp that survive

56

drying and rehydration with trehalose at these levels (Crowe et al., 2005; Hand
and Menze, 2015), but further optimization of the trehalose concentration may be
needed for ultrasound-mediated loading. Another limitation of this study is the low
erythrocyte concentration (5 million/mL), which was significantly lower than the
typical concentration in whole blood (~5 billion/mL). Further studies will need to
assess the feasibility of acoustofluidic molecular delivery at high concentrations.
An alternative approach could involve concentrating erythrocytes via centrifugation
after trehalose loading if required. Despite these limitations, the results of this study
still represent important steps toward addressing the challenges of effective
intracellular trehalose delivery into erythrocytes.
These results demonstrate that an acoustofluidic approach can significantly
enhance intracellular molecular delivery and increase recovery of viable, intact
erythrocytes after freeze-drying and rehydration. Dry storage of erythrocytes could
have a fundamental impact in transfusion medicine, particularly in austere
environments, air ambulance operations, remote medical centers, and longduration space missions. Further studies will need to assess optimal microfluidic
designs and other parameters (e.g., ultrasound frequency, cell concentration,
trehalose concentration, etc.) in order to further enhance intracellular trehalose
delivery to erythrocytes for dry preservation. This acoustofluidic system is a
platform technology which may also have utility for molecular delivery to other cell
types such as platelets, immune cells, and stem cells. The optimal acoustofluidic
parameters may be different for each cell type but it is expected that general trends
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will be similar and ultrasound pressure and microfluidic flow rates will be critical
factors for enhanced intracellular molecular delivery.

III.5. Conclusions
The results of this study demonstrate the feasibility of an acoustofluidic
approach to rapidly load human erythrocytes with molecular compounds. Key
parameters that affect the efficiency of intracellular delivery include the ultrasound
pressure level and the microfluidic flow rate. Acoustofluidic delivery of trehalose
into erythrocytes increased the recovery of intact, viable cells after freeze-drying
and rehydration. Further optimization to increase erythrocyte recovery after
rehydration could eventually lead to long-term storage of blood at ambient
temperatures, which would have a major impact on the feasibility of blood
transfusions in austere environments such as remote medical centers, air
ambulance services, far-forward military operations, and long-duration space
missions.
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CHAPTER IV – ACOUSTOFLUIDIC-MEDIATED
MOLECULAR DELIVERY TO HUMAN T CELLS
WITH A THREE-DIMENSIONAL-PRITNED
FLOW CHAMBER

3

3

Sections of text and figures in this chapter are reproduced from the following
reference:

Connor S. Centner, John T. Moore, Mary E. Baxter, Zachary T. Long, Jacob M.
Miller, Ekaterina S. Kovatsenko, Benjamin Xie, Michael A. Menze, R. Eric Berson,
Paula J. Bates, Kavitha Yaddanapudi, and Jonathan A. Kopechek “Acoustofluidicmediated molecular delivery to human T cells with a three-dimenisonal-printed flow
chamber,”
Journal of the Acoustical Society of America 150(6), 4534. (2021). Reprinted with
permission of Acoustical Society of America.
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IV.1. Introduction
Acoustofluidics (i.e., coupling of ultrasound and fluidic channels) has
increasingly been investigated to address challenges in manufacturing and clinical
applications,

especially

in

diagnostics

and

therapeutics.

Acoustofluidics

technologies have the potential to offer point-of-care (POC) devices for patient
bedside use due to improved simplicity and potential for rapid processing.
Acoustofluidic research has investigated many potential applications including
acoustophoresis (Petersson et al., 2007; Shi et al., 2009c; Wu et al., 2018),
biomarker analysis (Wang et al., 2020; Zhou et al., 2021), cell concentrator
applications (Li et al., 2007; Chen et al., 2014; Kurashina et al., 2017), fluid mixing
applications (Shilton et al., 2008; Friend and Yeo, 2011; Yeo et al., 2011), and
recently, biomolecular delivery (Belling et al., 2020a; Centner et al., 2020).
However, the key acoustofluidic parameters that affect biomolecular delivery to
cells have not been thoroughly investigated. In addition, the effect of ultrasounddriven microbubble oscillation on molecular delivery to cells within acoustofluidic
channels has not been fully characterized. Optimization of acoustofluidic
parameters for biomolecular delivery to cells could potentially enable utilization of
this technology for non-viral manufacturing of cell therapies and other applications.
Cell-based therapies represent the latest biotechnological revolution in
medicine. Potential therapeutic applications include treating cancers, treating
autoimmune diseases, treating infectious diseases, and repairing damaged tissue
(Buzhor et al., 2014). Recent breakthroughs in adoptive cell therapies, specifically
chimeric antigen receptor (CAR)-T cells, have had a significant impact on the
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treatment of B-cell malignancies, such as leukemia or lymphoma (Buzhor et al.,
2014; Kochenderfer et al., 2017; Turtle et al., 2017; Maude et al., 2018), with over
80% of patients achieving complete remission in some trials. CAR-T may also have
the potential to treat other forms of cancer and other diseases, such as HIV (Deeks
et al., 2002). CAR-T has indicated the ability to enhance targeted cytotoxic activity
while reducing off-target effects due to its specificity, which is a distinct advantage
over traditional treatment regimens (e.g., chemotherapy, radiation) for cancer
(Moghimi et al., 2021). However, the current manufacturing techniques for CAR-T,
which are heavily dependent on viral vectors, have several limitations that limit
more widespread adoption of this biotechnology.
Viral vectors, which are infectious entities that are adapted to deliver nucleic
acids to the cytoplasm or nucleus, are currently the primary technique utilized for
ex vivo modification of T cells (Wang and Riviere, 2015). Viral vectors have been
shown to have high efficacy in modifying T cells for clinical trials of new
immunotherapies (Ghani et al., 2009; Kochenderfer et al., 2015; Schuster et al.,
2017). However, there are several limitations with this technique, including
potential insertional mutagenesis and undesired multiplicity of infection (Piscopo
et al., 2018). In addition, viral vectors generally cannot deliver non-nucleic acid
biomolecules to cells.
To address these limitations, non-viral techniques are being developed
which can enhance intracellular molecular delivery. Techniques include
nanocarriers and nanoparticles where therapeutic agents may be loading internally
or liganded to the surface to improve molecular delivery to specific cells in vivo or
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in vitro (Majumder et al., 2019). These techniques, however, rely heavily on
endocytosis pathways, which may limit molecular delivery efficiency or loading rate
by biomodulatory signaling molecules such as mTOR, proton pumps, and
cathepsins (Sahay et al., 2013). Additionally, molecular delivery can be reduced
via exocytosis of these particles and associated therapeutic agents (Sahay et al.,
2013; Oh and Park, 2014). These could have important implications on treatment
efficacy as low delivery efficiency or slow loading rates could delay essential cellbased therapies for patients. Another treatment technique includes nanostraw
membrane stamping where the plasma membrane is mechanical penetrated. This
technique has shown over 85% delivery efficiency of small molecules in adherent
cell lines (Zhang et al., 2019). For anchorage independent cells, this technique
may be insufficient and has yet to be demonstrate feasibility.
Transient permeabilization of the plasma membrane has generated interest
since it may allow molecules to enter the cytosol rapidly. Electroporation is a
technique that induces transient permeabilization of the plasma membrane and
has generated significant interest as a potential method to overcome limitations of
viral vectors. However, bulk electroporation may not have the capacity to achieve
sufficient levels of molecular delivery that are required for functional applications,
such as CAR-T (Annesley et al., 2018a). In an attempt to improve delivery
efficiency, stimuli-responsive nanoparticles, conjugated nanoparticles, and
nanocarriers have been studied in conjugation with electroporation (Kim and Lee,
2017). Another fundamental limitation of electroporation is the risk of epigenetic
modifications that can induce a significant increase in cytokine release, which can
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cause severe immunomodulatory effects after treatment (Falk et al., 2017; He et
al., 2019). For example, unintended amplification of critical pro-inflammatory
interleukins, such as interleukin-2, may induce cytokine release syndrome where
the immune system inadvertently attacks native tissues and organ, which can be
fatal in severe cases. An alternative approach that has been explored for non-viral
molecular delivery involves microfluidic squeezing, where cells are passed through
microfluidic channels with small constrictions that transiently increase membrane
permeability for intracellular delivery of biomolecules (Sharei et al., 2013).
However, channel blockage and limited throughput are challenges that can occur
with constricted channels.
Acoustofluidics potentially offers an alternative method of biomolecular
delivery to T cells, which could address limitations of viral transduction and other
approaches. Recent advancements of targeted endonucleases that modify the
genome, such as clustered regulatory interspaced palindromic repeats (CRISPR)Cas9, offers efficient targeting of gene(s) for gene disruption, gene correction, or
gene insertion (Morgan et al., 2017). These target genome-editing techniques
require alternative intracellular delivery methods as viral vectors have size
limitations, which has hindered the encapsulation of targeted endonucleases into
a singular viral delivery vehicle (Hirsch et al., 2016; Yang et al., 2016).
Acoustofluidic approaches can rapidly deliver biomolecules into cells by transiently
increasing membrane permeability (Belling et al., 2020a; Centner et al., 2020).
Several previous studies have evaluated acoustofluidic-enhanced molecular
delivery without ultrasound contrast agents by utilizing acoustic radiation force and
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shear stress to induce transient perforation in the plasma membrane (Carugo et
al., 2011; Belling et al., 2020a). In this study, we have characterized acoustofluidicenhanced molecular delivery with microbubbles in order to understand the key
parameters that affect the efficiency of molecular delivery to human T cells.
Although the acoustofluidic device has the potential to address limitations
in viral transduction, current acoustofluidic devices utilized for molecular delivery
are likely untranslatable for cell manufacturing applications. These studies utilized
polydimethylsiloxane (PDMS)-based devices (Centner et al., 2020; Centner et al.,
2021b), which have several limitations such as batch-to-batch variability,
limitations with sterilization, frequent channel blockage, and high risk of device
failure after frequent use. Utilizing a 3D-printed acoustofluidic device further
enables the potential of an acoustofluidic utilization in a cell manufacturing setting
as it can be fabricated with low batch-to-batch variability and is a durable, scalable
design that can be easily sterilized for clinical applications.
The objective of this study was to assess the role of important acoustofluidic
parameters on molecular delivery and cell viability. The concepts of sonoporation
and ultrasound-mediated molecular delivery to cells are well-established in static
ultrasound systems and have demonstrated significant molecular delivery with
consistent treatment parameters (Miller et al., 1999). Recently, a PDMS-based
acoustofluidic device was utilized to assess physical effects of microbubbles on
enhancing molecular delivery to in situ tissue (Pereno et al., 2018); however, this
approach has not been thoroughly characterized in an acoustofluidic system as a
method to enhance molecular delivery in in vitro applications with lipid-coated
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microbubbles. This study aims to provide new insights into the effect of
microbubble phospholipid surface charge, acoustofluidic channel geometry,
molecular exposure time point, acoustic pressure, and microbubble concentration
on molecular delivery efficiency in a 3D-printed acoustofluidic device. These
parameters may have a key role in the development of effective acoustofluidic
approaches for manufacturing of cell-based therapies or other molecular delivery
applications.

IV.2. Methods
IV.2.1. Acoustofluidic device design and assembly
A

B

C

1 mm
1 mm
2 mm
concentric spiral rectilinear rectilinear

Figure 12: Rectilinear acoustofluidic device design with 1 mm channel width.
Right: Rectilinear acoustofluidic device design with 2 mm channel width. (B)
Experimental configuration of ultrasound transducer (P4-1) placed on top of
acoustofluidic device with ultrasound gel for acoustic coupling with the
acoustofluidic device. (C) Ultrasound waveform generated by P4-1 transducer as
measured by needle hydrophone.
Acoustofluidic devices were fabricated in Accura 60 plastic using
stereolithography 3D printing (Xometry, Gaithersburg, MD, USA). Stainless steel
barbed tube fittings (McMaster-Carr, Elmhurst, IL, USA) were inserted into prethreaded inlet and outlet ports for connection with PVC tubing (1/16” ID, 10-32
threads). Three different acoustofluidic channel geometries were designed in
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SolidWorks (Waltham, MA, USA) and fabricated for comparison of molecular
delivery efficiencies (Figure 12A). Two acoustofluidic designs had rectilinear
channels, with square cross-sectional diameters of 1 mm x 1 mm or 2 mm x 2 mm.
Additionally, a concentric spiral channel design was also fabricated with a square
cross-sectional diameter of 1 mm x 1 mm to increase residence time within the
ultrasound beam compared to the rectilinear channel geometry. 1 mm and 2 mm
will allow approximately 1.67 wavelengths and 3.33 wavelengths of ultrasound
signal in the acoustofluidic channel with a 2.5 MHz center frequency, respectively.
Additionally, the selected center frequency (2.5 MHz) is near the microbubble
resonance frequency and should provide sufficient oscillation power with lipidencapsulated microbubbles (Versluis et al., 2020).
All experiments were performed with the acoustofluidic devices connected
to a peristaltic pump at a flow rate of 1.5 mL/min. The ultrasound transducer was
placed directly on top of the acoustofluidic device with ultrasound gel for acoustic
coupling (Figure 12B). A P4-1 ultrasound transducer (96 elements, 2.5 MHz center
frequency, ATL, Bothell, WA, USA) was used to transmit B-mode pulses generated
by an ultrasound imaging system (Vantage 64LE, Verasonics, Kirkland, WA, USA).
The free-field ultrasound pressure output was measured using a calibrated 0.2mm needle hydrophone (Precision Acoustics, Dorset, UK) 40 mm away from P4-1
ultrasound transducer in a water tank with water as the medium. The -3 dB
beamwidth was 8 mm, and the peak negative ultrasound pressure output was 3.8
MPa for all experiments unless otherwise specified (waveform shown in Figure
12C).
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IV.2.2. Microbubble synthesis
Phospholipid-coated gas-filled microbubbles were custom synthesized to
enhance biomolecular delivery to T cells in the acoustofluidic devices.
Microbubbles with a cationic surface charge were synthesized using chloroform
solutions of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti Lipids,
Alabaster, AL, USA); 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC,
Avanti Lipids); 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG, Avanti Lipids);
and polyethylene glycol-40 stearate (Sigma-Aldrich, St. Louis, MO, USA) at a
molar ratio of 100:43:1:4.5. The cationic lipid DSEPC conferred a net positive
surface charge on the microbubbles as previously described (Kopechek et al.,
2015; Kopechek et al., 2016; Kopechek et al., 2019). Microbubbles with neutral
surface charge were synthesized with chloroform solutions of DSPC and 1,2
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene

glycol)-

2000] (DSPE-PEG2000, Avanti Lipids) at a molar ratio of 96:4 (Myrset et al., 2011).
Chloroform was evaporated under vacuum and an aqueous micellar lipid solution
was prepared by adding 1x phosphate buffered solution (PBS) and sonicating
(125W, Qsonica, Newtown, CT, USA) to disperse the lipids. The resulting 10
mg/mL lipid solution was diluted 1:4 in PBS and sealed in a glass vial. The vial
head space was filled with decafluorobutane gas (FlouroMed, Round Rock, TX,
USA), followed by amalgamation for 45 s at 4350 cpm (DB-338, COXO, Foshan
City, China) to form perfluorobutane gas-filled microbubbles (MBs). This process
yields microbubbles with a mean diameter of 2 µm as previously described
(Kopechek et al., 2015).

67

IV.2.3. Microbubble attenuation measurements
A

B

C

Recessed 1.3 cm
x 1.3 cm cuvette
holder

Figure 13: (A) Schematic of acoustic attenuation chamber with a recessed 1.3 cm
x 1.3 cm cuvette holder to ensure consistent cuvette sample placement. (B) Photo
of acoustic attenuation chamber with polystyrene cuvette placed at the center of
the ultrasound beam. The acoustic attenuation chamber contains two co-axially
aligned single-element transducers, with one transducer acting as the source and
the other transducer acting as the receiver. (C) Representative time-domain
waveforms acquired using the acoustic attenuation chamber with microbubbles
(2.5% v/v) and without microbubbles (reference). Acquired time-domain
waveforms were transformed to the frequency domain to calculate acoustic
attenuation coefficients using Equation 1.
Acoustic attenuation measurements of microbubble solutions were
conducted to assess effects of microbubble properties, acoustofluidic channel
geometries, and ultrasound parameters on microbubble destruction. A custom 3Dprinted acoustic chamber was designed in SolidWorks (Figure 13A) and fabricated
using fused filament deposition with 1.75-mm polylactic acid filament (PLA,
McMaster-Carr) with an Ender-3 3D printer (Creality, Shenzhen, China). Two lead
zirconate titanate (PZT) transducers (3.3 MHz center frequency, 25 mm diameter,
StemInc, Davenport, FL, USA) were aligned opposite each other 31 mm apart and
used as a source and receiver to measure acoustic attenuation. Microbubble
solutions (2.5% v/v in 3 mL PBS) were added to 4.5-mL disposable polystyrene
cuvettes (VWR, Radnor, PA, USA) which were placed in the acoustic chamber at
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the center of the ultrasound beam (Figure 13B). A waveform generator (DG822,
Rigol, Suzhou, China) was used to generate a 3.3-MHz pulse with 500 cycles at a
pulse interval of 10 ms. Received ultrasound signals (300 traces per sample) were
acquired with a digital oscilloscope (DS1202Z-E, Rigol) at a sampling rate of 10
MHz and transferred to a desktop computer for processing with MATLAB
(Mathworks, Natick, MA, USA). Representative waveforms are shown in Figure
13C. The attenuation coefficient was calculated as previously described
(Kopechek et al., 2011). Power spectra were computed for each waveform and
averaged to obtain the average power spectrum for each sample. The peak
magnitude was determined at 3.30 MHz for each sample, |S! |, and for each
corresponding reference measurement without microbubble solution, |S" |. The
acoustic path length through the sample (inside the cuvette) was 1 cm. Therefore,
the acoustic attenuation coefficient in decibels per unit length (dB/cm) can be
computed as follows:
'

𝛼#$ = 10 𝑙𝑜𝑔%& +'! ,. (1)
"

IV.2.4. Molecular delivery to human T cells
Jurkat T cells were cultured with complete RPMI-1640 (10% fetal bovine
serum, 1% penicillin/streptomycin) at 37 °C and 5% CO2 in a flat-bottom tissue
culture flask. Jurkat T cells were harvested when 70-90% confluent and were
resuspended in complete RPMI-1640 at a concentration of 100,000 cells/mL after
centrifugation at 1500g for 5 min at 4 °C. Microbubbles were added to cell solutions
at a 2.5% (v/v) concentration for calcein loading experiments, unless otherwise
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indicated. For delivery efficiency assessment with different microbubble
concentrations (0-10% v/v), 10 µg/mL (1 mM) of 10 kDa FITC-Dextran was utilized.
Additionally, 5% (v/v) concentration was used for intracellular delivery of 26 kDa
sfGFP. Microbubbles with a cationic surface charge were used for all acoustofluidic
experiments unless otherwise indicated. In separate experimental studies, calcein,
10 kDa FITC-Dextran, and 26 kDa sfGFP were added to Jurkat T cell/microbubble
solutions at a final concentration of 100 µg/mL, 10 µg/mL (1 mM), and 52 µg/mL
(2 µM), respectively. Unless otherwise noted, the molecular compound was added
to each sample 1 min prior to acoustofluidic treatment. After treatment, each
sample was washed three times via centrifugation with 3 mL of PBS to remove
extracellular calcein prior to flow cytometry analysis. After washing each sample,
propidium iodide (PI) was added 1-hour post-acoustofluidic treatment to a final
concentration of 20 µg/mL to detect non-viable cells via flow cytometry.
Flow cytometry was performed using a MACSQuant Analyzer 10 (Miltenyi
Biotec, Auburn, CA, USA) with 10,000 events recorded per sample. Data were
analyzed using FlowJo software (Ashland, OR, USA). Forward and side-scatter
plots were gated to the main cell population (based on untreated control samples)
and the mean fluorescence intensity in the FITC channel was calculated to assess
intracellular calcein delivery. Cell viability was assessed by gating PI fluorescence
intensity in the untreated control samples and determining the percentage of cells
in the treatment groups that exceeded the gated PI fluorescence threshold using
the PE/Texas Red channel.
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IV.2.5. Computational modeling of fluid dynamics
Fluid dynamics in the acoustofluidic devices were modeled using ANSYS
(Canonsburg, PA, USA). Acoustofluidic channel geometries were imported from
SolidWorks and transferred to the meshing component. Mesh sensitivity analysis
was performed for element sizes between 0.2 mm and 3 mm to determine the
optimal mesh sizes for each simulation. An element size of 0.5 mm (18,169
elements) was used for the 1-mm diameter rectilinear channel, an element size of
0.4 mm (49,495 elements) was used for the 2-mm diameter rectilinear channel,
and an element size of 0.4 mm (30,690 elements) was used for the 1-mm diameter
concentric spiral channel. Each mesh was transferred to ANSYS Fluent and a
discrete phase model was used to compute the wall shear stress throughout each
acoustofluidic channel, assuming laminar flow. To model perfluorobutane
microbubbles within the acoustofluidic channels, particles were generated with a
mean diameter of 2 µm, modeled as a Rosin-Rammler distribution, with a particle
density of 24.6 kg/m3 and a specific heat of 809 J/(kg*K) in the discrete phase
model. Given the very small microbubble diameter (2 µm) and the relatively short
duration within the device (~2-3 s), buoyancy is not expected to be a significant
factor and was therefore ignored in the computational model. The expected
terminal rise velocity of microbubbles in the acoustofluidic channel, 𝑈( , was
calculated assuming low Reynolds number as previously described (Stokes, 1851;
Parmar and Majumder, 2015):
𝑈( =

)#$ *+,% -,& .
%/0%
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, (2)

where 𝐷( represents microbubble diameter, 𝑔 represents acceleration due to
gravity, 𝜌1 represents density of the liquid, 𝜌* represents density of the gas, and 𝜇1
represents viscosity of the liquid. Assuming a microbubble diameter of 2 µm, a
liquid density of 1000 kg/m3 for water, a gas density of 11.2 kg/m3 for
perfluorobutane, and a liquid viscosity of 1 mPa·s for water, the terminal rise
velocity would be 2.1 µm/s. At this rate, the microbubble would be expected to rise
no more than 6.3 µm, or 0.63% of the 1-mm channel diameter, while passing
through the acoustofluidic device within 3 seconds. The fluid material was modeled
as water at 25 °C (density of 1000 kg/m3 and viscosity of 0.91 cP). The channel
inlet velocity was set to 0.002 m/s (1.5 mL/min) and the channel inlet pressure and
outlet pressure boundary conditions were set to 1 atm for each simulation. The
volume average wall shear stress was computed for each acoustofluidic channel
geometry.

IV.2.6. Protein generation and purification
sfGFP (plasmid #51562, Addgene, Watertown, MA) was expressed in
frame with a chitin-binding protein (CBP) and self-splicing intein protein spacer for
purification purposes. The plasmid was transformed into the Escherichia coli strain
BL21 Star (Thermo Fisher Scientific, Waltham, MA) and cells were grown on LuriaBertani (LB) medium-based agarose plates containing 100 µg/mL ampicillin.
Antibiotic resistant colonies were grown to an optical density of 0.6 using l= 595
nm in liquid culture on an orbital shaker at 225 rpm and 37˚C in LB containing 100
µg/mL ampicillin. Protein expression was induced for 2h after adding isopropyl-β-
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1-thiogalactopyranoside (IPTG) to a final concentration of 0.6 mM and the bacteria
were harvested via centrifugation at 5000g for 30 min at 4˚C. Cell pellets were
resuspended in a small volume of buffer A (1M NaCl, 50 mM Tris-HCl, pH 8.5)
containing 1 mM phenylmethylsulfonyl fluoride (PMSF) to inhibit serine protease
activity. The resuspended pellets were stored at -80 °C for up to 4 months before
purification. For sfGFP purification, cells were lysed by sonication (Q500, Qsonica,
Newtown, CT) and bacterial debris was removed by centrifugation for 30 min at
5000g at 4˚C. The supernatant was loaded via gravity flow onto a 15 mL chitin
resin (NEB Biolabs, Ipswich, MA) containing column. The column was then
washed with 20 column volumes of buffer A. The sfGFP protein was eluted after
incubation with 50 mM DTT dissolved in buffer A at 4 ˚C for 48 h. The eluted protein
was then dialyzed into 50 mM phosphate buffer at a pH of 7.0 and concentrated
using centrifugal filter units (Amicon Ultra 10 kDa, Millipore Sigma, St. Louis, MO).
The purity of the protein was confirmed by SDS-PAGE and averaged at least 95%.
Purified protein aliquots were snap frozen in liquid nitrogen and stored at -80˚C
until used in experiments.

IV.2.7. Statistical Analysis
Statistical analysis was conducted using SPSS 26 (Armonk, NY, USA).
Statistical comparisons between groups for were determined using ANOVA,
unless stated otherwise, with statistical significance defined as p<0.05 (two-tailed).
Post-hoc analysis was conducted using Tukey’s test for ANOVA. Bars represent
mean ± standard deviations.
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IV.3. Results
IV.3.1. Effect of microbubble surface charge on molecular delivery
Ultrasound-mediated intracellular delivery of calcein to Jurkat T cells was
evaluated with various microbubble phospholipid formulations at 2.5% (v/v) in PBS
as measured by flow cytometry post-treatment. Control groups without ultrasound
treatment were tested for each microbubble formulation to determine if
microbubbles alone enhanced calcein delivery when samples passed through the
fluidic channels without ultrasound exposure. In the absence of ultrasound
exposure there was no statistically significant difference in calcein delivery to T
cells between samples containing microbubbles with neutral surface charge and
samples containing microbubbles with a cationic surface charge. However,
significant uptake of calcein was observed in Jurkat T cell samples containing
microbubbles that were exposed to 3.8 MPa peak negative ultrasound pressure as
they passed through the 1 mm rectilinear channel acoustofluidic device, compared
to control groups without ultrasound treatment (Figure 14A, ANOVA p<0.001, n=56/group). Post-hoc analysis indicated that calcein delivery was significantly
enhanced in Jurkat T cell samples with cationic microbubbles that were treated
with

ultrasound

compared

to

ultrasound-treated

samples

with

neutral

microbubbles or ultrasound-treated samples with no microbubbles (ANOVA
p<0.001).
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PI was added to samples post-treatment to assess cell viability as
measured by flow cytometry. No statistically significant differences in cell viability
were observed in ultrasound-treated samples with neutral microbubbles or no
exogenous microbubbles compared to control groups without ultrasound treatment
for each condition, respectively. However, post-hoc analysis indicated that cell
viability was significantly reduced in ultrasound-treated samples with cationic
microbubbles after acoustofluidic treatment, compared to samples with cationic
microbubbles which were not exposed to ultrasound as they passed through the
acoustofluidic device (Figure 14B, ANOVA p=0.001, n=3/group). These results
indicate that microbubble surface charge has a significant impact on
acoustofluidic-mediated effects in Jurkat T cells and cationic surface charge
significantly enhances molecular delivery compared to neutral surface charge, but
moderately reduced cell viability compared to respective control groups.

Figure 14: Effect of microbubble surface charge on molecular delivery in the 1
mm rectilinear channel acoustofluidic device. (A) Microbubbles with cationic
surface charge enhanced calcein delivery to Jurkat T cells in the acoustofluidic
device compared to microbubbles with neutral surface charge (ANOVA p<0.001,
n=5-6/group). (B) Cell viability was moderately reduced after acoustofluidic
treatment with cationic microbubbles compared to neutral microbubbles (ANOVA
p<0.001, n=3/group). (C) There was no statistically significant difference in
acoustic attenuation between cationic microbubbles and neutral microbubbles
(p>0.05, n=15/group).
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IV.3.2. Effect of molecular exposure time point on intracellular delivery
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Figure 15: Effect of molecular exposure time point on calcein
uptake in Jurkat T cells. Calcein was added to cell solutions at
various timepoints before and after passing through the 1 mm
rectilinear acoustofluidic device with ultrasound treatment (3.8
MPa peak negative pressure) and cationic microbubbles.
Calcein delivery was enhanced when delivered prior to
treatment compared to all post-treatment exposure time points
(ANOVA p<0.001, n=5-6/group).
The impact of molecular exposure time points on intracellular delivery was
investigated using the 1 mm rectilinear acoustofluidic device with ultrasound
treatment at 3.8 MPa peak negative pressure output in Jurkat T cell samples with
cationic microbubbles. The highest level of molecular delivery occurred when
calcein was added 1 min prior to acoustofluidic treatment, with intracellular
fluorescence enhanced by 6.26 ± 3.66-fold compared to baseline. Post-hoc
analysis with Tukey’s test indicated that molecular delivery was significantly
enhanced when samples were exposed to calcein at 1 min prior to acoustofluidic
treatment compared to adding calcein at 1 min, 5 min, 15 min, or 30 min post76

acoustofluidic treatment (Figure 15, ANOVA p<0.001, n=5-6). These results
indicate that biomolecule presence in solution during acoustofluidic treatment has
a greater effect on molecular loading compared to biomolecule addition to solution
post-treatment, which suggests that molecular delivery occurs at a faster rate
during acoustofluidic treatment compared to other time points.

IV.3.3. Effect of acoustofluidic channel geometries on molecular delivery
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Figure 16: Effect of acoustofluidic channel geometry on molecular delivery. (A)
Ultrasound treatment (3.8 MPa peak negative pressure) enhanced calcein delivery
to Jurkat T cells in each channel geometry compared to control groups passed
through the channels without ultrasound treatment (ANOVA p<0.001, n=6/group).
With ultrasound treatment the 1 mm concentric spiral geometry significantly
enhanced calcein delivery to Jurkat T cells compared to the 1 mm and 2 mm
rectilinear channel geometry (ANOVA p<0.001) and 2 mm rectilinear channel
geometry (ANOVA p<0.001). (B) Ultrasound treatment reduced cell viability in
acoustofluidic devices (ANOVA p<0.001, n=3-6/group), but viability remained
above 75% in all groups. (C) Ultrasound treatment reduced acoustic attenuation of
microbubble solutions after treatment in each acoustofluidic channel geometry
compared to the no flow control condition (ANOVA p<0.001, n=6/group), indicating
that ultrasound treatment induced microbubble destruction in the channels. There
was no statistically significant difference in acoustic attenuation between each
channel geometry.
The impact of acoustofluidic channel geometries on molecular delivery was
investigated with three geometries (as shown in Figure 12): a 1-mm diameter
rectilinear channel, a 2-mm diameter rectilinear channel, and a concentric spiral
design with a 1 mm channel diameter, using flow cytometry for analysis after
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acoustofluidic treatment. In all three channel geometries, ultrasound treatment
significantly enhanced calcein delivery to Jurkat T cells compared to control groups
without ultrasound (Figure 16A, ANOVA p<0.001, n=6/group). Furthermore, posthoc analysis indicated that calcein delivery to Jurkat T cells was significantly
enhanced in samples passed through the 1 mm concentric spiral channel with
ultrasound treatment compared to ultrasound-treated samples passed through the
1 mm rectilinear channel (ANOVA p<0.001) and 2 mm rectilinear channel (ANOVA
p=0.001), respectively.
PI was added to samples post-treatment to assess cell viability as
measured by flow cytometry. Reduced cell viability was observed with ultrasound
treatment in acoustofluidic devices compared to control groups without ultrasound
(Figure 16B, ANOVA p<0.001, n=3-6/group). Although reduced viability was
observed, viability remained above 75% in all treatment groups. There was no
statistically significant difference in viability between each channel geometry.
The effect of acoustofluidic channel geometry on ultrasound-induced
microbubble destruction was also assessed using acoustic attenuation
measurements. Ultrasound treatment significantly reduced acoustic attenuation in
all geometries compared to the control group without ultrasound (Figure 16C,
ANOVA p<0.001, n=6/group). Post-hoc analysis indicated that there was no
statistically significant difference between acoustic attenuation after treatment in
the 1 mm concentric spiral channel, 1 mm rectilinear channel, and 2 mm rectilinear
channel, respectively.
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Figure 17: Computational modeling of wall shear stress in each
acoustofluidic channel geometry for a flow rate of 1.5 mL/min. (A)
Representative images of wall shear stress patterns from computational
modeling of each acoustofluidic channel geometry. (B) Average wall shear
stress was higher in the concentric spiral geometry compared to rectilinear
geometries.
Fluid dynamics within each acoustofluidic channel geometry were analyzed
using computational modeling in ANSYS to further assess factors that may
influence molecular delivery in each acoustofluidic channel geometry. The
simulated Reynolds number in each channel geometry was below 28, indicating
laminar flow within the acoustofluidic devices. As shown in Figure 17, the average
wall shear stress was ten-fold higher in the 1-mm diameter rectilinear channel
compared to the 2-mm diameter rectilinear channel, as would be expected given
the relatively higher fluid velocity within the smaller channels. However, the
average wall shear stress was even higher in the 1 mm concentric spiral channels
(2.8-fold higher compared to the 1 mm rectilinear channel), indicating that the
curvature of the concentric spiral channel geometry increases wall shear stress
separately from fluid velocity and this may be a key factor that influences
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acoustofluidic molecular delivery to cells within the concentric spiral channel
geometry.

IV.3.4. Effect of ultrasound pressure on molecular delivery

Figure 18: Effect of ultrasound pressure on molecular delivery to Jurkat T cells
in acoustofluidic device. (A) The highest ultrasound pressure evaluated (5.1 MPa
peak negative ultrasound output pressure) resulted in the highest amount of
intracellular calcein delivery compared to all other treatment groups (ANOVA
p<0.001, n=6/group). (B) Cell viability remained above 75% at all ultrasound
pressure conditions (n=3/group). (C) Acoustic attenuation was significantly
reduced in samples treated at peak negative ultrasound pressures 3.8 MPa and
higher, indicating ultrasound-mediated microbubble destruction at higher
acoustic pressures (ANOVA p<0.05, n=5-7/group).
Acoustofluidic-mediated molecular delivery was evaluated at various
ultrasound pressures using the 1-mm diameter concentric spiral design, as
measured with flow cytometry. Acoustofluidic treatment was tested at a range of
ultrasound pressures between 0-5.1 MPa peak negative ultrasound output
pressure. There were no statistically significant differences in calcein delivery to
Jurkat T cells at lower ultrasound output pressures (0-1.3 MPa, p>0.05), whereas
significant delivery was observed at ultrasound output pressures of 2.5 MPa and
higher. Post-hoc analysis indicated that calcein delivery was significantly
enhanced at ultrasound output pressures of 2.5 MPa and higher compared to lower
ultrasound output pressures (0-1.3 MPa; Figure 18A, ANOVA p<0.001,
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n=3/group). Post-hoc analysis also indicated that the highest acoustofluidic
ultrasound pressure evaluated (5.1 MPa peak negative ultrasound output
pressure) resulted in the highest amount of molecular delivery to Jurkat T cells
compared to all other acoustofluidic ultrasound pressures tested in this study
(ANOVA p<0.001), with detected intracellular fluorescence intensity increased by
a maximum of 22.09 ± 0.13-fold compared to the 0 MPa control group.
Flow cytometry analysis of PI staining indicated a general trend that as
acoustofluidic ultrasound pressures increased there was a corresponding
decrease in cell viability, although this difference was relatively small and cell
viability remained above 75% at all treatment conditions. These results indicate
that acoustofluidic treatment can significantly enhance molecular delivery without
significantly impacting cell viability.
Acoustic attenuation of each sample was measured to assess the effect of
acoustofluidic ultrasound pressures on microbubble destruction. No evidence of
microbubble destruction was observed at peak negative ultrasound output
pressures of 0-2.5 MPa, but there was a significant decrease in acoustic
attenuation after acoustofluidic treatment with ultrasound output pressures of 3.8
MPa and higher (Figure 18C; ANOVA p<0.05, n=5-7/group), indicating higher
levels of microbubble destruction at these conditions. The general trend of acoustic
attenuation as a function of ultrasound pressure was roughly inversely related to
the trend in molecular delivery, with acoustic attenuation generally lower at
ultrasound pressures where fluorescence intensity was higher. This suggests that
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microbubble destruction is associated with enhanced intracellular molecular
delivery during acoustofluidic treatment.

IV.3.5. Effect of microbubble dose on molecular delivery
Acoustofluidic treatment was tested with a range of cationic microbubble
concentrations (0-10% v/v) at 5.1 MPa peak negative ultrasound output pressure
to assess molecular delivery with a large molecule (≥1 kDa). Molecular delivery
was assessed using 10 kDa FITC-Dextran and a poor linear correlation with
microbubble concentration was observed (R2=0.19). This indicates that a
microbubble concentration within a specific therapeutic window is required for
optimal molecular delivery. A microbubble concentration of 5% (v/v) improved
molecular delivery compared to lower microbubble concentrations (0-1% v/v,
ANOVA p<0.001, n=6-9/group) and higher microbubble concentrations (10% v/v,
p<0.01, n=6-9).
Trypan blue assay indicated a weak negative linear correlation with
microbubble concentration and cell viability (R2=0.17), which indicated that an
increase in microbubble concentration is a poor predicator variable for cell viability.
A microbubble concentration of 5% (v/v) reduced viability compared to flow only
(0% v/v, ANOVA p<0.01, n=3/group) and 1% (v/v), 2.5% (v/v), 10% (v/v, ANOVA
p<0.05). Of significant interest, no correlation was found between molecular
loading and cell viability (R2=0.50), suggesting that increased molecular delivery
can be achieved without compromising cell viability.
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Figure 19: Intracellular delivery of 10 kDa FITC-dextran at various cationic
microbubble concentrations, using a concentric spiral acoustofluidic device at 5.1
MPa peak negative ultrasound output pressure. (A) Acoustofluidic treatment with
10 µg/mL (1 mM) of 10 kDa FITC-Dextran increased intracellular delivery to
Jurkat T cells at a microbubble concentration of 5% (v/v) compared to lower
microbubble concentrations (0-1% v/v, ANOVA p<0.001, n=6-9/group) and higher
microbubble concentrations (10% v/v, p<0.01). (B) Acoustofluidic treatment with
a cationic microbubble concentration of 5% (v/v) had reduced cell viability
compared to the 0% (v/v) microbubble concentration control group (ANOVA
p<0.001, n=6-9/group), 1-2.5% (v/v) microbubble concentrations (p<0.05), and
10% (v/v) microbubble concentration (p<0.05).

IV.3.6. sfGFP loading in acoustofluidic device
A proteinaceous molecule, sfGFP (26 kDa), was utilized to assess
acoustofluidic delivery efficiency at an ultrasound output pressure of 5.1 MPa and
a microbubble concentration of 5% (v/v) in the concentric spiral acoustofluidic
device. At an extracellular sgGFP concentration of 52 µg/mL (2 µM), a statistically
significant increase in intracellular fluorescence was observed compared to the
flow only control group without ultrasound treatment (1.86 ± 0.81-fold, Figure 20A,
Student’s t-test p<0.05, n=6/group). Cell viability was reduced after acoustofluidic
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treatment compared to the flow only control group without ultrasound treatment
(Figure 20B, Student’s t-test p<0.001, n=6/group), but viability remained above
90% in both groups.

Figure 20: Intracellular delivery of green fluorescent protein (GFP) using the
concentric spiral acoustofluidic device at 5.1 MPa peak negative ultrasound
output pressure and a cationic microbubble concentration of 5% (v/v). (A)
Molecular delivery with 2 µM of 26 kDa sfGFP was increased after acoustofluidic
treatment compared to flow only without ultrasound (negative control; Student’s
T-test p<0.05, n=6/group). (B) Cell viability was reduced after acoustofluidic
treatment compared to flow only without ultrasound (Student’s T-test p<0.001,
n=6/group), but viability remained above 90% in each group.

IV.4. Discussion
Acoustofluidics is a rapidly developing field with a wide range of applications
(Bruus et al., 2011; Gedge and Hill, 2012b; Lenshof et al., 2012; Carugo et al.,
2017; Wu et al., 2017; Belling et al., 2020a). In this study, 3D-printed acoustofluidic
devices were designed and evaluated to enhance molecular delivery to human T
cells via microbubble-mediated mechanisms. Although single-element transducers
with high duty cycle are often used for acoustofluidic applications, in this study we
utilized a clinical ultrasound probe to transmit B-mode pulses into the
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acoustofluidic channels similar to our previous studies (Centner et al., 2020). The
use of gas-filled microbubbles as ultrasound contrast agents reduces the amount
of ultrasound energy necessary for molecular delivery compared to approaches
without contrast agents. By adding microbubbles to cell solutions that pass through
the 3D-printed acoustofluidic device, ultrasound-mediated biomolecular delivery to
cells can be achieved rapidly as a single device can process volumes of at least
90 mL/hr.
The results of this study demonstrate for the first time that the microbubble
phospholipid surface charge and the molecular exposure time point both have
important implications on biomolecular delivery to human T cells in acoustofluidic
devices. The experimental findings in this study demonstrate several key
parameters in the 3D-printed acoustofluidic devices that have significant effects on
intracellular biomolecular delivery. Although this study focused on delivery of a
small fluorescent molecule (calcein) for detection via flow cytometry, it is likely that
optimization of the important parameters identified in this study will also enable
enhanced delivery of many other biomolecules to cells using acoustofluidic
devices, including proteins and nucleic acid molecules. Therefore, these findings
provide new insights into the development of potential acoustofluidic techniques
for manufacturing of cell-based therapies.
In this study, there was a statistically significant difference in molecular
delivery based on the surface charge of the microbubble phospholipid coating
(Figure 14a), with the highest level of calcein delivery detected when cationic
microbubbles were used with ultrasound treatment (3.8 MPa peak negative
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pressure output, p<0.001 compared to control group without ultrasound treatment).
It was previously determined that microbubble phospholipid surface charge could
enhance ultrasound-mediated molecular delivery to HEK 293 cells (Tlaxca et al.,
2010). However, there were distinct differences in the previous study by Tlaxca, et
al., including utilization of biotinylated-PEG substrate to conjugate the molecules,
assessment using anchorage-dependent cells (unlike anchorage-independent
Jurkat T cells), and the use of a static ultrasound configuration. These differences
may account for the lack of differences in molecular delivery between cationic and
neutral lipid-coated microbubbles when treated with ultrasound in other cell lines
using the same ultrasound conditions (Tlaxca et al., 2010). It is likely that the
positive surface charge on cationic microbubbles increases interactions with
negatively-charged components of the T cell surface, such as the glycocalyx, via
non-covalent charge-charge interactions (Springer, 1990). These interactions
would reduce the distance between the microbubbles and cells, which may play a
role in enhancing molecular delivery during ultrasound-driven microbubble activity,
possibly through sonoporation mechanisms. However, variance in glycocalyx
expression levels can influence microbubble-cell interaction. It is possible that low
glycocalyx levels could significantly reduce molecular loading with cationic
microbubbles. Microbubbles with a neutral surface charge are also responsive to
ultrasound waves as indicated by the acoustic attenuation measurements,
however the amount of molecular delivery was significantly reduced when neutral
microbubbles were used at equivalent ultrasound conditions compared to cationic
microbubbles. This suggests that the neutral microbubbles were cavitating at a
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further distance from the cells and therefore had minimal effect on intracellular
molecular delivery.
The effects of molecular exposure time point before and after acoustofluidic
treatment was a critical factor in calcein delivery, with maximum delivery detected
when calcein was added prior to acoustofluidic treatment. Intracellular calcein
delivery was also enhanced, albeit to a lesser degree, when calcein was added at
various timepoints after acoustofluidic treatment. One potential mechanism to
explain this finding is an extended duration of membrane pore opening prior to
resealing, but this appears to be unlikely given that pores typically reseal within
less than 15 minutes after ultrasound treatment (Zhou et al., 2008; Helfield et al.,
2016c). A more likely explanation is the possibility that endocytosis activity may
have increased after acoustofluidic treatment due to mechanical stress on cell
membranes induced by ultrasound-driven microbubble activity (Juffermans et al.,
2009). Although enhanced endocytosis activity may play some role, this does not
appear to be the primary mode of intracellular delivery within the 3D-printed
acoustofluidic channels given that much higher levels of molecular delivery were
detected when calcein was added prior to acoustofluidic treatment.
This study also revealed that channel geometry is another key factor that
influences acoustofluidic-enhanced molecular delivery, but this parameter had
limited influence on cell viability. Acoustofluidic treatment with a concentric spiral
channel geometry caused significantly higher levels of intracellular calcein delivery
compared to acoustofluidic treatment with rectilinear channel geometries. The
residence time of cells within the ultrasound beam is significantly increased in the
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concentric spiral channel geometry compared to rectilinear channel geometries,
with a total channel length within the ultrasound beam of 57.7 mm for the
concentric spiral geometry compared to 10 mm for each rectilinear geometry
tested in this study. Residence time does not appear to have important implications
on cell viability with the experimental parameters used in this study when
comparing three different acoustofluidic device designs. Although residence time
is likely a factor in acoustofluidic-enhanced molecular delivery, but it does not
appear to solely explain the differences in results between each channel geometry.
Acoustofluidic

treatment

in

rectilinear

channels

enhanced

intracellular

fluorescence by approximately three-fold compared to control groups without
ultrasound treatment. However, there was no statistically significant difference in
acoustofluidic-mediated molecular delivery between the two rectilinear channel
geometries that were tested in this study, despite the fact that the average fluid
velocity would have been four times faster in the 1-mm channel compared to the
2-mm channel. If residence time was the only factor, one would expect that the 2mm rectilinear channel would have higher molecular delivery compared to the 1mm rectilinear channel, due to the four-fold increase in residence time for cells
within the ultrasound beam, but this was not observed. Therefore, other differences
in fluid dynamics between channel geometries may also be a key factor. Indeed,
computational analysis of wall shear stress for each channel geometry revealed
that the concentric spiral had significantly higher average wall shear stress
compared to the rectilinear channels, even when the channel diameters were
identical. The centrifugal force in spiral geometries creates accelerated velocity
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near the outer wall, resulting in a sharper velocity gradient and, hence, higher wall
shear stress. These results suggest that the curvature of the acoustofluidic channel
may also be a key factor in molecular delivery efficiency.
Additionally, the effect of ultrasound pressure amplitude was also found to
play a key role on enhancing intracellular molecular delivery. As shown in Figure
18, higher ultrasound pressures (2.4-5.1 MPa peak negative ultrasound pressure
output) showed enhanced delivery of calcein compared to lower ultrasound
pressures (0-1.4 MPa peak negative ultrasound pressure output). This indicates
that molecular delivery is significantly enhanced above a specific ultrasound
pressure threshold. Fundamental acoustic parameters that influence molecular
delivery in anchorage independent cells have yet to be fully characterized, as
multiple modalities could influence molecular delivery, including thermal and
mechanical bioeffects. Thermal bioeffects have been observed with ultrasoundbased platforms (Haar and Coussios, 2007; Bruningk et al., 2019); however,
thermal effects were reduced in this acoustofluidic system by utilization of short Bmode pulses (2 µs) with a low duty cycle (below 1%) and short residence time (~23 s in concentric spiral), which is more likely to be conducive to mechanical
bioeffects over thermal bioeffects (Haar and Coussios, 2007). Mechanical
bioeffects, specifically acoustic radiation force, could influence cell-microbubble
interaction by displacing cells and particles to certain regions of the acoustofluidic
device (Bruus et al., 2011; Bruus, 2012). Previous studies have shown the capacity
for low pressure, pulsed ultrasound to facilitate displacement of ultrasound contrast
agents toward vessel walls (Dayton et al., 1999a; Dayton et al., 1999b; Zhao et
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al., 2004). This could help facilitate molecular delivery to cells via cell-microbubble
interactions and migrating towards vessel walls where shear stress is higher.
Shear stress has been shown to facilitate molecular delivery in acoustofluidic
systems (Belling et al., 2020a). However, the effect of shear stress on molecular
delivery with higher acoustic pressures and microbubbles is not fully understood
and requires further investigation. Furthermore, our study utilized short ultrasound
pulses (duty cycle less than 1%) which may reduce acoustic radiation force effects
within the acoustofluidic channel compared to high duty cycles. Prior studies in
static chambers have demonstrated that stable or inertial cavitation activity can
enhance molecular delivery via sonoporation or other mechanisms (Paula et al.,
2011; Fan et al., 2014b; Delalande et al., 2015; Helfield et al., 2016c). Although
microbubble cavitation activity was not directly measured in this study, there was
a significant decrease in acoustic attenuation after acoustofluidic treatment which
indicates microbubbles were destroyed during ultrasound exposure at higher
pressures, as would be expected with higher levels of cavitation activity.
Additionally, increased ultrasound pressures have been shown to play a critical
role in molecular delivery via stable cavitation and inertial cavitation effects (Wu
and Nyborg, 2008). For molecular delivery applications to T cells, inertial cavitation
may be required for sufficient delivery, which requires higher acoustic pressures.
Although the specific mechanisms of action have not been fully elucidated, this
study provides evidence that ultrasound-driven microbubble activity has a key role
in acoustofluidic-enhanced molecular delivery to cells.
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Additionally, microbubble concentration influenced molecular delivery and
cell viability. A weak relationship was observed between microbubble
concentration and molecular delivery (R2=0.19), even with a significant (5.1 MPa)
peak negative ultrasound output pressure. Interestingly, the highest microbubble
concentration (10% v/v) was associated with reduced molecular delivery while
maintaining higher cell viability. It is typically presumed that an increased
microbubble concentration corresponds to increased molecular delivery while
potentially inducing more cytotoxic effects. In this circumstance, it feasible that a
high microbubble concentration (³10% v/v) could induce high levels of ultrasound
multiple scattering within the acoustofluidic channels and reduce the acoustic
pressure in situ. A similar trend has also been reported in a previous acoustofluidic
study, albeit with a different cell type (erythrocytes), a different device design
(polydimethylsiloxane), and different acoustic parameters with a lower peak
negative output pressure (Centner et al., 2020). In this study, the ultrasound
frequency was aligned with the microbubble resonance frequency in an attempt to
induce sufficient microbubble oscillation for microbubble destruction and
intracellular molecular delivery (Doinikov et al., 2009). However, at high
microbubble concentrations there may be significant scattering of ultrasound
waves which reduces acoustic pressures within most of the acoustofluidic channel
and causes less oscillation. This may be particularly critical with short ultrasound
pulses in an acoustofluidic device where the microbubbles and cells are typically
exposed to ultrasound waves for only ~2-3 seconds.
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This study explored ultrasound-enhanced delivery of a small molecule (i.e.,
calcein) and large molecules (i.e., 10 kDa FITC-Dextran and 26 kDa sfGFP) to
human T cells in acoustofluidic channels to assess feasibility for potential cellbased therapy applications, such as CAR-T. The selected molecules are highly
fluorescent and do not readily cross cell membranes, thus they are useful for
assessing intracellular molecular delivery via flow cytometry. In our study, we
demonstrated that the delivery efficiency of larger biomolecules (molecular weight
³10 kDa) could be achieved with an acoustofluidic device, which is necessary for
proteinaceous or nucleic acid intracellular delivery. With 1 mM of 10 kDa FITCDextran in solution, over a 20-fold increase in intracellular fluorescence was
observed at microbubble concentrations between 2.5%-5% (v/v), compared to the
flow only control group without ultrasound treatment. Intracellular fluorescence
after acoustofluidic treatment with sfGFP was only 1.86 ± 0.81-fold higher than the
flow only control group, but this lower amount of sfGFP delivery compared to FITCdextran delivery is not surprising given the 500x difference in extracellular molarity
between sfGFP (2 µM) and 10 kDa FITC-Dextran (1 mM) in this study. The
extracellular fluorophore concentration could play a significant role in delivery
efficiency as we have previously described (Bhutto et al., 2018). Even though
significant molecular loading was achieved with 10 kDa FITC-Dextran, it is likely
lower compared to small molecules such as calcein (molecular weight of 0.6 kDa),
but may still be sufficient to provide the functional effects that are needed for
therapeutic efficacy (Bhutto et al., 2018). Further studies are required to determine
required cell transfection efficiency for therapeutic applications with an
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acoustofluidic device. A multitude of factors likely will influence efficiency of
molecular delivery, including cell type, donor source, required cell dose, and cell
viability. In addition, multiple doses may also increase molecular delivery to T cells.
These factors will likely allow optimization of the acoustofluidic platform to enable
manipulation of cells via CRISPR-cas9 gene editing or other techniques that are
often used for cell therapy manufacturing applications.

IV.5. Conclusion
The results of this study demonstrate the feasibility of utilizing a 3D-printed
acoustofluidic device to rapidly load biomolecular compounds into human Jurkat T
cells. Additionally, this study identifies several key acoustic and fluidic parameters
that significantly influence the efficiency of intracellular delivery, including
microbubble surface charge, microbubble concentration, the time point when the
molecular compound is added to solution relative to the acoustofluidic treatment
time point, flow channel geometries, and ultrasound pressure. These results
provide new insights into techniques to optimize acoustofluidic delivery of
biomolecules to human T cells. Further development and validation of
acoustofluidic platforms may enable utilization of this technique to improve
manufacturing of cell-based therapies, such as CAR-T immunotherapies for
treatment of cancer and other diseases.
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CHAPTER V – COMPARISION OF
ACOUSTOFLUIDIC AND STATIC SYSTEMS
FOR ULTRASOUND-MEDIATED MOLECULAR
DELIVERY TO T LYMPHOCYTES
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V.1. Introduction
Cell-based therapies have the capacity to significantly improve treatment
regimens for many diseases, including cancer, autoimmune diseases, infectious
diseases, and metabolic diseases (Deeks et al., 2002; Brentjens et al., 2007;
Buzhor et al., 2014; Schuster et al., 2017; Annesley et al., 2018a; Ying et al., 2019).
Recent developments in adoptive cell therapies, specifically chimeric antigen
receptor (CAR) T cells, have significantly improved patient outcomes in B-cell
malignancies, such as leukemia or lymphoma (Annesley et al., 2018a). In fact,
complete remission rates have been observed in up to 80-90% of B-cell acute
lymphoblastic leukemia patients after treatment in clinical trials (Davila et al., 2014;
Turtle et al., 2016; Gardner et al., 2017). Although similar efficacy has yet to be
observed with CAR T treatment for other diseases, there is significant potential to
develop improved CAR T and other cell-based therapies which can enhance
targeted cytotoxic activity while reducing off-target effects (Choe et al., 2021). This
approach offers a distinct advantage over traditional cancer treatment regimens,
such as chemotherapy and radiation, by engineering a patient’s own immune cells
to directly attack cancer cells. However, limitations with current processing
techniques and technologies for CAR T manufacturing have prevented widespread
adoption of this biotechnology therapy, such as genotoxicity due to viral vectors
(Stoiber et al., 2019).
For ex vivo modification of T lymphocytes, viral vector technology is primarily
being utilized. Viral vectors have been shown to have high efficacy in delivery of
nucleic acids to T lymphocytes; however, these results are not reproducible in all
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cell types since intrinsic properties of certain cells make it difficult to consistently
deliver nucleic acids intracellularly. For example, innate immune cells, such as
dendritic cells and macrophages, have evolved to rapidly recognize microbes (e.g.,
viruses) through pattern recognition receptors, which are able to recognize
common components observed in invading microbes (Kawai and Akira, 2010).
This subsequently triggers downstream pathways to destroy the detected
microbes. Limitations with viral vector techniques may include potential insertional
mutagenesis, undesired multiplicity of infection, and limited non-nucleic acid
delivery, such as therapeutic proteins for example. Non-viral transfection
approaches have focused on passive loading of human T lymphocytes via physical
techniques such as electroporation or shear stress-mediated membrane
permeabilization (Sugar and Neumann, 1984a; Hashimoto and Takemoto, 2015a;
DiTommaso et al., 2018). Static electroporation techniques have generated
significant interest as this method utilizes an applied voltage to induce transient
perforation in the plasma membrane and temporally improve intracellular uptake
(Sugar and Neumann, 1984a). However, current electroporation methods have
several limitations, including challenges with scale-up for manufacturing processes
and generally lower delivery efficacy compared to viral vectors (Nayerossadat et
al., 2012b). For example, one recent study demonstrated more than 95%
transduction in HeLa cells using viral delivery (Prel et al., 2015), while another
study reported a transfection efficiency of 66% with electroporation (Chicaybam et
al., 2016). Recently, a microfluidic squeezing platform has been developed that
induces transient perforations in the plasma membrane by taking advantage of the
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compression forces and the shear stress induced as cells pass through a very
narrow constricted channel at a high velocity (Sharei et al., 2013; DiTommaso et
al., 2018). The formation of transient perforations enables biomolecules to diffuse
from the extracellular buffer into the cytosol (Sharei et al., 2013). However, a
fundamental limitation of this technology is the potential for cell debris to cause
blockage of the narrow microfluidic channels and prevent consistent processing
(Dressaire and Sauret, 2016).
To address these limitations, ultrasound technology has demonstrated to the
ability to rapidly delivery biomolecules intracellularly using ultrasound contrast
agents (i.e., microbubbles) to induce a mechanism known as “sonoporation”
(Bhutto et al., 2018; Centner et al., 2020). Sonoporation occurs when ultrasoundinduced microbubble cavitation occurs near cell membranes. This phenomenon
induces transient perforation of the plasma membrane, which allows intracellular
transport of macromolecules that may otherwise be an impermeant due to
macromolecular properties such as size, charge, and polarity. The pores in the cell
membrane typically repair quickly via active repair mechanisms influenced by
factors such as pore size and Ca2+ concentration (Zhou et al., 2008; Hu et al.,
2013b). This approach can potentially enable rapid loading of biomolecules into
cells with higher efficacy and viability compared to other physical delivery methods.
Microbubbles are currently FDA-approved for clinical applications involving cardiac
imaging, and they are also in development for gene therapy and biomolecular
delivery applications, including antigenic protein delivery or transfection of immune
cells such as Dendritic Cells and T lymphocytes (Dewitte et al., 2014; Centner et
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al., 2021b). The efficiency of intracellular delivery is a fundamental parameter for
effective ex vivo modifications of cells. The coupling of ultrasound and
microbubbles potentially offers a solution to address the intracellular delivery
limitations of other physical systems. Static ultrasound delivery systems are often
utilized for ultrasound-based molecular delivery systems, which involve singleelement transducers or transducer arrays placed in a medium, such as water or
cell culture media, with cells suspended or adhered in a static sample chamber,
such as a well plate, petri dish, or test tube. However, the volume of these static
systems is generally limited due to heterogeneous ultrasound pressures outside
of the ultrasound focus, and throughput is a significant limitation for potential largescale processing of cell-based therapies. Previously, 500-µL solutions with 1
minute of ultrasound exposure were utilized for molecular delivery applications
(Janis et al., 2021), which enables a maximum processing rate of 30 mL/hr.
Acoustofluidic technologies (i.e., coupling of ultrasound and fluidic channels)
represent a potential solution to these challenges. Previous studies have
demonstrated that acoustofluidics can rapidly enhance intracellular delivery of
molecular compounds (Belling et al., 2020a; Centner et al., 2020). Some studies
have investigated contrast agent-free acoustofluidic methods for molecular
delivery applications (Carugo et al., 2011; Longsine-Parker et al., 2013; Belling et
al., 2020a). Initial studies, however, had limited processing rates (0.1 mL/min) or
required coupling of electroporation to induce sufficient transient perforation
(Carugo et al., 2011; Longsine-Parker et al., 2013). Recently, contrast agent-free
acoustofluidic methods have also induced molecular delivery by utilizing acoustic
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radiation force to push cells toward the capillary wall coated with a tethered DNA
molecule (Belling et al., 2020a). Tethering molecules to the capillary wall may not
be feasible for some types of biomolecules and the tethering process may not be
compatible with typical aseptic processing methods used for cell therapy
manufacturing. We have previously developed acoustofluidic systems that utilize
exogenous microbubbles to enhance molecular delivery to multiple cell types,
including cancer cells, erythrocytes, and T lymphocytes (Centner et al., 2020;
Centner et al., 2021b; Janis et al., 2021). This approach has the capacity to
process cell solutions with continuous flow rates above 100 mL/hr, which
significantly increases throughput compared to static systems (Centner et al.,
2020; Janis et al., 2021). Although acoustofluidics technology has the potential to
address limitations of static ultrasound systems for cell processing, the delivery
efficiency of each system has not been directly compared.
The objective of this study was to optimize and compare the molecular delivery
efficiency using a static ultrasound system and an acoustofluidic system, by
modulating

microbubble

concentration,

ultrasound

output

pressure,

and

ultrasound exposure duration. Although the concept of sonoporation and
ultrasound-mediated molecular delivery are well established, ultrasound-mediated
molecular delivery with acoustofluidic systems is not well characterized. In this
study, we initially assessed the effect of several key parameters on intracellular
delivery efficiency of a fluorescent compound (calcein) in human T lymphocytes.
After optimizing key parameters for the static ultrasound system and the
acoustofluidic system, we also compared the intracellular delivery efficiency of

99

molecular compounds with different size (0.6 kDa calcein and 150 kDa fluorescein
isothiocyanate (FITC)-dextran) after treatment in each system. The molecular
weight of 150 kDa FITC-dextran is similar to or larger than many proteins (Billett,
1990), including clustered regulatory interspaced palindromic repeats (CRISPR)
enzymes which can be used for gene editing in CAR T therapy. These results aim
to provide new insights into the optimal system and conditions for ultrasoundenhanced molecular delivery of anchorage-independent cells such as T
lymphocytes.
V.2. Methods
V.2.1. Molecular Delivery to Human T Lymphocytes
Jurkat T lymphocytes were cultured in RPMI-1640 medium (Cytiva Life
Sciences, Marlborough, MA, USA) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin at 37 °C and 5% CO2 in a flat-bottom tissue
culture flask. Jurkat T lymphocytes were harvested when 70-90% confluent and

Figure 21: (A) Static configuration with an ultrasound imaging probe transmitting
pulsed ultrasound signal to induce microbubble cavitation in cell solution for
enhanced molecular delivery to Jurkat T lymphocytes (not to scale). (B)
Acoustofluidic device with an ultrasound imaging probe transmitting pulsed
ultrasound signal into fluidic channel so that microbubble cavitation occurs in cell
solution for enhanced molecular delivery to Jurkat T lymphocytes (not to scale).
(C) Concentric spiral acoustofluidic device design with 1 mm x 1 mm channel
geometry (not to scale).
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were resuspended in complete RPMI-1640 at a concentration of 100,000 cells/mL
after centrifugation at 1500g for 5 minutes at 4 °C. Intracellular delivery of calcein
(Sigma-Aldrich, St. Louis, MO, USA) was utilized to determine optimal parameters
in each system for microbubble concentrations, ultrasound pressure, and
ultrasound exposure duration, after ultrasound treatment with an extracellular
calcein concentration of 160 µM. Microbubble concentrations were tested between
0-94 µg/mL, peak negative ultrasound output pressures were tested between 05.1 MPa, and ultrasound exposure durations up to 60 s were tested. 0 µg/mL, 5
µg/mL, 9 µg/mL, 24 µg/mL, 47 µg/mL, and 94 µg/mL microbubble concentration
correspond to 0% v/v, 0.5% v/v, 1%, 2.5% v/v, 5% v/v, and 10% v/v microbubble
concentration values denoted in other chapters. After optimization of microbubble
concentrations, ultrasound pressure, and ultrasound exposure duration for the
static system (Figure 21A) and the acoustofluidic system (Figure 21B), a direct
comparison of delivery efficiency was assessed by utilizing a small molecule (0.6
kDa calcein) and a large molecule (150 kDa FITC-Dextran; Sigma-Aldrich) at a
concentration of 1 µM.
Following ultrasound treatment, cells were centrifuged and washed
three times with phosphate buffer solution (PBS) to remove extracellular
fluorescent compounds. Flow cytometry (MACSquant, Miltenyi Biotec, Bergisch
Gladbach, Germany) was utilized to measure intracellular molecular delivery by
computing the mean fluorescence intensity after gating out non-viable cells as
determined by propidium iodide (PI) staining. Based on prior studies, membrane
repair typically occurs within less than 5 minutes after sonoporation (Fan et al.,
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2012; Hu et al., 2013b; Centner et al., 2021a). Therefore, PI was added to samples
30-60 min after ultrasound treatment to ensure sufficient time for membrane repair
so that DNA staining was minimized in viable cells. A representative scatter plot is
shown in Figure 22 to illustrate the gating procedure after ultrasound treatment.
Cells that stained positive for PI were gated out, and the mean fluorescence
intensity was computed for all viable cells, which were in the left-hand quadrants
(PI-negative). The FITC gate (between upper and lower quadrants) was not used
for fluorescence intensity analysis but is shown in the image to illustrate the shift
in fluorescence above baseline after ultrasound treatment, indicating intracellular
delivery of fluorescent compounds in viable T lymphocytes.
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Figure 22: Representative flow cytometry scatter plot of Jurkat T lymphocytes
population based on FITC Fluorescence Intensity and Propidium Iodide
Fluorescence Intensity. Values in the left-half plane indicate viable cells (PI-) and
values in the right-half plane represent non-viable cells (PI+), respectively. (A)
Representative flow cytometry scatter plot for a flow only control sample without
ultrasound treatment. (B) Representative flow cytometry scatter plot for a sample
with acoustofluidic treatment, indicating that FITC fluorescence is significantly
increased for both viable (PI-) and non-viable (PI+) cells.
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V.2.2. Static Ultrasound Treatment
Static ultrasound treatment was performed in a custom setup as illustrated
in Figure 1A, where ‘static’ refers to the fluid dynamics of the cell solution rather
than the dynamic ultrasound wave. This setup was utilized in previous
sonoporation studies (Janis et al., 2021) and is based on similar static
sonoporation chambers described in the literature (Miller et al., 1999; Kopechek et
al., 2015). Jurkat T lymphocytes (100,000 cells in 1 mL of supplemented RPMI
medium) were transferred to 15-mL centrifuge tubes with fluorescent compound
(calcein or FITC-dextran) and cationic microbubbles one minute prior to ultrasound
treatment. The centrifuge tube was placed in a water tank 40 mm away (ultrasound
focus) from P4-1 ultrasound transducer (2.5 MHz center frequency, ATL, Bothell,
WA, USA) and B-mode pulses were generated by an ultrasound imaging system
(Vantage 64LE, Verasonics, Kirkland, WA, USA) with a pulse repetition frequency
(PRF) of 3333 Hz and duty cycle below 1%. The free-field ultrasound pressure
output was measured using a 0.2-mm needle hydrophone (Precision Acoustics,
Dorset, UK) at 40 mm away from P4-1 transducer.
V.2.3. Acoustofluidic Treatment
Acoustofluidic treatment was performed in a flow chamber as illustrated in
Figure 1B and Figure 1C. The acoustofluidic flow chamber consisted of a
concentric spiral channel geometry designed in SolidWorks (Waltham, MA, USA)
and fabricated in Accura 60 plastic using stereolithography 3D printing (Xometry,
Gaithersburg, MD, USA) with a cross-sectional channel diameter of 1 mm x 1 mm.
The concentric spiral design was used to maximize the exposure duration for cells
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within the ultrasound beam. Stainless steel barbed tube fittings (10-32 threads,
McMaster-Carr, Elmhurst, IL, USA) were inserted into pre-threaded inlet and outlet
ports for connection with PVC tubing (1/16” ID, McMaster-Carr). Cells were
pumped through acoustofluidic channels using a peristaltic pump at a flow rate of
1.5 mL/min (Boxer GmbH, Ottobeuren, Germany) leading to approximately 2-3 s
of ultrasound exposure. A peristaltic pump was used in this study since these are
often utilized for aseptic cell therapy manufacturing processes, but it should be
noted that this pump causes pulsatile flow. An ATL P4-1 ultrasound transducer
was placed directly on top of the plastic acoustofluidic device with a thin layer of
ultrasound gel used for acoustic coupling, and B-mode pulses (2.5 MHz, 12 mm
focus, 3333 Hz PRF) were generated by a Verasonics Vantage 64LE ultrasound
imaging system. The free-field ultrasound pressure output was measured using a
0.2 mm needle hydrophone (Precision Acoustics) 40 mm away from P4-1
transducer. In situ ultrasound pressures within the acoustofluidic channel could not
be measured directly. Current approaches to characterize ultrasound fields within
acoustofluidic channels typically utilize theoretical simulations of the acoustic field
or measurements of motile cells that redistribute spatially based on acoustic
pressure patterns within the channels (Barnkob and Bruus, 2009; Kim et al., 2021).
In this study, we reported calibrated free-field output pressure measurements as
previously described (Centner et al., 2020; Centner et al., 2021a; Janis et al.,
2021).
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V.2.4. Microbubble Synthesis
Cationic microbubbles were synthesized as previously described to form
gas-filled microspheres encapsulated by a phospholipid shell (Kopechek et al.,
2019). A microbubble formulation with cationic surface charge was utilized in this
study for molecular delivery applications to T lymphocytes, as we previously
demonstrated that acoustofluidic treatment with cationic microbubbles significantly
enhanced molecular delivery compared to a microbubble formulation with a neutral
surface charge (Centner et al., 2021a). Chloroform solutions of 1,2-distearoyl-snglycero-3-phosphocholine (DSPC, Avanti Lipids, Alabaster, AL, USA); 1,2distearoyl-sn-glycero-3-ethylphosphocholine

(DSEPC,

Avanti

Lipids);

1,2-

distearoyl-sn-glycero-3-phosphoglycerol (DSPG, Avanti Lipids); and polyethylene
glycol-40 stearate (Sigma-Aldrich, St. Louis, MO, USA) at a molar ratio of
100:43:1:4.5 were combined in a 20-mL glass vial and desiccated to remove
chloroform. An aqueous micellar lipid solution was prepared by adding PBS and
sonicating (Qsonica, Newtown, CT, USA) to resuspend the dry lipid film. The
resulting 10 mg/mL phospholipid solution was diluted 1:4 in PBS and sealed in a
glass vial. The vial head space was filled with decafluorobutane gas (FlouroMed,
Round Rock, TX, USA), followed by amalgamation for 45 s at 4350 cpm (DB-338,
COXO, Foshan City, China) to form perfluorobutane gas-filled microbubbles
(MBs). This synthesis process yields approximately 2 x 109 microbubbles/mL with
a mean diameter of 2 ± 1 µm determined by Coulter counter as previously
described (Kopechek et al., 2019). A representative brightfield microscopy image
of the microbubble solution is shown in Figure 23.
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Figure 23: Representative brightfield microscopy image of cationic microbubbles,
which can oscillate in response to ultrasound waves and enhance molecular
delivery to nearby cells. Scale bar represents 50 µm.
V.2.5. Microbubble Attenuation Measurement
Acoustic attenuation measurements of microbubble solutions, which
contained 100,000 T lymphocytes per mL in supplemented RPMI media, were
conducted in a separate acoustic chamber to assess the effect of microbubble
concentrations, ultrasound treatment pressure, and treatment time duration on
microbubble destruction in the static and acoustofluidic configurations. A 3Dprinted acoustic chamber was designed in SolidWorks and fabricated using an
Ender-3 3D printer (Creality, Shenzhen, China) with a fused filament deposition of
1.75-mm polylatic acid (PLA) filament (McMaster-Carr). Two lead zirconate
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titanate (PZT) transducers with a center frequency of 3.3 MHz and a diameter of
25 mm (StemInc, Davenport, FL, USA) were aligned opposite each other at a
distance of 31 mm. The transducers were used as a source and receiver,
respectively, to measure acoustic attenuation through each microbubble sample.
The microbubble solution was added to 4.5-mL disposable polystyrene cuvettes
(VWR, Radnor, PA, USA) with a 1-cm acoustic path length, which were placed in
the acoustic chamber at the center of the ultrasound beam. Samples that were
tested at different microbubble concentrations were diluted at a 1:4 ratio in 3 mL
of PBS to prevent saturation of the acoustic attenuation signal. A waveform
generator (DG822, Rigol, Suzhou, China) was used to generate a 3.3 MHz pulse
with 500 cycle pulses at an interval of 10 ms. Received ultrasound signals were
acquired using a digital oscilloscope (DS1202Z-E, Rigol) at a sampling rate of 10
MHz. All signals were transferred to a desktop computer for processing with
MATLAB (Mathworks, Natick, MA, USA). The attenuation coefficient was
calculated using previously descried methods(Kopechek et al., 2011). Attenuation
coefficient in decibels per centimeter, αdB/cm, was calculated where Sr and Ss are
the average power spectrum with and without ultrasound scatter, respectively, and
x is the acoustic path distance, measured in cm between the acoustic source and
acoustic receiver.

𝛼#$/34 =
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6
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The peak magnitude in the frequency domain was determined at 3.3 MHz
for each sample. Without ultrasound scatter references were acquired with Jurkat
T solution containing no microbubbles diluted at a 1:4 ratio in 3 mL of PBS.
108

V.2.6. Statistical Analysis
Statistical analysis was performed using ANOVA with the statistical
significance defined as p<0.05 and n represents individual repeats for each
experiment. Between group comparisons were applied by using post-hoc analysis
with Tukey’s test. Statistical analysis was performed using SPSS 26 (Armonk, NY,
USA). Bars in figures represent means ± standard error.

V.3. Results
V.3.1. Effect of Microbubble Concentration on Intracellular Calcein Delivery in
Static Ultrasound System

Figure 24: (A) Delivery efficacy of calcein (100 µg/mL) with varying microbubble
concentrations using static ultrasound treatment (3.8 MPa, 30s). 94 µg/mL
microbubble concentration enhanced biomolecular delivery of calcein compared
to 0-9 µg/mL microbubble concentrations (ANOVA p<0.001, n=7-8/group) and 24
µg/mL microbubble concentration (p<0.01). (B) 94 µg/mL microbubble
concentration had reduced viability compared to 0-24 µg/mL microbubble
concentrations (p<0.001) and 47 µg/mL microbubble concentration (p<0.05),
respectively. Cell viability remained above 80% for all treatment groups. (C)
Acoustic attenuation was significantly reduced for 47 and 94 µg/mL microbubble
concentrations when treated with ultrasound compared to no ultrasound
treatment controls, indicating significant microbubble destruction occurred at
these concentrations (ANOVA p<0.001, n=6/group).
Ultrasound-mediated delivery of calcein to Jurkat T lymphocytes at various
microbubble concentrations were evaluated using flow cytometry measurements
after ultrasound treatment at an output pressure of 3.8 MPa with an ultrasound
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exposure time of 30 s. The ultrasound output pressure of 3.8 MPa was previously
identified to be the minimum acoustic pressure required for complete microbubble
destruction during acoustofluidic treatment (Centner et al., 2021a). Cationic
microbubble concentrations between 0-94 µg/mL were tested, and the highest
level of molecular delivery occurred after ultrasound treatment at a microbubble
concentration of 94 µg/mL (Figure 24A, ANOVA p<0.001, n=7-8/group). Post-hoc
analysis indicated that intracellular fluorescence was significantly higher after
ultrasound treatment at 94 µg/mL microbubble concentration compared to 0
µg/mL, 5 µg/mL, 9 µg/mL, or 24 µg/mL, respectively (p<0.01). No statistically
significant difference in molecular delivery was detected between the 47 µg/mL
and 94 µg/mL microbubble concentrations (p>0.05). Measurements of cell
membrane integrity using PI staining, as an indicator of cell viability, revealed a
general decreasing trend at increasing microbubble concentrations (Figure 24B,
ANOVA p<0.001, n=7-8/group). Cell viability was significantly lower after
ultrasound treatment with 94 µg/mL microbubble concentration compared to
treatment with 0 µg/mL, 5 µg/mL, 9 µg/mL, 24 µg/mL, or 47 µg/mL, respectively
(p<0.05), although differences in cell viability between treatment conditions were
relatively small and viability remained above 80% after treatment at all microbubble
concentrations between 0-94 µg/mL. Acoustic attenuation of each sample was
also measured to assess the effect of ultrasound treatment on microbubble
destruction at each microbubble concentration. Compared to acoustic attenuation
measurements in negative control samples without ultrasound treatment, no
statistically significant differences in microbubble destruction were observed at
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microbubble concentrations of 5 µg/mL, 9 µg/mL, and 24 µg/mL, respectively
(Figure 24C, ANOVA p>0.05, n=6/group), possibly due to low sensitivity of the
acoustic attenuation measurements at these microbubble concentrations.
However, significant microbubble destruction was detected after ultrasound
treatment at microbubble concentrations of 47 µg/mL and 94 µg/mL, respectively
(p<0.001). Intracellular fluorescence intensity levels were highly correlated with
levels of microbubble destruction (R2 = 0.94), which suggests that increased
microbubble destruction is associated with enhanced intracellular molecular
delivery during ultrasound treatment in a static system. Furthermore, cell viability
was inversely correlated with microbubble destruction (R2 = 0.99).
V.3.2. Effect of Microbubble Concentration on Intracellular Calcein Delivery in
Acoustofluidic Device

Figure 25: (A) Delivery efficacy of calcein (100 µg/mL) with varying microbubble
concentrations using acoustofluidic treatment (3.8 MPa). 24 µg/mL microbubble
concentration enhanced molecular delivery of calcein compared to all other
microbubble concentrations (ANOVA p<0.001, n=5-6/group). (B) 24 µg/mL
microbubble concentration had decreased viability compared to lower
microbubble concentrations (0-9 µg/mL). However, cell viability remained above
85% for all treatment groups. (C) Acoustic attenuation was significantly reduced
for 47 µg/mL (ANOVA p<0.05, n=6/group) and 94 µg/mL (p<0.001) microbubble
concentrations when treated with ultrasound compared to no ultrasound
treatment controls, indicating significant microbubble destruction occurred at
these concentrations.
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Intracellular delivery of calcein in Jurkat T lymphocytes was evaluated using
flow

cytometry

after

acoustofluidic

treatment

at

various

microbubble

concentrations. Post-hoc analysis indicated that calcein delivery was significantly
enhanced after acoustofluidic treatment with 24 µg/mL microbubble concentration,
compared to all other microbubble concentrations tested with the acoustofluidic
system (Figure 25A, ANOVA p<0.001, 5-6/group). Cell viability was slightly lower
after acoustofluidic treatment at 24 µg/mL microbubble concentration compared to
the negative control group without acoustofluidic treatment or compared to
acoustofluidic treatment at microbubble concentrations of 5 µg/mL or 9 µg/mL,
respectively (Figure 25B, ANOVA p<0.001, n=5-6/group), but cell viability
remained above 85% after acoustofluidic treatment at all microbubble
concentrations tested between 0-94 µg/mL. Acoustic attenuation was very low
after acoustofluidic treatment with microbubble concentrations of 5 µg/mL, 9
µg/mL, and 24 µg/mL, although there were no statistically significant differences
(Figure 25C, ANOVA p>0.05, n=6/group). Significant microbubble destruction was
observed after acoustofluidic treatment at 47 µg/mL and 94 µg/mL microbubble
concentrations, respectively, compared to measurements at microbubble
concentrations of 47 µg/mL and 94 µg/mL without ultrasound treatment (p<0.05
and p<0.001, respectively). Microbubble destruction was poorly correlated with
relative intracellular fluorescence levels (R2=0.00), which suggest that increased
microbubble destruction is not associated with enhanced molecular delivery based
on microbubble concentration in the acoustofluidic system.
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V.3.3. Effect of Ultrasound Output Pressure on Molecular Delivery in Static
Ultrasound System
Molecular delivery was evaluated with flow cytometry after treatment with a
static ultrasound system at various ultrasound pressures for 30 seconds with a
microbubble concentration of 94 µg/mL. Ultrasound treatment significantly
enhanced molecular delivery compared to the negative control group without
ultrasound treatment (Figure 26A, ANOVA p<0.001, n=9-10/group). Post-hoc
analysis indicated that there was a statistically significant increase in molecular
delivery at a peak negative output pressure of 5.1 MPa compared to no ultrasound
(0 MPa) and 2.5 MPa ultrasound pressure output (p<0.001), but no statistically
significant differences were detected between ultrasound output pressures of 3.8
MPa and 5.1 MPa (p>0.05). Flow cytometry analysis of PI staining indicated a
general trend of decreasing cell viability with increasing ultrasound output
pressure. Post-hoc analysis indicated that cell viability after treatment with at an
ultrasound output pressure of 5.1 MPa was significantly lower compared to
treatment with ultrasound output pressures of 0 MPa (no ultrasound) or 2.5 MPa
(Figure 26B, ANOVA p<0.001, n=9-10/group). Although cell viability was reduced
with ultrasound treatment, in all treatment conditions over 65% of cells remained
viable. Acoustic attenuation of each sample was measured to assess the effect of
ultrasound output pressure on microbubble destruction during treatment in the
static system. A significant decrease in acoustic attenuation was observed with
ultrasound treatment compared no ultrasound treatment (Figure 26C, ANOVA
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p<0.001, n=6/group). Post-hoc analysis indicated that there was a statistically
significant difference in attenuation after treatment at ultrasound output pressures
of 3.8 MPa and 5.1 MPa compared to no ultrasound treatment (p<0.001), indicating
that higher ultrasound pressures are required for significant levels of microbubble
destruction during treatment for 30 seconds with a microbubble concentration of
94 µg/mL. No statistically significant differences in microbubble destruction were
observed between ultrasound output pressures of 3.8 MPa and 5.1 MPa (p>0.05).
Microbubble destruction was highly correlated with relative intracellular
fluorescence levels (R2 = 0.91), which suggests that increased microbubble
destruction is associated with enhanced intracellular molecular delivery during
ultrasound treatment in a static system.

Figure 26: (A) Static ultrasound treatment (30s) with 94 µg/mL microbubble
concentration and varying peak negative output pressure. 5.1 MPa peak negative
pressure enhanced calcein (100 µg/mL) delivery compared to all other 0 MPa and
2.5 MPa, respectively (ANOVA p<0.001, n=9-10/group). (B) Cell viability
remained above 65% in all samples. Cationic microbubble present with and
without ultrasound treatment at different treatment pressure. (C) Acoustic
attenuation was significantly reduced in samples treated with ultrasound
pressures above 2.5 MPa (ANOVA p<0.001, n=6/group), indicating microbubble
destruction at higher acoustic pressures.
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V.3.4. Effect of Ultrasound Output Pressure on Molecular Delivery in Acoustofluidic
System
Acoustofluidic-mediated molecular delivery was evaluated with flow
cytometry after treatment at various peak negative ultrasound output pressures
between 0-5.1 MPa. A significant increase in calcein delivery was detected after
ultrasound treatment with the acoustofluidic device, compared to the negative
control group without ultrasound treatment (Figure 27A, ANOVA p<0.001, n=67/group). Post-hoc analysis indicated that molecular delivery in the acoustofluidic
system was significantly enhanced at ultrasound output pressures of 3.8 MPa and
5.1 MPa compared to 0 MPa (no ultrasound) and 2.5 MPa (p<0.001). Post-hoc
analysis also indicated that there was no statistically significant difference in
molecular delivery between ultrasound output pressures of 3.8 MPa and 5.1 MPa
(p>0.05). Flow cytometry analysis of PI staining indicated that acoustofluidic
treatment reduced cell viability compared to the negative control group without
ultrasound (Figure 27B, ANOVA p<0.001, n=6-7/group). Treatment with higher
ultrasound output pressures (3.8 MPa and 5.1 MPa) caused a statistically
significant decrease in viability compared to no ultrasound treatment (0 MPa) and
treatment at lower ultrasound output pressures (2.5 MPa, p<0.001), respectively.
However, cell viability remained above 75% viability after acoustofluidic treatment
at all treatment conditions (peak negative ultrasound output pressure between 05.1 MPa). Acoustic attenuation of each sample was measured to assess the effect
of acoustofluidic ultrasound pressures on microbubble destruction. No statistically
significant differences in microbubble destruction were observed after treatment at
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ultrasound output pressures of 0 MPa (no ultrasound) or 2.5 MPa (Figure 27C,
ANOVA p>0.05, n=4-6/group), but there was a significant decrease in acoustic
attenuation after acoustofluidic treatment at ultrasound output pressures of 3.8
MPa and 5.1 MPa, compared to the control group without ultrasound. Additionally,
acoustic attenuation was higher after acoustofluidic treatment at an ultrasound
output pressure of 2.5 MPa compared to treatment at ultrasound output pressures
of 3.8 MPa (p<0.05) and 5.1 MPa (p<0.01), indicating higher levels of microbubble
destruction at increased ultrasound pressures in the acoustofluidic device.
Intracellular fluorescence levels and microbubble destruction were highly
correlated (R2 = 0.99), which suggest that increased microbubble destruction is
associated with intracellular molecular delivery during acoustofluidic treatment.

Figure 27: (A) Acoustofluidic device delivery efficacy of calcein (100 µg/mL) with
24 µg/mL microbubble concentration and varying peak negative output pressures.
3.8 and 5.1 MPa conditions enhanced calcein delivery in Jurkat T lymphocytes
compared to 0 MPa (no ultrasound treatment) and 2.5 MPa, respectively (ANOVA
p<0.001, n=6-7/group). (B) Cell viability was reduced in 3.8 MPa and 5.1 MPa
treatment conditions compared to 0 MPa and 2.5 MPa treatment conditions,
respectively (p<0.001). Cell viability remained above 75% in all samples. (C)
Acoustic attenuation was significantly reduced in samples treated with ultrasound
pressures above 2.5 MPa compared to flow conditions without ultrasound
treatment (ANOVA p<0.001, n=4-6/group). Additionally, 3.8 MPa (p<0.05) and 5.1
MPa (p<0.01) had decreased acoustic attenuation compared to 2.5 MPa,
indicating microbubble destruction at higher acoustic pressures.
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V.3.5. Effect of Ultrasound Treatment Time on Molecular Delivery in Static System

Figure 28: (A) Delivery efficacy of calcein (100 µg/mL) with varying treatment
time for acoustofluidic treatment (3.8 MPa, 24 µg/mL microbubble concentration).
1x acoustofluidic treatment and 2x acoustofluidic treatment enhanced
biomolecular delivery of calcein compared to their no ultrasound treatment
control, respectively (ANOVA p<0.001, n=6/group). (B) Cell viability remained
above 85% for all treatment groups with no statistical significance detected
between groups. (C) Acoustic attenuation was significantly reduced in samples
with multiple acoustofluidic treatments compared to multiple flow only control
where microbubbles were added prior to each treatment (ANOVA p<0.001,
n=6/group).

The effect of various ultrasound treatment durations between 0-60 s was
tested with flow cytometry after treatment in the static system at a microbubble
concentration of 94 µg/mL. Ultrasound treatment increased molecular delivery
compared to the negative control group without ultrasound treatment (0 s treatment
duration; Figure 28A, ANOVA p<0.001, n=7-9/group). Post-hoc indicated that
molecular delivery was significantly higher with a 45 s treatment duration
compared to 15 s treatment duration (p<0.001) or 30 s treatment duration (p<0.01),
but no statistical difference was detected between 45 s treatment duration and 60
s treatment duration (p>0.05). Flow cytometry analysis of PI staining indicated a
general trend that as treatment time increased there was a corresponding
decrease in cell viability. Post-hoc analysis revealed a statistically significant
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decrease in cell viability after ultrasound treatment compared to the negative
control group without ultrasound treatment (Figure 28B, ANOVA p<0.01, n=79/group), but there were no statistically significant differences in cell viability
between ultrasound treatment groups, and cell viability remained 75% in all
treatment conditions (ultrasound treatment durations between 0 – 60 s). Acoustic
attenuation of each sample was measured to assess the effect of ultrasound
treatment duration in a static system on intracellular molecular delivery. Post-hoc
analysis indicated that acoustic attenuation was significantly decreased in samples
with ultrasound treatment durations of 30 s or longer compared to the negative
control group without ultrasound treatment (0 s, Figure 28C, ANOVA p<0.01, n=612/group), indicating that microbubble destruction persists for more than 15 s
during ultrasound treatment. However, no statistically significant differences in
acoustic attenuation were detected between ultrasound treatment durations of 30
s, 45 s, and 60 s (p>0.05). A significant correlation was still observed between
microbubble destruction and molecular delivery with an R2 = 0.94, suggesting that
increased microbubble destruction is highly correlated with increased molecular
delivery.
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V.3.6. Effect of Ultrasound Duration on Molecular Delivery in Acoustofluidic
System

Figure 29: (A) Delivery efficacy of calcein (100 µg/mL) with varying treatment
time for static ultrasound treatment (5.1 MPa, 94 µg/mL microbubble
concentration). 45 and 60 seconds of static ultrasound treatment time enhanced
biomolecular delivery of calcein compared to no ultrasound treatment (0 seconds)
and 15 seconds of static ultrasound treatment time (ANOVA p<0.001, n=79/group). Additionally, 45 second static ultrasound treatment time enhanced
calcein delivery compared to 30 seconds of static ultrasound treatment time
(p<0.01). Similar results were observed between 45 seconds and 30 seconds of
ultrasound treatment time (p<0.05). (B) Cell viability was reduced with 60 seconds
of treatment time compared to 0 second treatment time (no ultrasound; p<0.01).
Cell viability remained above 70% for all treatment groups. (C) Acoustic
attenuation was significantly reduced in samples with 30 seconds or above of
ultrasound treatment time compared to 0 seconds (ANOVA p<0.01, n=612/group).
The impact of ultrasound treatment duration on calcein delivery to Jurkat T
lymphocytes was investigated with flow cytometry after treatment in the
acoustofluidic system. Samples were circulated through the acoustofluidic device
one time or two times (1x and 2x ultrasound durations, respectively, with a
microbubble concentration of 24 µg/mL added before each pass through the
device) and ultrasound treatment (3.8 MPa ultrasound output pressure) or without
ultrasound. Exposure time for the acoustofluidic group is approximately 2-3
seconds per exposure with a flow rate of 100 mL/hr. Molecular delivery was
significantly higher after 1x and 2x ultrasound treatment compared to their
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respective negative control groups without ultrasound treatment (Figure 29A,
ANOVA p<0.001, n=6/group). Although the ultrasound treatment duration was
double in the 2x treatment group, post-hoc analysis indicated that there was no
statistically significant difference in calcein delivery between the two ultrasound
treatment duration groups, as measured by flow cytometry (p>0.05). Flow
cytometry analysis of PI staining indicated that there were no significant
differences in cell viability between ultrasound treatment groups and control groups
without ultrasound treatment, and cell viability remained above 85% in each group
(Figure 29B, ANOVA p>0.05, n=6/group).
The effect of ultrasound treatment on microbubble destruction was
assessed after acoustofluidic treatment. No statistically significant difference in
acoustic attenuation was detected between the 1x ultrasound treatment duration
and no ultrasound treatment (Figure 29C, ANOVA p>0.05, n=6/group), but a
significant difference in attenuation was measured between the 2x ultrasound
treatment duration and no ultrasound treatment (p<0.001).
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V.3.7. Comparison of Refined Static and Acoustofluidic Conditions on Intracellular
Molecular Delivery

Figure 30: (A) Delivery efficacy using 0.6 µg/mL (1 mM) of calcein (0.6 kDa) and
150 µg/mL (1 mM) of 150 kDa FITC-Dextran were assessed with refined static
treatment (5.1 MPa, 45 s, and 94 µg/mL microbubble concentration) and
acoustofluidic treatment (5.1 MPa, 24 µg/mL microbubble concentration)
parameters. Static treatment and acoustofluidic treatment enhanced biomolecular
delivery of calcein (ANOVA p<0.01, n=5-6/group) and 150 kDa FITC-Dextran
(p<0.001) compared to negative control (no ultrasound treatment), respectively.
(B) Static and acoustofluidic treatment had decreased cell viability compared to
negative control (p<0.001). No statistically significant differences in cell viability
were detected between static and acoustofluidic treatment for calcein and 150
kDa FITC-Dextran treatment groups, respectively (p>0.05).
The efficiency of intracellular molecular delivery in Jurkat T lymphocytes
was measured after treatment in the static system and the acoustofluidic system
at refined conditions for direct comparison between each configuration. Delivery of
a small molecule (calcein; 0.6 kDa) and a large molecule (150 kDa FITC-Dextran)
were both measured for comparison. Static ultrasound treatment and
acoustofluidic treatment significantly enhanced molecular delivery of calcein
(Figure 30A, ANOVA p<0.01, n=5-6/group) and 150 kDa FITC-Dextran (p<0.001)
compared to negative control groups without ultrasound treatment. There was not
a statistically difference in intracellular delivery of calcein or 150 kDa FITC-Dextran
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between static ultrasound treatment and acoustofluidic treatment (p>0.05),
indicating that the acoustofluidic system achieved similar molecular delivery
results to static ultrasound treatment. Flow cytometry analysis of PI staining
indicated that there was a statistically significant decrease in cell viability after
treatment with the static ultrasound system (Figure 30B, ANOVA p<0.001, n=56/group) and acoustofluidic treatment (p<0.001) compared to negative control
groups without ultrasound. However, no statistically significant differences in cell

Figure 31: Cell viability and proliferation after acoustofluidic treatment, as
measured with trypan blue assay. Immediately after treatment (day 0), the
number of viable cells was not statistically different between acoustofluidic
treatment and the flow only control group (ANOVA p>0.05, n=5/group). At two
days after treatment, the number of viable cells was higher in the flow only control
group compared to the acoustofluidic treatment group (p<0.001), but cell
proliferation was evident by higher numbers of viable cells in both groups
compared to day 0 (p<0.001).
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viability were detected between each ultrasound configuration (p>0.05) and cell
viability remained above 70% after all treatment conditions tested.
Cell viability was also measured using trypan blue assay immediately after
treatment (day 0) and two days after treatment to assess cell survival and
proliferation over time after treatment. As shown in Figure 31, the number of viable
cells was not statistically different between acoustofluidic treatment and the flow
only control group immediately after treatment (ANOVA p>0.05, n=5/group). At two
days after treatment, the number of viable cells was higher in the flow only control
group compared to the acoustofluidic treatment group (p<0.001), but cell
proliferation was evident in both groups due to the higher numbers of viable cells
compared to day 0 (p<0.001). These results indicate that a high number of cells
remain viable and continue to proliferate after acoustofluidic treatment.
V.4. Discussion
Acoustofluidics is a rapidly developing field with a broad range of
applications such as particle/cell manipulation and separation (Bruus et al., 2011;
Gedge and Hill, 2012b; Lenshof et al., 2012; Wu et al., 2017). More recently,
acoustofluidic-mediated delivery has generated significant interest (Belling et al.,
2020a; Centner et al., 2020; Centner et al., 2021b; Salari et al., 2021). However,
acoustofluidic-mediated molecular delivery to cells has not been directly compared
with static ultrasound systems. In this study, a 3D-printed concentric spiral
acoustofluidic system was tested in comparison with a static ultrasound system
using the same P4-1 ultrasound transducer array. The impact of various treatment
conditions on intracellular molecular delivery was evaluated in each ultrasound
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treatment system. Intracellular delivery of small molecules (0.6 kDa calcein) and
large molecules (150 kDa FITC-dextran) were assessed in each system.
Intracellular delivery of large molecules, such as clustered regularly interspaced
short palindromic repeats (CRISPR) endonucleases and proteins, are of clinical
significance since they have the capacity to modulate protein expression, induce
genome editing, alter cell behavior, and inhibit or enhance interactions in desired
cells, such as T lymphocytes, for immune therapies, gene correction, and
cell/tissue engineering (Cho et al., 2013; Ebina et al., 2013; Barrangou and
Doudna, 2016; Lee et al., 2019). 150 kDa FITC-dextran is similar in molecular
weight to CRISPR endonucleases, which are promising techniques for genomic
modification with high specificity (Kocak et al., 2019). Additionally, 150 kDa FITCdextran has a larger molecular weight than most mammalian proteins. For
example, hemoglobin, a proteinaceous macromolecule in red blood cells that
carries oxygen to tissue, has a molecular weight of approximately 65 kDa (Billett,
1990). Thus, our findings provide important insights into molecular delivery of large
molecules in acoustofluidic systems, relative to a traditionally utilized static
configuration.
Previous acoustofluidics applications for molecular delivery have generally
utilized polydimethylsiloxane (PDMS)-based photolithography techniques or a
glass substrate to generate acoustofluidic devices (Belling et al., 2020a; Centner
et al., 2020; Centner et al., 2021b; Salari et al., 2021). PDMS-based
acoustofluidics devices offer distinct advantages, such as rapid device generation
and the ability to produce very small channel dimensions. However, PDMS-based
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acoustofluidic devices have important limitations since PDMS can have batch-tobatch variability in geometric dimensions, which can alter the ultrasound field in
the acoustofluidic channel for each batch of devices (Hill et al., 2002). This can
have a significant impact on reproducibility for applications such as particle/cell
sorting, enrichment, and molecular delivery (Hill et al., 2002; Johansson et al.,
2009; Centner et al., 2020; Centner et al., 2021b). Glass substrate-based
acoustofluidic devices allows certain molecules and cells to adhere to the channel
walls (Belling et al., 2020a; Salari et al., 2021). T lymphocytes, however, are
anchorage independent and tethering biomolecules to a capillary wall may
severely reduce processing rate, which can limit availability of essential therapies.
Processing rate is fundamentally important for T lymphocyte therapies, such as
CAR T, which often require approximately 108 cells for each treatment (Neelapu et
al., 2017; Maude et al., 2018; Schuster et al., 2019). To address these limitations,
a 3D-printed plastic-based concentric spiral acoustofluidic device allows consistent
fabrication of acoustofluidic devices with consistent channel and device
dimensions, which can increase reproducibility and consistency for acoustofluidic
applications.
Unique to our acoustofluidic delivery technique is the utilization of
microbubbles as a mediator of molecular delivery. Other studies have focused on
other effects of ultrasound, such as acoustic radiation forces and microstreaming
effects, where ultrasound is applied continuously to induce these effects (Belling
et al., 2020a; Salari et al., 2021). Acoustic radiation force has been utilized to force
cells to the distal portion of the channel where cells shear against the wall for
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enhanced molecular delivery (Belling et al., 2020a). With our acoustofluidic
configuration, acoustic radiation force is not expected to force cells to pressure
nodes and antinodes, as a short pulse (less than 1% duty cycle) was utilized in this
study instead of continuous ultrasound. Additionally, thermal effects are not
expected to play an important role in molecular delivery due to the low duty cycle
(<1%) and short exposure time (~2-3 s) in our acoustofluidic device (Centner et
al., 2021a). However, acoustic radiation force may still potentially play a role in
delivery as microbubbles can be forced radially toward cells even with short
ultrasound pulse durations (Zhou et al., 2012). Microbubble destruction resulting
from cavitation has been shown to induce temporary pores in the plasma
membrane for effective sonoporation (Zhou et al., 2012; Hu et al., 2013b).
Additionally, microstreaming is induced by microbubble oscillation/cavitation and
may contribute to molecular delivery (Marmottant and Hilgenfeldt, 2003; Collis et
al., 2010). Although the in situ acoustofluidic pressures within the channels have
not been directly measured, it’s feasible that microbubble oscillation/cavitation may
be a predominant mechanism as our ultrasound output pressure is significantly
above the stable/inertial cavitation threshold for lipid-coated microbubbles (Helfield
et al., 2016a). These effects could potentially facilitate molecular delivery via
sonoporation, but further research is required to determine predominant
mechanisms.
In this study, acoustic attenuation was measured to assess the correlation
between microbubble destruction and molecular delivery. In the static
configuration, reduced microbubble attenuation relative to the control group was
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positively correlated with increased molecular delivery (R2= 0.91). This is
consistent with prior studies that observed reduced microbubble attenuation with
increased ultrasound treatment time in a static configuration (Escoffre et al., 2013).
Interestingly, a similar trend was not observed with acoustofluidic treatment
(R2=0.00), indicating that there was no linear relationship between microbubble
attenuation and molecular delivery. With the acoustofluidic device, a microbubble
concentration of 24 µg/mL enhanced molecular delivery to Jurkat T lymphocytes
compared to all other microbubble concentrations tested with the acoustofluidic
device. We previously reported a similar trend with acoustofluidic delivery in
erythrocytes (Centner et al., 2020). A possible explanation for this effect is that
higher microbubble concentrations can induce “shadowing” effects due to
increased scattering and attenuation of ultrasound waves through microbubble
solutions, resulting in reduced ultrasound pressures in more distal locations. The
residence time in the 1-mm concentric spiral acoustofluidic channel is significantly
shorter (~2-3 s) compared to the 45 s treatment duration in the static configuration.
Thus, there is an optimal “therapeutic window” for microbubble concentration that
will enhance molecular delivery to cells with the selected acoustofluidic
parameters.
The effect of ultrasound output pressure on molecular delivery has been
previously described using a static ultrasound setup (Bhutto et al., 2018); however,
few studies have utilized cationic microbubbles for molecular delivery to T
lymphocytes, which express anionic glycoproteins and glycolipids on the plasma
membrane surface (Springer, 1990). Cationic microbubbles may have increased

127

affinity to the plasma membrane due to charge-charge interactions, and it has been
previously shown that cationic microbubble induce increased molecular delivery
levels to T lymphocytes compared to neutral microbubbles when undergoing
ultrasound treatment (Centner et al., 2021a). Similar trends were observed with
static treatment and acoustofluidic treatment, as both conditions had a general
increase in molecular delivery at higher ultrasound output pressures (>3.8 MPa).
Ultrasound treatment duration was also investigated in the static treatment
configuration and the acoustofluidic system. An increase in molecular delivery was
observed with static treatment until 45 s, with no differences detected between 45
s and 60 s. Yet, static treatment had similar acoustic attenuation for ultrasound
durations of 30-60 s. It is possible that the microbubble lipid shell may rupture
within 30 s but cavitation activity may continue for a longer duration of time. Without
an intact lipid shell, the perfluorocarbon gas molecules may rapidly dissolve into
the liquid medium before acoustic attenuation measurements are acquired (Sarkar
et al., 2009). Unlike static treatment, acoustofluidic treatment did not have a
statistically significant difference in molecular delivery when comparing
acoustofluidic treatment with one pass and two passes through the device
(p>0.05), suggesting that repeated exposure does not enhance molecular delivery.
We previously determined that residence time within the acoustofluidic device can
influence molecular delivery (Centner et al., 2020), but the parameters in the earlier
study were significantly different (slower flow rate, lower ultrasound pressure,
different channel dimensions, and different cell type). In this study, it is possible
that the amount of microbubble destruction that occurred during the first pass
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caused maximum levels of molecular delivery, which was not further enhanced
during the second pass through the acoustofluidic device.
Refined static treatment and refined acoustofluidic treatment enhanced
molecular delivery for calcein (p<0.01) and FITC-dextran (p<0.001) compared to
respective negative controls. No statistically significant differences were detected
between static treatment and acoustofluidic treatment regardless of molecular
size, indicating that similar levels of molecular delivery were achieved with each
configuration. Although the level of molecular delivery was similar between each
configuration, the acoustofluidic system offers distinct advantages compared to
static treatment, especially for anchorage independent cells such as T
lymphocytes. Static treatment is labor intensive, has limited throughput, and has
increased risk of variability between batches, whereas the acoustofluidic system
enables faster processing rate, less treatment time, and a lower microbubble
concentration compared to static treatment while achieving similar levels of
molecular delivery with small and large molecules. Future integration of a singleelement transducer within a 3D-printed fluidic chamber with preprogrammed
acoustic settings will enable non-specialized personnel to easily operate this
device in a closed flow system to maintain a sterile environment. Increased cell
concentration, increased flow rate, and parallelization are feasible options to
further improve scalability for cell manufacturing applications. Our findings in this
study represent an early step towards development of optimized methods for
molecular delivery of exogenous macromolecules for potential T lymphocyte
therapies, such as CAR-T.
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V.5. Conclusion
This study indicates that microbubble concentration and ultrasound
pressure are key factors in optimizing molecular delivery to T lymphocytes using
static ultrasound systems or acoustofluidic systems. Additionally, ultrasound
treatment duration was a significant factor in delivery efficiency using the static
ultrasound system. Similar levels of molecular delivery were achieved for small
and large molecules with refined parameters in each system, yet acoustofluidic
treatment required only ~2-3 s treatment duration and 24 µg/mL microbubble
concentration for optimal delivery, whereas static ultrasound treatment required 45
s treatment duration and 94 µg/mL microbubble concentration. These results
indicate that acoustofluidic treatment is an effective approach for intracellular
delivery of biomolecules and offers distinct advantages for cell manufacturing
applications. Further development of this technology could potentially improve
manufacturing processes for cell-based therapies such as CAR T, which may
expand treatment availability and improve patient outcomes.
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CHAPTER VI– BIOMODULATORY EFFECTS
OF MOLECULAR DELIVERY IN HUMAN T
CELLS USING A 3D-PRINTED
ACOUSTOFLUIDIC DEVICES
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VI.1. Introduction
Cell-based therapies have the capacity to significantly improve patient
outcomes for a variety of diseases that include cancer, autoimmune diseases,
infectious diseases, and metabolic diseases (Deeks et al., 2002; Brentjens et al.,
2007; Buzhor et al., 2014; Schuster et al., 2017; Annesley et al., 2018a; Ying et
al., 2019). Chimeric antigen receptor (CAR)-T cells are genetically-engineered T
cells that express receptors to target specific proteins, and CAR-T treatments have
significantly improved patient outcomes in B-cell malignancies, such as leukemia
or lymphoma (Annesley et al., 2018a). In clinical trials, complete remission has
been observed in up to 90% of B-cell acute lymphoblastic leukemia patients after
treatment with CAR-T cells (Davila et al., 2014; Turtle et al., 2016; Gardner et al.,
2017). Although tremendous results have been observed with CAR-T for treatment
of certain diseases (Choe et al., 2021), challenges with current CAR-T
manufacturing techniques, in particular the exogenous delivery of biomolecules
into T cells, have prevented widespread adoption of this promising therapy (Stoiber
et al., 2019).
Viral vector technology is the primary approach being utilized for ex vivo
modification of T cells. Viral vectors can efficiently deliver nucleic acids to T cells;
however, the efficiency of viral delivery is highly variable between individual cells
due to variations in intrinsic properties of certain cells. Additionally, viral vector
delivery techniques can potentially have adverse effects such as insertional
mutagenesis and undesired multiplicity of infection (Wahlers et al., 2001a; Piscopo
et al., 2018). Non-viral transfection approaches have generally focused on passive
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delivery methods in mammalian cells via physical techniques such as
electroporation or shear stress-mediated membrane permeabilization (Sugar and
Neumann, 1984a; Hashimoto and Takemoto, 2015a; DiTommaso et al., 2018).
Static electroporation techniques have generated significant interest by utilizing an
applied voltage to induce transient perforation in the plasma membrane and
transiently enhance intracellular uptake of biomolecules (Sugar and Neumann,
1984a). Standard methods for electroporation currently have several limitations,
including challenges with scale-up for manufacturing processes, generally lower
delivery efficiency compared to viral vectors, limited types of buffers that can be
used during electroporation processing, and significant risk of epigenetic
modifications (Nayerossadat et al., 2012b; Falk et al., 2017). Epigenetic
modifications can induce a significant increase in cytokine release, which can
cause severe immunomodulatory effects after treatment (Falk et al., 2017).
Recently, a microfluidic squeezing platform has been developed that induces
transient perforations in the plasma membrane of cells passing through a very
narrow constricted channel at a high velocity, which induces higher shear stress
forces on the cell membranes and enhances molecular delivery (DiTommaso et
al., 2018). A fundamental limitation of this technology is the potential for
aggregates of cells or other material to cause blockage of the narrow microfluidic
channels which are required for efficient delivery, which can be a challenge for
large-scale processing (Dressaire and Sauret, 2016).
Functionally loaded drug delivery vehicles could be another potential option for
ex vivo modifications of cells. Drug delivery vehicles have generated significant
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interest for therapeutic applications in humans by improving drug uptake in cells
through mechanisms such pH-sensitive release, temperature-sensitive release,
and enhanced endocytosis activity (Oh and Park, 2014; Sun et al., 2017b; Zhang
et al., 2021). These drug delivery vehicles have significant potential for therapeutic
applications in humans, as they can improve uptake in target cells while
diminishing uptake in non-specific cells. However, this is less critical in ex vivo
modification as non-target cells can be separated through other techniques, such
as centrifugation and magnetic-activated cell sorting (MACS). Thus, the capacity
to improve delivery of molecular compounds to T cells more quickly, efficiently, and
reliably, is a fundamental need for cell therapy manufacturing.
To address these limitations, ultrasound technology has been utilized to rapidly
deliver

biomolecules

into

cells

using

ultrasound

contrast

agents

(i.e.,

microbubbles), typically through a mechanism known as “sonoporation” (Bhutto et
al., 2018; Centner et al., 2020). Sonoporation can occur when ultrasound-mediated
microbubble cavitation induces transient perforation of cell membranes, which
enables intracellular transport of macromolecules that may otherwise impermeable
due to properties such as size and charge. Cavitation-induced pores in the cell
membrane typically reseal quickly via active repair mechanisms that are influenced
by factors such as membrane pore size and extracellular solute concentration, but
biomolecules can be rapidly delivered directly into the cytoplasm within seconds
during sonoporation before the pores reseal (Zhou et al., 2008; Hu et al., 2013b).
Microbubbles are currently FDA-approved for clinical applications involving cardiac
imaging, and they are also in development for gene therapy and biomolecular
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delivery applications, including antigenic protein delivery or transfection of immune
cells such as Dendritic Cells and T cells (Dewitte et al., 2014; Centner et al.,
2021b). Enhancing molecular delivery efficiency is a fundamental parameter for
achieving more effective ex vivo modifications of cells, including transformation of
immune cells for cell therapy applications. The coupling of ultrasound and
microbubbles potentially offers a solution to address the molecular delivery
limitations of other approaches. Custom ultrasound setups with static solutions are
typically utilized for studies involving ultrasound-mediated molecular delivery to
cells, using a single-element transducer or transducer array placed in a medium
(such as water or cell culture media) with cells suspended or adhered in a static
sample chamber (such as a well plate, petri dish, or test tube) (Bhutto et al., 2018;
Janis et al., 2021). However, these static sample chambers for ultrasound delivery
generally have limited throughput, which is a significant limitation for potential
large-scale manufacturing of cell therapies.
Acoustofluidic technologies, which deliver ultrasound into fluidic channels, offer
a potential solution to increase throughput of sonoporation-based molecular
delivery processing. Previous studies have demonstrated that acoustofluidics can
rapidly enhance intracellular delivery of small (≤ kDa) and large (≥ kDa) molecular
compounds (Belling et al., 2020a; Centner et al., 2020). We have previously
developed acoustofluidic systems that utilize exogenous microbubbles to enhance
molecular delivery to multiple cell types, including cancer cells, erythrocytes, and
T cells (Centner et al., 2020; Centner et al., 2021b; Janis et al., 2021). This
approach has the capacity to process cell solutions with continuous flow rates
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above 100 mL/hr, which significantly increases throughput compared to static
systems (Centner et al., 2020; Janis et al., 2021).
Although the concept of ultrasound-mediated molecular delivery is well
established, the effect of biological factors on intracellular molecular delivery in an
acoustofluidic device has yet to be characterized. The objective of this study was
to determine the effect of biological and biochemical factors, including cell cycle
phases, extracellular serum protein concentration, and extracellular calcium levels,
that influence the efficiency of intracellular molecular delivery to human T cells in
acoustofluidic channels. In this study, we initially assessed the effect of several
key parameters on intracellular delivery efficiency of a fluorescent soluble
compound (calcein) in human T cells. Additionally, a fluorescent macromolecule
(150 kDa FITC-Dextran) was also utilized to study the effect of cell cycle phases
on molecular delivery and to assess the effect of microbubble concentration on
molecular delivery efficiency in a variety of human cell lines, demonstrating the
potential utility of this approach as a platform technology. Furthermore, changes
to actin and organelle structures in human T cells were assessed with confocal
microscopy after acoustofluidic treatment. These results aim to provide new
insights into key biological parameters that affect acoustofluidic-mediated
molecular delivery in human T cells.
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VI.2. Methods
VI.2.1. Molecular Delivery to Human T Lymphocytes
Jurkat T lymphocytes were cultured in RPMI-1640 medium (Cytiva Life
Sciences, Marlborough, MA, USA) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin at 37 °C and 5% CO2 in a flat-bottom tissue
culture flask. A549 cells, MDA-MB-231 cells, and HEK293 cells were cultured in
DMEM medium (Cytiva Life Sciences) supplemented with 10% FBS and 1%
penicillin/streptomycin at 37 °C and 5% CO2 in a flat-bottom tissue culture flask.
Cells were seeded at a concentration of 100,000 cells/mL. To assess the effect of
cell plating density on molecular delivery efficiency, Jurkat T lymphocytes were
also seeded at concentrations of 200,000 cells/mL and 300,000 cells/mL. Cells
were harvested 2 days after initial seeding and were resuspended in complete
RPMI-1640 (for Jurkat T cells) or complete DMEM (for other cell types) at a

Figure 32: Schematic of acoustofluidic setup for intracellular molecular delivery
to human cells. The acoustofluidic system utilizes an ultrasound transducer
coupled with a 3D-printed flow chamber. A peristaltic pump is used to push
solutions through the acoustofluidic channels and enhance intracellular molecular
delivery (schematic is not to scale).
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concentration of 100,000 cells/mL after centrifugation at 1500g for 5 minutes at 4
°C. Intracellular molecular delivery was assessed using 100 µg/mL calcein (SigmaAldrich, St. Louis, MO, USA) or 1.5 mg/mL 150 kDa-FITC Dextran (Sigma-Aldrich,
St. Louis, MO, USA).
Acoustofluidic treatment was performed in a 1 mm x 1 mm 3D-printed flow
chamber driven by a peristaltic pump, shown in figure 32. The flow chamber was
designed in SolidWorks (Waltham, MA, USA) and fabricated in Accura 60 plastic
using stereolithography 3D printing (Xometry, Gaithersburg, MD, USA). A
concentric spiral channel design was utilized to increase residence time for cells
within the ultrasound beam as they pass through the acoustofluidic channels
(Centner et al., 2021a). Input and output ports in the 3D-printed acoustofluidic
device were threaded for stainless steel barbed tube fittings (10-32 threads,
McMaster-Carr, Elmhurst, IL, USA) for connection to PVC tubing (1/16” ID,
McMaster-Carr). Cells were pumped through the acoustofluidic device using a
peristaltic pump at a flow rate of 1.5 mL/min (Boxer GmbH, Ottobeuren, Germany).
An ATL P4-1 ultrasound transducer was placed directly on top of the plastic
acoustofluidic device with a thin layer of ultrasound gel between surfaces to allow
acoustic coupling, and B-mode pulses with a 2.5 MHz center frequency were
generated by a Verasonics Vantage 64LE ultrasound imaging system. The freefield ultrasound pressure output was measured in a water tank using a 0.2 mm
needle hydrophone (Precision Acoustics) at a distance of 40 mm from the P4-1
transducer.
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Figure 33: Representative flow cytometry histogram plot indicating the gating
windows used to determine cell cycle phases of human Jurkat T cells with Vybrant
DyeCycle staining. Values on the left portion (red), middle portion (blue), and right
portion (black) of the x-axis represent G0/G1 Phase, S Phase, and G2/M Phase,
respectively. The number of cells in each category are plotted on the y-axis.
Following acoustofluidic treatment, cells were centrifuged and washed three
times with phosphate buffer solution (PBS) to remove extracellular fluorescent
compounds. For analysis of cell cycle phases, cells were resuspended in complete
RPMI instead of PBS after the final wash and incubated at 37 °C and 5% CO2 for
30 minutes after adding Vybrant DyeCycle (Violet Stain; ThermoFisher Scientific,
Walthan, MA, USA) at a final concentration of 5 µM. Flow cytometry (MACSquant,
Miltenyi Biotec, Bergisch Gladbach, Germany) was utilized to assess intracellular
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molecular delivery by measuring the mean fluorescence intensity of viable cells,
as determined by absence of propidium iodide (PI) staining. A representative flow
cytometry histogram plot is shown in figure 33 to illustrate the gating procedure for
identifying cells in each phase of the cell cycle.

VI.2.2. Microbubble Synthesis
Microbubbles were synthesized as previously described to form
perfluorobutane gas-filled microbubbles encapsulated by a cationic-charged
phospholipid shell with a mean diameter of 2 ± 1 µm (Kopechek et al., 2019).
Briefly,

chloroform

(DSPC,

Avanti

solutions

Lipids,

ethylphosphocholine

of

Alabaster,

(DSEPC,

1,2-distearoyl-sn-glycero-3-phosphocholine
AL,

Avanti

USA);

1,2-distearoyl-sn-glycero-3-

Lipids);

1,2-distearoyl-sn-glycero-3-

phosphoglycerol (DSPG, Avanti Lipids); and polyethylene glycol-40 stearate
(Sigma-Aldrich, St. Louis, MO, USA) at a molar ratio of 100:43:1:4.5 were
combined in a 20-mL glass vial and desiccated to remove chloroform. An aqueous
micellar lipid solution was prepared by adding 1x PBS and sonicating (Qsonica,
Newtown, CT, USA) to resuspend the dry lipid film. The resulting 10 mg/mL
phospholipid solution was sealed in a 2-mL glass vial and the vial head space was
filled with decafluorobutane gas (FlouroMed, Round Rock, TX, USA), followed by
amalgamation for 45 s at 4350 cpm (DB-338, COXO, Foshan City, China) to form
perfluorobutane gas-filled microbubbles. Cationic microbubble solution was added
to cell solutions at concentrations of 2.5% v/v prior to acoustofluidic treatment,
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except for microbubble concentration experiment (0-10% v/v) using different cell
lines.

VI.2.3. Confocal Microscope Imaging
Prior to confocal microscopy, Jurkat T cells were plated at 5x105
cells/chamber in a 4-chambered, 35-mm CELLview cell culture dish (Greiner BioOne, Kremsmünster, Austria) and incubated for 30 min at room temperature to
allow cells to settle. Media was then removed, and cells were stained with 200 µL
of staining solution for 10 min at room temperature. CellMask Orange
(ThermoFisher Scientific) was used to label F-actin filaments. A CytoPainter kit
(Abcam, Cambridge, UK) was used to stain the ER and Golgi. Mitochondria were
stained with 1 µM of MitoView Blue and lysosomes were stained with 0.01X
LysoView 405 (Biotium, Fremont, CA, USA). MitoView Blue and LysoView stains
were brought to working concentration in the staining buffer provided by the
CytoPainter kit. All dye stocks were made to their respective manufacturer’s
instructions and suggested working concentrations were used unless otherwise
stated. After staining, cells were gently washed with 200 µL of DPBS and
subsequently imaged in 200 µL of DPBS. All images were taken on a Nikon A1R
confocal microscope (Nikon Instruments Inc., Melville, NY, USA).

VI.2.4. Statistical Analysis
Statistical analysis was performed using ANOVA with the statistical
significance defined as p<0.05. Between group comparisons were applied by using
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post-hoc analysis with Tukey’s test. Statistical analysis was performed using SPSS
28 (Armonk, NY, USA). Bars in figures represent means ± standard error.

VI.3. Results
VI.3.1. Effect of Cell Plating Density on Molecular Delivery

Figure 34: Effect of cell plating density on molecular delivery in Jurkat T cells. (A)
Delivery efficiency of calcein (100 µg/mL) in Jurkat T cells after acoustofluidic
treatment with 2.5% v/v microbubbles dose and a peak rarefaction ultrasound
pressure output of 5.1 MPa. Cells were resuspended at 100,000 cells/mL prior to
acoustofluidic treatment after 2 days of culture with varying plating densities.
Delivery efficiency was significantly enhanced after acoustofluidic treatment
compared to corresponding flow only control groups (ANOVA p<0.001, n=78/group). Molecular delivery was higher after acoustofluidic treatment in cells
harvested from flasks with a plating density of 100,000 cells/mL compared to cells
harvested from flasks with plating densities of 200,000 cells/mL (p<0.01) and
300,000 cells/mL (p<0.001). (B) Cell viability was reduced after acoustofluidic
treatment compared to flow only conditions (ANOVA p<0.001, n=7-8/group) but
viability remained above 70% in all conditions. Viability was slightly lower after
acoustofluidic treatment in cells harvested from flasks with plating densities of
200,000 cells/mL compared to plating densities of 100,000 cells/mL (p<0.01) and
300,000 cells/mL (p<0.001).
Acoustofluidic-mediated delivery of calcein to Jurkat T cells was evaluated
after gating viable cells to determine the effect of initial plating density on molecular
delivery after incubation for 2 days. Viable cells were counted using a trypan blue
assay after harvesting cells from each flask, and all cell solutions were
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resuspended at a concentration of 100,000 cells/mL. A microbubble concentration
of 2.5% v/v was added to cell solutions for acoustofluidic treatment at a peak
rarefaction ultrasound pressure output of 5.1 MPa. Fluorescence intensity was
significantly increased for all acoustofluidic treatment groups regardless of initial
plating density, relative to respective flow only control groups without ultrasound
treatment (Figure 34A, ANOVA p<0.001, n=7-8/group). Additionally, fluorescence
intensity was significantly higher in cells harvested from flasks with an initial plating
density of 100,000 cells/mL, compared to cells harvested from flasks with plating
densities of 200,000 cells/mL (p<0.01) and 300,000 cells/mL (p<0.001).
Measurements of cell membrane integrity, using PI staining as an indicator of cell
viability, indicated that acoustofluidic treatment decreased cell viability for all initial
plating densities tested in this study, compared to each respective flow only control
group (Figure 34B, ANOVA p<0.001, n=7-8/group). Additionally, cells harvested
from flasks with an initial plating of 200,000 cells/mL had slightly lower viability after
acoustofluidic treatment compared to plating densities of 100,000 cells/mL
(p<0.01) and 300,000 cells/mL (p<0.001), but viability remained above 70% in all
conditions. These results indicate that cell plating density can impact the efficiency
of acoustofluidic-mediated molecular delivery in Jurkat T cells.
Modification of the actin cytoskeleton network was generally observed in
cells after acoustofluidic treatment compared to cells in the flow only control groups
(Figure 35). Small sites of F-actin accumulation occurred proximal to the cytoplasm
(white arrows) in the acoustofluidic treatment group, whereas similar sites were
not observed in the control groups without ultrasound treatment. Additionally,
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filopodia formation was observed in the acoustofluidic treatment group, especially
in cells harvested at lower plating density. Subsequently, increased numbers of F
actin filaments propagated to other parts of the actin cytoskeleton and appear to
form dense actin patches in cells with acoustofluidic treatment.

Figure 35: Confocal microscopy imaging of F-acting staining revealed
differences in the cytoskeleton network between Jurkat T cells treated with flow
only (control, left panels) and acoustofluidic treatment (right panels) for cells
harvested from flasks seeded at different plating densities 2 days prior to
treatment. Qualitative assessment indicates that polymeric F-actin increased in
cells after acoustofluidic treatment compared to respective control samples.
Additionally, confocal imaging indicates that increased polymerization occurred
in cells harvested from flasks at low plating density (100,000 cells/mL) compared
to medium plating density (200,000 cells/mL) and high plating density (300,000
cells/mL). Scale bar indicates 10 µm.
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VI.3.2. Effect of Serum Concentration on Molecular Delivery

Figure 36: Effect of fetal bovine serum (FBS) concentrations on acoustofluidicmediated molecular delivery in Jurkat T cells. (A) Delivery efficiency of calcein
(100 µg/mL) with varying concentrations of fetal bovine serum (0% and 10%) and
acoustofluidic treatment using a cationic microbubble concentration of 2.5% and
a peak rarefaction ultrasound pressure output of 5.1 MPa. Acoustofluidic
treatment without FBS (0%) and with 10% FBS in loading media increased
molecular delivery compared to the respective flow only control groups (ANOVA
p<0.001, n=10-12/group). Additionally, molecular delivery was significantly
increased after acoustofluidic treatment with 0% FBS compared to 10% FBS
(p<0.001). (B) Cell viability was reduced after acoustofluidic treatment with 0%
FBS and 10% FBS compared to respective flow only control groups (ANOVA
p<0.001, n=10-12/group). Additionally, viability was further reduced after
acoustofluidic treatment in cells without FBS compared to cells in 10% FBS
(p<0.001).
Acoustofluidic-mediated delivery of calcein to Jurkat T cells was evaluated
with flow cytometry analysis in viable cells to determine the effect of fetal bovine
serum concentration on molecular delivery efficiency. Viable cells were counted
prior to experiments by using a trypan blue assay and cells were resuspended at
100,000 cells/mL in RPMI-1640 media without FBS (0% condition) or 10% FBS.
Molecular delivery was significantly higher in cells with acoustofluidic treatment
compared to the flow only control groups, regardless of FBS concentration (Figure
36A, ANOVA p<0.001, n=10-12/group). Tukey’s test indicated that fluorescence
intensity was significantly higher in cells after acoustofluidic treatment without FBS
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relative to cells in 10% FBS (p<0.001). Cell viability decreased after acoustofluidic
treatment regardless of FBS concentration compared to respective flow only
control groups (Figure 36B, ANOVA p<0.001, n=10-12/group). Viability was further
reduced in cells after acoustofluidic treatment without FBS (less than 20% viability)
compared to cells in 10% FBS (p<0.001). These results indicate that serum
concentrations can impact the efficiency of acoustofluidic-mediated molecular
delivery in Jurkat T cells.
VI.3.3. Effect of Calcium Chelator on Molecular Delivery

Figure 37: Effect of extracellular calcium on molecular delivery in Jurkat T cells.
(A) Delivery efficiency of calcein (100 µg/mL) was measured with varying loading
media (RPMI and 1x PBS) with and without calcium chelator (1 mM EGTA) and
acoustofluidic treatment using a cationic microbubble concentration of 2.5% and
a peak rarefaction ultrasound pressure output of 5.1 MPa. Acoustofluidic
treatment with RPMI media significantly enhanced molecular delivery compared
to flow only control groups or compared to acoustofluidic treatment in other media
(ANOVA p<0.001, n=6/group). Acoustofluidic-mediated molecular delivery was
significantly reduced for cells in RPMI + EGTA, indicating that addition of a calcium
chelator influenced acoustofluidic delivery efficiency in Jurkat cells. (B) Cell
viability was reduced after acoustofluidic treatment for all loading media compared
to flow only control groups. Viability was further reduced for cells in PBS compared
to cells in RPMI media for each treatment condition (ANOVA p<0.01, n=6/group).
Calcein delivery and cell viability were assessed for cells in complete FBSsupplemented RPMI or in PBS solutions with or without addition of a calcium
chelator (1 mM EGTA). Molecular delivery was significantly higher for Jurkat T cells

146

in complete RPMI media compared to all flow only control groups and also cells
with acoustofluidic treatment in PBS without calcium (Figure 37A, ANOVA
p<0.001, n=6/group). Addition of a calcium chelator significantly reduced
acoustofluidic-mediated molecular delivery efficiency for cells in complete RPMI
media (p<0.001). However, there was no statistically significant difference in
molecular delivery for cells in PBS with or without calcium chelators. Cell viability
was significantly reduced after acoustofluidic treatment for cells in PBS without
calcium, compared to cells in complete RPMI media (Figure 37B, ANOVA p<0.01,
n=6/group). Cell viability decreased slightly after addition of calcium chelators.
These results indicate that extracellular calcium levels can impact the efficiency of
acoustofluidic-mediated molecular delivery in Jurkat T cells.

VI.3.4. Effect of Cell Cycle Phases on Molecular Delivery
Acoustofluidic-mediated delivery of 150 kDa FITC-Dextran to Jurkat T cells
was evaluated for cells at different cell cycle phases to assess whether cell cycle
phase has an impact on molecular delivery efficiency. Viable cells were counted
prior to experiments by using a trypan blue assay and cells were resuspended at
100,000 cells/mL in complete RPMI media with 10% FBS. Acoustofluidic treatment
was conducted using a cationic microbubble concentration of 2.5% and a peak
rarefaction ultrasound pressure output of 5.1 MPa. Molecular delivery was
significantly higher after acoustofluidic treatment for cells in each phase of the cell
cycle compared to their respective flow only control groups (Figure 38A, ANOVA
p<0.001, n=9/group). Furthermore, molecular delivery was significant increased

147

after acoustofluidic treatment for cells in the S phase compared to cells in the
G0/G1 phase (p<0.01) or cells in the G2/M phase (p<0.001). However, viability
was lower after acoustofluidic treatment for cells in the G0/G1 phase compared to
cells in the G2/M phase or the S phase after acoustofluidic treatment (Figure 38B,
ANOVA p<0.001, n=9/group). Viability was slightly lower after acoustofluidic
treatment for cells in the S phase compared to the respective flow only control
group (p<0.05), while no difference in cell viability was detected between
acoustofluidic treatment and the flow only control group for cells in the G2/M
phase. These results indicate that cell cycle phases can impact the efficiency of
acoustofluidic-mediated molecular delivery in Jurkat T cells.

Figure 38: Effect of cell cycle phases on molecular delivery in Jurkat T cells. (A)
Delivery efficiency of 150 kDa FITC-Dextran (1.5 mg/mL) was analyzed for cells
in various cell cycle phases (G0/G1, G2/M, S) with acoustofluidic treatment using
a cationic microbubble concentration of 2.5% and a peak rarefaction ultrasound
pressure output of 5.1 MPa. Molecular delivery was significant higher after
acoustofluidic treatment for cells in all cell cycle phases compared to their
respective flow only control groups (ANOVA p<0.001, n=9/group). Molecular
delivery was further enhanced for cells in the S phase compared to cells in the
G0/G1 phase (p<0.01) or G2/M phase (p<0.001). (B) Cell viability was reduced
after acoustofluidic treatment for cells in the G0/G1 phase (p<0.001) and S phase
(p<0.05) compared to their respective flow only control groups. Viability was lower
for cells in the G0/G1 phase after acoustofluidic treatment compared to cells in
the G2/M phase or S phase after acoustofluidic treatment (p<0.001).
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VI.3.5. Effect of Acoustofluidic Treatment on Cell Cycle Phase and Proliferation
Rates

Figure 39: Effect of acoustofluidic treatment on cell cycle phases and proliferation
rates. (A-C) The relative percentage of cells in each cell cycle phase was
measured at 0 days and 2 days after acoustofluidic treatment compared to flow
only control or no treatment groups. The percentage of cells in the G0/G1 phase
and the S phase was significantly higher at 2 days after acoustofluidic treatment
compared to their respective no treatment groups (ANOVA p<0.05, n=6/group),
whereas the percentage of cells in the G2/M phase was significantly lower at 2
days after acoustofluidic treatment compared to the respective no treatment
group. (D) The number of viable cells was significantly lower at 2 days after
acoustofluidic treatment compared to no treatment and flow only control groups,
as measured by trypan blue assay (ANOVA p≤0.001, n=4/group). (E) High
viability was observed for cells at 2 days after acoustofluidic treatment as
measured by trypan blue assay, even though the overall number of cells was
lower in the acoustofluidic treatment group compared to the control groups. (F)
Cells were resuspended at a concentration of 100,000 cells/mL at 2 days after
acoustofluidic treatment and cultured for an additional 2 days. After 4 days of
culture post-treatment there was no statistically significant difference in the
number of viable cells for the acoustofluidic treatment group compared to no
treatment and flow only control groups, as measured by trypan blue assay
(ANOVA p>0.05, n=4/group).
The impact of acoustofluidic treatment on cell cycle phases and proliferation
of Jurkat T cells were evaluated using Vybrant DyeCycle staining and trypan blue
assay, respectively (Fig. 39). The percentage of viable cells in the G2/M phase
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was significantly lower at 2 days after acoustofluidic treatment compared to the
respective no treatment control group (Figure 39B, ANOVA p<0.05, n=6/group).
However, the percentage of viable cells in the G0/G1 phase and the S phase was
significantly higher at 2 days after acoustofluidic treatment compared to their
respective no treatment control groups (Figure 39A and 39C, p<0.05). These
results suggest that acoustofluidic treatment induces a shift in some cells toward
the G0/G1 and S phases of the cell cycle and temporarily reduces mitosis. This
trend is also observed in measurements of cell proliferation at 2 days after
acoustofluidic treatment. Trypan blue measurements indicated that Jurkat T cells
proliferated more slowly within 2 days after acoustofluidic treatment compared to
no treatment and flow only control groups (Figure 39D, ANOVA p≤0.001,
n=4/group), but high viability was observed in all groups (Figure 39E). After 2 days
of culture, cells from each group were resuspended at a concentration of
100,000/mL and cultured for 2 additional days. At 4 days of culture after
acoustofluidic treatment (2 days after resuspending the cells), no statistically
significant differences in proliferation were observed (Figure 39F, ANOVA p>0.05,
n=4/group). Confocal microscopy images revealed significant differences in Factin content in Jurkat T cells after acoustofluidic treatment, compared to cells in
the flow only control group (Figure 40). However, at 2 days and 4 days after
acoustofluidic treatment, differences in F-actin structure were minimal compared
to cells in the flow only control group (Figure 40). These results suggest that
acoustofluidic treatment has a transient impact on actin structure and proliferation
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of Jurkat T cells, but they return to normal actin structure and proliferation rates
within 4 days after treatment.

Figure 40: CellMask Orange was used to stain F-actin (indicated in red).
Higher localized fluorescence indicated the presence of increased F-actin
levels. A significant increase in F-actin levels was observed in Jurkat T cells
after acoustofluidic treatment at day 0, compared to cells in the flow only
control group. However, minimal differences in F-actin levels were observed
at day 2 and day 4 after acoustofluidic treatment. Scale bar represents 10 µm.
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VI.3.6. Effect of Acoustofluidic Treatment on Cellular Structures

Figure 41: Effect of acoustofluidic treatment on cellular structures. Panel A
represents cells in the flow only control group, whereas panels B-D represent cells
after acoustofluidic treatment. Cells were stained with an ER (red), Golgi (green),
and nuclear (dark blue) stain using the CytoPainter kit, while LysoView 405 was
used to stain lysosomes (light blue). Panel A shows that minimal disruption to
cellular structures occurred in the flow only control group. Panel B is an example
of a cell that underwent acoustofluidic treatment but had minimal disruption to cell
structures. Panels C and D represent a cell at different planes of view to illustrate
structural changes that occurred after acoustofluidic treatment, including
permeabilization of the nucleus. These images demonstrate that acoustofluidic
treatment can cause significant disruption of cellular structures, including the
nucleus, ER, Golgi, and lysosomes. Scale bar represents 10 µm.
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Figure 42: Effect of acoustofluidic treatment on cellular and nuclear structures.
Panel A represents cells in the flow only control group, while panels B-D
represent cells after acoustofluidic treatment. Cells were stained with an ER
(red), Golgi (green), and nuclear (dark blue) stain using the CytoPainter kit, while
MitoView Blue was used to stain mitochondria (light blue). Purple coloration is
due to the very tight overlap of ER and mitochondria (red and light blue overlap).
Panel B demonstrates cells with relatively minor disruption of the nucleus but
major disruption of the ER, Golgi, and mitochondria. Panels C and D provide two
examples of cells where the sonoporation wounds (white arrows and red arrows)
are visible after acoustofluidic treatment. In panels B-D, blue fluorescence in the
cytoplasm and as a node(s) in the nucleus is may be due to off-staining of the
cationic mitochondrial dye, as it competes for anionic interaction partners with
the cationic lipids and cationic ions that enter the cells during acoustofluidic
treatment. Scale bar represents 10 µm.
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Confocal microscopy images were acquired to assess the effect of
acoustofluidic treatment on cellular structures and organelles. Representative cells
from the flow only control group are shown in Figure 41A, where red represents
ER, green represents Golgi, dark blue represents the nucleus, and light blue
represents lysosomes. Figures 41B-D represent cells with acoustofluidic treatment
using the same organelle staining methods. Figure 41B demonstrates a cell with
minimal disruption of organelles after acoustofluidic treatment, whereas Figure
41C-D demonstrate significant disruption of organelles, including disruption of the
nucleus (dark blue).
Confocal microscopy images were also acquired to assess the effect of
acoustofluidic

treatment

on

mitochondria

and

other

cellular

structures.

Representative cells from the flow only control group as shown in Figure 42A,
where green represents Golgi, light blue represents mitochondria, red represents
ER, and purple represents overlap of mitochondria (light blue) and ER (red). The
same dyes were also utilized to stain cells after acoustofluidic treatment (Figure
42B-D), but the blue mitochondria stain appeared to off-stain the cytoplasm and
regions within the nucleus. This may be due to organelle disruption, which allows
the cationic mitochondrial dye to bind to negatively charged components in other
parts of the cell. Subsequently, the blue mitochondrial dye may be competing for
anionic interaction partners with the cationic lipids and cationic ions that can enter
the cell during acoustofluidic treatment. Furthermore, acoustofluidic treatment can
induce transient sonoporation wounds (white arrows and red arrows), as shown in
Figures 42C-D. These results demonstrate that acoustofluidic treatment can
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induce transient changes in cellular structures, including the nucleus, which
enables rapid uptake of therapeutic compounds into the cytoplasm or nucleus.

VI.3.7. Effect of Microbubble Concentration on Acoustofluidic Molecular Delivery
in Different Cell Lines
To assess the efficiency of acoustofluidic-mediated molecular delivery in
different cell lines, intracellular delivery of 150 kDa FITC-Dextran was assessed
after acoustofluidic treatment in Jurkat T cells, MDA-MB-231 human breast
carcinoma cells, human A549 lung carcinoma cells, and HEK293 cells at various
microbubble concentrations. For Jurkat T cells, the highest amount of
acoustofluidic-mediated intracellular delivery was observed at a microbubble
concentration of 5% v/compared to microbubble concentrations between 0% v/v 1% v/v (Figure 43A, ANOVA p<0.01, n=6/group). and 10% v/v (p<0.05). Viability
was reduced after acoustofluidic treatment for all microbubble concentrations
compared to the negative control condition without microbubbles (0% v/v, Figure
43B, ANOVA p<0.001, n=6/group). Additionally, cell viability was reduced after
acoustofluidic treatment at microbubble concentrations of 2.5% v/v - 7.5% v/v
compared to microbubble concentrations of 1% v/v and 10% v/v (p<0.001).
Acoustofluidic-mediated intracellular delivery of 150 kDa FITC-Dextran to
MDA-MB-231 cells was highest with a microbubble concentration of 5% v/v
compared to lower microbubble concentrations or the negative control condition
without microbubbles (0% v/v - 2.5% v/v; Figure 43C, ANOVA p<0.001, n=6/group)
and compared to higher microbubble concentrations (7.5% v/v - 10% v/v;
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p<0.001). A slightly different trend was observed for cell viability, which indicated
that cell viability was reduced after acoustofluidic treatment with microbubble
concentrations of 2.5% v/v - 7.5% v/v compared to the negative control condition
without microbubbles (0% v/v, Figure 43D, ANOVA p<0.001, n=6/group).
Intracellular delivery of 150 kDa FITC-Dextran was highest for A549 cells
after acoustofluidic delivery with a microbubble concentration of 5% v/v compared
to the negative control condition without microbubbles (0% v/v, Figure 43E,
ANOVA p<0.001, n=9/group). Cell viability was reduced after acoustofluidic
treatment with a microbubble concentration of 5% v/v compared to all other
microbubble concentrations (Figure 43F, ANOVA p<0.001, n=9/group), but
viability remaining above 80% for all groups.
For HEK293 cells, intracellular delivery of 150 kDa FITC-Dextran was
significantly higher after acoustofluidic treatment with microbubble concentrations
between 1% v/v - 10% v/v compared to the negative control condition without
microbubbles (0% v/v, Figure 43G, ANOVA p<0.01, n=3-6/group). Additionally,
acoustofluidic delivery was higher with a microbubble concentration of 5% v/v
compared to 7.5% v/v (p<0.01). Cell viability was reduced after acoustofluidic
treatment with microbubble concentrations of 5% v/v - 10% v/v (p<0.001, Figure
43H, ANOVA p<0.05, n=3-6/group) and 2.5% v/v (p<0.05) compared to the
negative control condition without microbubbles (0% v/v). Viability remained above
80% cell viability for all groups.
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Figure 43: Comparison of acoustofluidic-mediated molecular delivery in different
cell lines. (A) Delivery efficiency of 150 kDa FITC-Dextran (1 mM) to Jurkat T cells
with varying microbubble concentration using acoustofluidic treatment (5.1 MPa).
A microbubble concentration of 5% v/v significantly enhanced intracellular delivery
of 150 kDa FITC-Dextran compared to microbubble concentrations of 0-1% v/v
(ANOVA p<0.01, n=6/group) and compared to a microbubble concentration of 10%
v/v (p<0.05), respectively. (B) Cell viability was reduced after acoustofluidic
treatment for all microbubble concentrations compared to the negative control
condition without microbubbles (0% v/v; ANOVA p<0.001, n=6/group).
Additionally, cell viability was reduced after acoustofluidic treatment at
microbubble concentrations of 2.5%-7.5% v/v compared to microbubble
concentrations of 1% v/v and 10% v/v (p<0.001). (C) Delivery efficiency of 150 kDa
FITC-Dextran (1 mM) to MDA-MB-231 human breast carcinoma cells with varying
microbubble concentration using acoustofluidic treatment (5.1 MPa). A
microbubble concentration of 5% v/v significantly enhanced intracellular delivery
of 150 kDa FITC-Dextran compared to microbubble concentrations of 0-2.5% v/v
or 7.5-10% v/v (ANOVA p<0.001, n=6/group). (D) Cell viability was reduced after
acoustofluidic treatment at microbubble concentrations of 2.5%-7.5% v/v
compared to the negative control condition without microbubbles (0% v/v, ANOVA
p<0.001, n=6/group). (E) Delivery efficiency of 150 kDa FITC-Dextran (1 mM) to
A549 human lung carcinoma cells with varying microbubble concentration using
acoustofluidic treatment (5.1 MPa). A microbubble concentration of 5% v/v
significantly enhanced intracellular delivery of 150 kDa FITC-Dextran compared to
the negative control conditions without microbubbles (0% v/v, ANOVA p<0.001,
n=9/group). (F) Cell viability was reduced after acoustofluidic treatment with a
microbubble concentration of 5% v/v compared to microbubble concentrations of
0-2.5% v/v or 7.5%-10% v/v (ANOVA p<0.001, n=9/group), respectively. (G)
Delivery efficiency of 150 kDa FITC-Dextran (1 mM) to HEK293 cells with varying
microbubble concentration using acoustofluidic treatment (5.1 MPa). A
microbubble concentration of 1-10% v/v significantly enhanced intracellular
delivery of 150 kDa FITC-Dextran compared to the negative control condition
without microbubbles (0% v/v, ANOVA p<0.01, n=3-6/group). Additionally,
acoustofluidic treatment with a microbubble concentration of 5% v/v increased
molecular delivery compared to 7.5% v/v (p<0.01) (H) Cell viability was reduced
after acoustofluidic treatment with a microbubble concentration of 5-10% v/v
(ANOVA p<0.001, n=3-6/group) and 2.5% v/v (p<0.05) compared to the negative
control condition without microbubbles (0% v/v). Cell viability remained above 80%
for all treatment conditions.
VI.4. Discussion
Acoustofluidic-mediated delivery of biomolecules to cells has the potential
to become an important technology due to its capacity for rapid and efficient
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delivery while potentially avoiding the limitations of viral vectors (Belling et al.,
2020a; Centner et al., 2021b). The results of this study demonstrate for the first
time that several key factors affect molecular delivery to human T cells with an
acoustofluidic device, including the initial cell plating concentration, serum
concentrations, extracellular Ca2+ levels in the media, and cell cycle phases.
Additionally, biological characterization was further assessed using confocal
microscopy to understand the impact of acoustofluidic treatment on changes in
actin structure during cell membrane repair processes and on disruption of cellular
organelles.
Initial plating density of human T cells was found to have a significant impact
on molecular delivery and on cytoskeleton structure after treatment in the
acoustofluidic device with exogenous microbubbles in the loading media. It was
determined that lower initial cell plating density yielded improved molecular
delivery with acoustofluidic treatment, but the exact reason is not fully understood.
In addition, initial plating density may impact actin levels and also alter the relative
percentage of cells in each phase of the cell cycle, which could both affect
molecular delivery. This suggests that cell concentration may be a key factor for
molecular delivery of biomolecules used in cell manufacturing applications, such
as CAR-T. It appears that initial cell recovery dynamics (including actin
polymerization) were sufficient to maintain viability for most cells after
acoustofluidic treatment. Previous studies have indicated that modifications to the
cytoskeleton occur where microbubble cavitation induces a transient pore in the
plasma membrane (sonoporation) (Wang et al., 2018; Yang et al., 2020). Although
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microbubble cavitation was not directly measured in this study, our prior studies
demonstrated that acoustofluidic treatment in a 3D-printed device can cause
significant microbubble destruction (Centner et al., 2021a), which may be due to
inertial cavitation activity. Acoustofluidic-driven microbubble cavitation near cell
membranes can enable rapid delivery of exogenous biomolecules into cells.
Unintended consequences of sonoporation include diffusion of additional
compounds, such as ions and proteins, across the cell membrane and disruption
of cellular homeostasis (McNeil and Kirchhausen, 2005), which may induce
upregulation of exocytosis and endocytosis (Lentacker et al., 2014). Actin
polymerization has been suggested to have multiple functions, such as formation,
invagination, and constriction of clathrin-coated vesicles, in addition to scission and
departure of clathrin-coated vesicles (Yarar et al., 2005; Kaksonen et al., 2006;
Aghamohammadzadeh and Ayscough, 2009; Ferguson et al., 2009). Upregulation
of clathrin-depedent endocytic vesicles have been observed after sonoporation,
which could further enhance molecular delivery after acoustofluidic treatment
(Fekri et al., 2016). However, our previous work indicates that molecular delivery
primarily occurs within 1 minute after acoustofluidic treatment (Centner et al.,
2021a), with a low level of additional molecular uptake continuing for at least 30
minutes after treatment.
The results indicate that cell cycle phases have an important impact on
molecular delivery and cell viability after acoustofluidic treatment. Interestingly,
molecular delivery and cell viability were not associated, suggesting that certain
cell cycle phases may be optimal for molecular delivery and maintenance of cell

160

viability. Prior studies suggest that the typical deformation force required for
perforation of the cell membrane may change based on the cell cycle, with S phase
found to have the lowest Young’s modulus in HeLa cells (Fan et al., 2019). Given
that there is an inverse relationship between the Young modulus of a biomaterial
and the microjetting speed during cavitation, this may explain why molecular
delivery was significantly higher in cells at the S phase compared to other cell cycle
phases (Fong et al., 2006). These intrinsic properties associated with cell cycle
phases may be due to rearrangement of the cytoskeleton system throughout each
phase of the cell cycle. Further studies are ultimately required to determine the
effect of cell cycle phases on membrane pore formation and recovery rate.
Additionally, cell cycle phases may also play a critical role in modulating molecular
delivery to certain organelles, as certain components of the cell are modified and
duplicated during each cell cycle phase. For example, during M phase the nuclear
membrane is disrupted to enable cell division, which may allow direct intranuclear
delivery of DNA for genome editing. The results of our study suggest that
techniques to temporarily sync T cells to the S phase of the cell cycle may further
enhance acoustofluidic-mediated molecular delivery.
Additionally, the effect of acoustofluidic treatment on cell proliferation, longterm viability (2+ days), and the percentage of cells in each cell cycle phase were
assessed. At day 0, minimal differences were detected in the percentage of cells
at each cell cycle phase for each treatment condition, with only a moderately
significant difference found between no treatment and flow only control groups
(without ultrasound) for cells in the G2/M phase. Interestingly, significant
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differences in G0/G1 phase, S phase, and G2 phase were observed at 2 days after
acoustofluidic treatment compared to the no treatment control group without
ultrasound. Recently, a study investigated the effect of sonoporation on cell cycle
phases in immortalized B cells and found that within 12 hr post-treatment there
were significant changes in the relative number of cells in the G0/G1 phase and in
the S phase, compared to control samples without sonoporation (Duan et al.,
2021).
Multiple factors could affect the relative percentage of cells in each cell cycle
phase, such as apoptosis, necrosis, and reduced proliferation (Duan et al., 2021).
These factors could explain the lower number of viable cells that we observed at
2 days after acoustofluidic treatment compared to control groups without
ultrasound treatment. Interestingly, no increase in the percentage of non-viable
cells was detected at 2 days after acoustofluidic treatment compared control
groups without ultrasound treatment. This suggests that the lower number of viable
cells observed at 2 days after acoustofluidic treatment may be due to a reduction
in proliferation rate rather than a loss of viability. However, this reduced
proliferation rate appears to be transient, since there were no significant
differences in the number of viable cells at 4 days after acoustofluidic treatment
compared to control groups without ultrasound treatment, after cells were replated
at a concentration of 100,000/mL at 2 days post-treatment. These results suggest
that cells resume normal function and proliferation rates within 2 days after
acoustofluidic treatment.
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The impact of cell culture media supplements and metabolites (i.e.,
extracellular fetal bovine serum and Ca2+ levels) on acoustofluidic-mediated
molecular delivery and cell viability were also assessed. Serum contains vital
components that include attachment-promoting proteins, hormones, vitamins, and
growth factors which are essential for the cell growth and maintenance during
culture for mammalian cells (Milo et al., 1976; Marmottant and Hilgenfeldt, 2003;
van der Valk et al., 2010). In our study, we showed that using serum supplemented
culture media during acoustofluidic treatment improved cell viability while reducing
molecular delivery when treating with the acoustofluidic device. Multiple factors
could explain this outcome: i.) serum proteins can modify metabolic processes
which can alter cell viability and molecular delivery efficiency, ii.) anionic chargedsurfaces on serum proteins may interact with cationic microbubbles via chargecharge interaction and subsequently reduce microbubble interaction with cells, iii.)
serum proteins may compete with cationic microbubbles for binding sites on the
plasma membrane of cells. Reduced-serum culture media was previously reported
to reduce cell viability in immortal cell lines compared to serum-supplemented
media (Rashid and Coombs, 2019). Interestingly, the study reported that serum
proteins can also compete with transfection vehicles for cell surface receptors
(Rashid and Coombs, 2019). This may be explained by the high number of reactive
amino acid residues in serum proteins (e.g., aspartic acid, glutamic acid) (Wu et
al., 2013). In fact, serum albumin proteins have been attached to microbubbles in
some studies to stabilize the microbubble shell, although temporary disruption to
the tertiary albumin structure by reduction of disulfide bonds is required for
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enhanced binding to microbubbles (Du et al., 2018). Given that conjugation of
albumin proteins can affect microbubble interactions with cells, native albumin and
other proteins in serum are also likely to interact with microbubbles and influence
their interactions with the plasma membrane surface on cells. Negatively-charged
amino acids on the exterior surface of proteins may have similar interactions with
cationic microbubbles, which could reduce microbubble-cell interactions and limit
plasma membrane damage during sonoporation.
Another key metabolite that can influence intracellular molecular delivery is
Ca2+, which is closely associated with regulation of many key biochemical
functions of cells and has been shown to have an important role in cell membrane
repair (Berridge et al., 2003; Zhou et al., 2008). In addition, extracellular Ca2+ (3
mM) has been shown to improve recovery of Xenopus oocytes after sonoporation
by facilitating enhanced membrane repair compared to oocytes with lower levels
of extracellular Ca2+ (Zhou et al., 2008). In our study, we investigated the effect of
a potent calcium chelator (EGTA) on molecular delivery and cell recovery when
cells were suspended in RPMI culture media or PBS solutions. RPMI contains 0.42
mM Ca2+ in solution before FBS supplementation but Ca2+ is chelated in the
presence of EGTA, which may reduce extracellular calcium being accessible
intracellularly during sonoporation. Reduced amounts of extracellular calcium have
been shown to cause decreased levels of contraction, exocytosis, endocytosis,
membrane patching, and plugging after plasma membrane damage (Bement and
Capco, 1991; Steinhardt et al., 1994; Eddleman et al., 1997; Terasaki et al., 1997;
Idone et al., 2008; Moe et al., 2015). In fact, extracellular Ca2+ influx has been
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shown to improve F-actin patching of cell membranes. Without sufficient levels of
intracellular Ca2+, plasma membrane repair can be significantly inhibited, and the
membrane can become very susceptible to irreversible damage. It’s feasible that
unbound EGTA can sequester intracellular Ca2+, especially during sonoporation
where plasma membrane and organelles are modified. This may explain the
significant decrease in viability after acoustofluidic treatment for cells in PBS and
1mM EGTA solution. However, high cell viability was maintained after
acoustofluidic treatment in FBS-supplemented RPMI solutions even with calcium
chelators (1 mM EGTA). This finding may be due to EGTA binding to extracellular
Ca2+ in FBS-supplemented RPMI solutions, such that very little unbound EGTA
remains available to bind to intracellular Ca2+. However, FBS-supplemented RPMI
also contains many other ions and proteins which are absent from PBS, and these
factors may also influence molecular delivery and cell viability. It’s feasible that
additional factors in FBS-supplemented RPMI solution may aid in repairing the
plasma membrane and restoring cell homeostasis after sonoporation.
Another fundamental parameter that may influence molecular delivery is the
temperature of the cell solution. In this study, the cell solution was stored on ice
(~0 °C) before and after treatment. Temperature may have important implications
on lipid membrane properties as lower temperatures promote gel phase
consistency where the cell membrane maintains a rigid layer, while higher
temperatures promote membrane fluidity. In fact, a prior study investigated laserinduced transfection efficiency between 37 °C – 45 °C with different cell types and
found that transfection efficiency at these temperatures may be cell type
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dependent (Terakawa et al., 2006). This outcome is likely caused by complex
biological differences between cell types that may be influenced by different
temperature responses (Terakawa et al., 2006). Ultimately, further studies are
required to understand thermal implications on molecular delivery in our
acoustofluidic device.
The effect of exogenous microbubbles on acoustofluidic-mediated
molecular delivery to human T cells and the impact of acoustofluidic treatment on
organelle structures has not been previously characterized. Interestingly, we found
that there is significant disruption of subcellular organelles with only 2-3 seconds
of exposure time to ultrasound in the acoustofluidic channels. Importantly, we
observed evidence that the nuclear membrane was disrupted, which may indicate
that rapid, direct delivery of genomic material to the nucleus could be feasible with
acoustofluidic treatment. Rapid delivery of genomic material to the nucleus is a
challenge with current genomic delivery platforms, so acoustofluidic technology
may offer advantages for rapid intranuclear delivery of DNA or other biomolecules.
Additionally, we observed off-staining of the cationic blue dye in the nucleus after
acoustofluidic treatment. It’s possible that cationic lipids from microbubbles are
being delivered into the nucleus. If so, genomic editing material, such as CRISPRCas9 components, could potentially be delivered directly into the nucleus during
acoustofluidic treatment. Further studies are required to assess the efficacy of this
platform for gene editing or other functional gene delivery applications.
The effect of microbubble concentration on intracellular delivery of
molecular compounds after acoustofluidic treatment has been described
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previously (Centner et al., 2021a), but only with one cell line (Jurkat T cells). In this
study, we also evaluated molecular delivery of a macromolecule (150 kDa) using
the 3D-printed acoustofluidic device with multiple cell lines to assess whether
differences in cell phenotype affect acoustofluidic-mediated molecular delivery and
cell viability. For all cell lines tested in this study, a microbubble concentration of
5% v/v significantly enhanced intracellular delivery of 150 kDa FITC-Dextran
compared to negative control groups without ultrasound treatment. However, at
higher microbubble concentrations we observed reduced molecular delivery in
each cell type. This trend may be explained by higher levels of multiple scattering
within the acoustofluidic channels when high microbubble concentrations are
present, which can reduce the ultrasound pressures to cells further away from the
source transducer and lead to reduced levels of sonoporation. These results
indicate that microbubble concentrations must be optimized for acoustofluidicmediated molecular delivery, but the optimal parameters may be similar for
multiple cell types.
Multiple biological parameters likely influence molecular delivery to cells.
The activity of our cationic microbubble formulation is likely influenced by anionic
charges expressed on the plasma membrane but may also be influenced by cell
size. If plasma membrane surface charge is maintained, increased cell diameter
should facilitate more microbubble-cell interactions and may enable higher levels
of molecular delivery. For example, Jurkat T cells have a diameter of 10-16 µm,
while naïve primary T cells have a diameter of 5-7 µm (Rosenbluth et al., 2006;
Tasnim et al., 2018). If they have the similar membrane potentials, naïve primary
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T cells should have less microbubble-cell interactions compared to Jurkat T cells
and subsequently have reduced sonoporation effects on the cells. This may
ultimately lead to lower levels of molecular delivery. For subcellular molecular
delivery, it may be further complicated by organelle size and distance from the
plasma membrane as microstreaming/microjetting effects from microbubble
cavitation are reduced as distance increases. Thus, small distal organelle
structures may be more challenging to modify by microbubble cavitation. Further
studies are ultimately required to understand the impact of microbubble cavitation
dynamics in our acoustofluidic device.
Prior acoustofluidic studies have extensively characterized the impact of
physical parameters, such as ultrasound pressure amplitude, acoustofluidic
channel geometry, and microbubble surface charge, on acoustofluidic-mediated
molecular delivery (Centner et al., 2021a). However, the impact of biological
parameters such as cell cycle phase, cell plating density, and extracellular
biological supplements on acoustofluidic-mediated molecular delivery was largely
unknown. The results of this study demonstrate that key biological factors must be
carefully regulated to achieve optimal delivery of biomolecules with acoustofluidic
treatment, which may potentially lead to improved non-viral methods for
manufacturing of cell therapies.

VI.5. Conclusions
This study provides new insights into biomodulatory effects of non-viral
molecular delivery to human T cells using a novel 3D-printed plastic acoustofluidic
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device requiring only 2-3 seconds of treatment time. These results demonstrate
that changes in initial cell plating density have implications on the efficiency of
acoustofluidic-mediated molecular delivery in human T cells. In addition, the
results indicate that cell cycle phase can affect acoustofluidic molecular delivery to
human T cells. This study also reveals that acoustofluidic treatment can induce
changes to cellular organelle structures, which may enable delivery of
biomolecules directly into the nucleus for gene editing or other applications. This
study suggests that acoustofluidic technology holds promise for improved non-viral
transfection and manufacturing of human T cell therapies.
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CHAPTER VII – CONCLUSIONS AND FUTURE
WORK
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VII.1. Summary
The role of microbubbles in acoustofluidic delivery has not been previously
studied. The central hypothesis of this dissertation is that an acoustofluidic
platform and microbubbles enhance molecular delivery to human cells.
Experiments in this dissertation were designed to address several relevant
research questions:
1. What are fundamental parameters that modulate molecular delivery
efficiency?
Fundamental properties that modulate molecular delivery efficiency in the
PDMS-based acoustofluidic were determined and are described in Chapter
III. Fundamental parameters that effect biomolecular delivery to
erythrocytes were determined experimentally.
2. Does microbubble destruction in the acoustofluidic channel correlate with
molecular delivery to cells?
The relationship between microbubble destruction and molecular delivery
in 3D-printed acoustofluidic device were determined and are described in
Chapter IV. Microbubble destruction and molecular delivery to human T
cells were determined experimentally and the results were compared to
assess their relationship.
3. Does acoustofluidic treatment achieve similar molecular delivery levels as
static ultrasound treatment?
Molecular delivery levels to human T cells with acoustofluidic treatment and
static ultrasound treatment were determined and are described in Chapter
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V. With refined parameters, acoustofluidic treatment and static ultrasound
treatment were experimentally determined with small molecules (£1 kDa)
and large molecules (³ 10 kDa).
4. What effects do acoustofluidic treatment and cell culture media formulations
induce on molecular delivery and subcellular organelle structures?
Acoustofluidic treatment in a 3D-printed acoustofluidic device and the effect
of different cell culture media formulations were determined and are
described in Chapter VI. Fundamental biological parameters that effect
molecular delivery to T cells were determined experimentally.

VII.2. Results & Future Directions
The results of this dissertation imply that multiple parameters modulate
biomolecular delivery to erythrocytes, such as flow rate, microbubble
concentration, and ultrasound peak negative pressure generated with B-mode
imaging. Additionally, increased microbubble destruction was observed with
increasing ultrasound pressures when utilizing low ultrasound peak negative
pressures (0.5-1.3 MPa). Having sufficient levels of microbubble cavitation is
critical to enable intracellular delivery of impermeant compounds such as trehalose
to erythrocytes. Acoustofluidic treatment showed the ability to increase recovery
of freeze-dried erythrocytes compared to respective controls. This preliminary
study laid the groundwork for subsequent experimental studies that further
enhanced long-term storage of erythrocytes at ambient temperatures (Janis et al.,
2021).
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Feasibility of the acoustofluidic platform was demonstrate using
erythrocytes, but the PDMS-based acoustofluidic device had several limitations,
including low processing rates, inconsistent device dimensions due to batch-tobatch variability, and frequency clogging or device damage during operation. Thus,
a 3D-printed device was designed to enable consistent device dimensions and to
increase device channel diameters for faster processing rates. Human T cells were
utilized for these studies as acoustofluidic-mediated molecular delivery has the
capacity to address current T-cell manufacturing limitations, which includes long
processing times, inconsistent molecular delivery, and insertional mutagenesis. It
was found that acoustofluidic channel geometry had important implications on
molecular delivery, which may be influenced by fluidic properties, such as shear
stress, and acoustic properties, such as ultrasound exposure time. Microbubble
charge and microbubble dose were found to be critical parameters as they may
influence microbubble-cell interaction and microbubble cavitation, respectively.
Mechanisms of molecular delivery in acoustofluidic devices with exogenous
microbubbles have not been previously described; however, it is feasible that
multiple mechanisms may enhance molecular delivery, such as transient
perforation and/or enhanced endocytosis. This study revealed that the fastest
uptake of biomolecules with our acoustofluidic device was within minutes,
indicating that formation of transient pores in cell membranes is likely the dominant
mechanism of molecular delivery. Previous studies have shown that transient
perforations can repair rapidly (Hu et al., 2013b). Our acoustofluidic device also
showed the ability to induce molecular delivery while maintaining high cell viability.
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Although our acoustofluidic device has significant potential for a variety of
applications, its ability to induce molecular delivery has not been directly compared
to static ultrasound treatment methods. To properly assess this, acoustofluidic
treatment and static ultrasound treatment parameters were refined based on
ultrasound pressure, microbubble dose, and ultrasound exposure time. Refined
parameters were directly compared using a small molecule (0.6 kDa calcein) and
a large molecule (150 kDa-FITC Dextran). Acoustofluidic treatment and static
ultrasound treatment achieved similar levels of molecular delivery for small and
large molecules, even though acoustofluidic treatment was able to achieve this
with a lower microbubble concentration and approximately 20x less exposure time
(~2-3 s vs. 45 s) in human T cells.
Previous studies have shown that sonoporation can influence cell
proliferation, cell viability, and cell cycle phases. These studies, however, were
conducted in static ultrasound configurations with different acoustic parameters,
microbubble properties, and different cell types. Furthermore, these studies did not
characterize ultrasound effects on organelle structures and also did not assess the
effects of biological and cell culture media formulation parameters on molecular
delivery. Further characterization of acoustofluidic treatment on organelle
structural modification, cell repair mechanisms, and cell proliferation is required for
potential cell manufacturing applications. In our study, we found that acoustofluidic
treatment can induce modification to the plasma membrane and nuclear
membrane. Our acoustofluidic device can potentially induce rapid delivery of
biomolecules to the nucleus for genome modification, if desired. This is a
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significant advantage compared to current cell manufacturing technologies, which
generally rely on viral vectors to induce delivery across the plasma membrane.
Viral delivery then requires further time and molecular signaling to transport
payloads into the nucleus. If cytosol delivery is only required, acoustofluidic
parameters, such as ultrasound pressure, could be optimized to reduce nuclear
delivery. Although perforations are formed in the plasma membrane, actin patches
are rapidly formed to reverse perforation and help cells achieve homeostasis.
Additionally, acoustofluidic treatment induces temporary disruptions in the cell
cycle and briefly reduces proliferation, but it appears that normal cell proliferation
resumes within 2 days after acoustofluidic treatment. This likely signifies that repair
of organelle structures may be required after acoustofluidic treatment before
entering subsequent cell division cycles. Future studies are ultimately required to
understand the relationship between high molecular delivery levels and prolonged
cell viability as initial studies only utilized PI staining as a proxy of cell viability
within an hour of acoustofluidic treatment. This ultimately may not be
representative of cell viability of high molecular delivery across a prolonged
timeframe. Cells may be sorted based on molecular delivery levels to be assessed
at longer timepoints. This will likely provide insights into reasons for reduced cell
counts 48 hours post-treatment compared to respective controls. Additionally, cell
cycle phase also influences molecular delivery and cell viability. Thus, syncing the
cell cycle may potentially be utilized to further enhance molecular delivery and
improve cell viability. Finally, cell plating density and cell culture media
formulations were found to have important implications on molecular delivery and
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cell viability. These results indicate that biological properties have a significant
impact on acoustofluidic-mediated molecular delivery to human T cells along with
cell viability.
Acoustofluidic treatment showed the capacity to modify both the plasma
membrane and subcellular organelles, but implications on cellular signaling and
functional activity have yet to be characterized. To understand the implications of
acoustofluidic treatment, further studies are required to characterize changes in
cellular signaling through techniques such as RNA sequencing and proteomics.
Additionally, functional assays such as cytotoxicity assay, intracellular cytokine
staining, and proliferation assay are required to ensure intended immunological
function is achieved. These studies will provide critical information prior to
conducting animal studies.
In summary, 3D-printed acoustofluidic devices represent a platform
technology for cell manufacturing applications that can be used a variety of cell
types and applications. The system allows users to modulate numerous
parameters, including acoustofluidic and biological parameters, for their tailored
applications. Further studies are ultimately required to assess the ability of
acoustofluidic treatment to induce functional delivery compared to current cell
manufacturing techniques. However, this dissertation was able to satisfy the
central hypothesis and address underlying questions regarding acoustofluidicmediated molecular delivery to human cells.
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